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1. INTRODUCTION 
1.1 | Introduction to endogenous retroviruses   
Retroviruses belong to the family Retroviridae, which comprises a diverse range of 
single-stranded RNA viruses capable of reversing the flow of genetic information from RNA to 
DNA1. The enzyme Reverse Transcriptase (RT), which generates a DNA copy of the RNA 
genome1, imparts this unique characteristic to retroviruses (Figure 1). Another remarkable 
feature of retroviruses is their ability to insert this DNA copy of the viral genome into genomic 
material of the host cell – a process mediated by the viral enzyme Integrase1 (Figure 1). This 
integrated copy of the retrovirus is called a provirus1. Thus, exogenous retroviruses have the 
capacity to permanently incorporate themselves into the genome of the host cells they infect. 
 
 
Figure 1. Integration process of an exogenous retrovirus into the genome of the host cell. The 
exogenous retrovirus binds to the host cell (1) and releases the nucleocapsid containing the viral  
RNA genome and enzymes into the cytoplasm of the infected cell (2). Un -coating of the 
nucleocapsid releases viral RNA, Reverse Transcriptase (red),  and Integrase (l ight blue) into the 
cytoplasm. Reverse Transcriptase synthesizes a DNA copy of  the viral  RNA (3).  This single -
stranded DNA is converted to a double -stranded DNA (dsDNA) (4), and inserted into the genome 
of the infected cell via Integrase (5). Artwork by M.  Manghera.  
Retroviruses usually infect only somatic cells, and are thus only transmitted horizontally. 
Nonetheless, some retroviruses are able to infect germ line cells (eggs and sperm) and 
incorporate their viral genes into the genomic material of the infected gametes1. During 
10 
 
fertilization, the fusion of infected, yet viable, gametes results in the vertical transmission of 
these integrated retroviral elements to progeny. These proviruses are inherited by the 
subsequent generations in a Mendelian fashion2. Thus, exogenous retroviruses (XRVs) that 
become permanent residents of the host genome are called endogenous retroviruses (ERVs).  
Endogenous retroviruses have been identified in a diverse range of ancient and modern 
vertebrate host species; and, humans are no exception. Ancient exogenous retroviruses 
permanently entered the human lineage through infection of germ line cells of our ancestors 
dating as far back as 55 million years ago3. These human endogenous retroviruses now 
constitute over 8% of our genetic material, whereas vertebrate genes comprise merely 1.5% of 
our DNA4. Our genome harbours approximately 203,000 copies of ERVs, with human 
endogenous retrovirus-K (ERVK; former HERV-K5) being the most recently integrated and the 
best preserved3,6. It is estimated that ERVK alone contributes 6400 solitary Long Terminal 
Repeats (LTRs; viral promoters) and 550 proviruses – a total of about 7000 retroviral elements – 
to our genetic material3. ERVs are named according to the type of transfer RNA (tRNA) used to 
prime reverse transcription; since ERVK uses lysine tRNA (abbreviated as K) for this process, it is 
designated as “K”6. ERVK is most closely related to a murine betaretrovirus – mouse mammary 
tumor virus (MMTV); hence, the ERVK group is further divided into ten human MMTV-like 
(HML) families, designated as HML-1 to HML-103. The ERVK HML-2 family is thought be the 
youngest, as it comprises retroviruses that may have endogenized into the human genome as 
recently as 200,000 to 2 million years ago3,7. Clearly, humans are holobiontic organisms, with a 
genetic inheritance comprising dynamic interactions between the human and retroviral 
genomes.    
1.2 | Role of Human Endogenous Retroviruses in health and disease 
Over evolutionary time, the majority of ERVs have been silenced through accumulation 
of point mutations and deletions, as well as through epigenetic mechanisms such as DNA 
methylation and cytosine deamination, providing a natural defense against these intragenomic 
parasites8–11. Nonetheless, some ERVs remain transcriptionally active and have become crucial 
for a variety of biological processes within us, resulting in a symbiotic relationship between 
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these endogenous retroviruses and their human hosts. For instance, the env (envelope) genes 
of ERVW encode syncytin proteins, which are crucial for the differentiation of 
syncytiotrophoblast in chorionic villi, and thus aid in normal development of the human 
placenta12. The syncytin proteins also have immunosuppressive properties, allowing the 
embryo to escape immune rejection and thus survive during pregnancy12. More recently, ERVK 
expression has been shown to upregulate a specific viral restriction pathway in early stages of 
human pre-implantation embryos. As a result, it has been postulated that ERVK expression 
during early embryogenesis may protect human embryos against infections from either 
infectious ERV particles or exogenous viruses sensitive to restriction by innate immune 
pathways13. In addition, ERVK elements serve as alternative gene promoters and enhancers, 
and play a key role in regulating the expression of a wide variety of human genes4,14,15, such as 
INSL4 (encodes insulin-like protein 4)16,17. Some ERV sequences are also known to silence 
human gene transcription, as they produce mRNA complementary to cellular gene transcripts, 
thus down-regulating the expression of select human genes through RNA interference18. Hence, 
the symbiogenesis between endogenous retroviruses and the human genome has contributed 
enormously towards shaping human evolution and physiology.      
Given the huge retroviral presence in our genome and their ability to express viral RNA 
and proteins, ERVs may be deleterious and play an important role in human diseases. The ERVK 
(HML-2) loci are of particular relevance in this context, as they comprise the most recently 
integrated and most intact proviruses present within the human genome. More than 90 ERVK 
proviruses belonging to the HML-2 family have full length open reading frames encoding 
functional retroviral proteins3. The enhanced expression of these ERVK loci has often been 
associated with inflammatory diseases including neurological disorders19, rheumatic 
diseases20,21, multiple types of cancers22, and infections23,24,25. There is also evidence that some 
ERVK proviruses are capable of producing mature virus particles23,26-27. Accordingly, ERVK 
virions have been detected in the blood of patients with human immunodeficiency virus-1 (HIV-
1) infection23, breast cancer23, and lymphoma26. In addition, structurally intact ERVK virus 
particles have been shown to be produced in cancer cell lines derived from teratocarcinomas28, 
breast cancer29, and melanomas27.  
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Yet, the infectivity of these ERVK particles has not been clearly demonstrated. Due to a 
non-functional envelope protein, ERVK virions are generally thought to be non-infectious27,28,30. 
However, a recent study depicted that ERVK particles derived from teratocarcinoma and breast 
cancer cell lines, as well as from peripheral blood lymphocytes obtained from lymphoma 
patients, are able to package a synthetic ERVK HML-2 genetic probe and transmit it to other 
cells29. This probe was also shown to be reverse transcribed in target cells and form episomes 
(integrase-mediated circularization of proviral DNA), but it did not integrate into the genetic 
material of the host cells29. This may be attributed to a lack of unique sequences in the 
synthetic probe that are crucial for integration. Nevertheless, these findings challenge the 
prevailing notion that human endogenous retroviruses, such as ERVK, are non-infectious and 
lack transmission capacity. Although there is no documented evidence of a causal relationship 
between ERVK activity and disease, transient cellular transmission of ERVK sequences through 
viral particles may activate typical anti-retroviral immune responses against infected host cells, 
leading to inflammation and subsequent cellular damage. Overall, not only do ERVs confer 
biological benefits to their human hosts, but retroviral activity stemming from particular ERV 
loci may also play crucial roles in the pathophysiology of their associated inflammatory 
diseases.  
1.3 | Human Endogenous Retrovirus-K and neuroinflammatory diseases 
Evidence of enhanced ERVK activity in a variety of neuroinflammatory diseases has 
accumulated over the recent years. Patients with neurological disorders, including Amyotrophic 
Lateral Sclerosis (ALS), Schizophrenia (SCZ), Multiple Sclerosis (MS), and HIV-associated 
neurocognitive disorder (HAND) exhibit augmented ERVK RNA and protein levels in their post-
mortem brain tissue, blood, and/or cerebrospinal fluid31,32,33,34,35,36. As with other ERVK-
associated inflammatory diseases, enhanced ERVK expression has not been conclusively 
demonstrated to be a causative agent of the aforementioned neurological disorders.  
Nonetheless, ERVK re-activation has the potential to influence the pathogenesis of the 
associated neurodegenerative diseases through a variety of mechanisms, which have been 
extensively reviewed in our Publication 1. Most importantly, ERVK RNA and protein detection 
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by the host immune system may trigger chronic inflammation in the central nervous system 
(CNS), leading to extensive neuronal damage. Indeed, exacerbated immune signaling and 
chronic production of inflammatory mediators known as cytokines are common hallmarks of 
ERVK-associated neurodegenerative diseases37,38,39,40. However, the ability of the human 
immune system to detect ERVK RNA and proteins has been scarcely studied to date. Few 
studies have depicted antibodies against ERVK gag and envelope proteins in the sera of 
individuals with ERVK-associated cancers and HIV infection22,41–44. In patients with breast 
cancer, ERVK-specific cytotoxic T lymphocytes, which are effector cells of the adaptive immune 
system and are responsible for killing pathogen-infected host cells, have also been detected41. 
Thus, the literature provides some evidence of immune recognition of ERVK proteins, but this 
area of ERVK research clearly needs further exploration in order to establish any relationships 
between ERVK expression, chronic immune activation, and the resulting inflammatory 
pathology in neurodegenerative disorders. 
1.3.1 | Enhanced expression of ERVK in Amyotrophic Lateral Sclerosis  
Amyotrophic Lateral Sclerosis (ALS) is the most common type of motor neuron disease. 
It is characterized by gradual degeneration of both upper (in the brain) and lower (in the spinal 
cord) motor neurons; this leads to progressive deterioration of associated muscle tissues, 
causing paralysis and ultimately death45. ALS neuropathology and the resulting muscle atrophy 
progresses in several stages. The earliest symptoms include fasciculations, muscle spasticity, 
muscle weakness affecting the limbs, slurred speech, and difficulty swallowing46. As 
neurodegeneration progresses throughout the CNS, muscle weakness and atrophy spreads to 
other parts of the body46. At this point, patients experience difficulty moving and speaking, as 
well as exhibit exaggerated or abnormal reflexes46. In the final stages of ALS, deterioration of 
respiratory muscles leads to respiratory failure, culminating in death46.  
Currently, this devastating and incurable disease strikes six to eight individuals per 
100,000 population47,48. This means that approximately 3000 Canadians are currently living with 
ALS49. It is estimated that two to three Canadians die from ALS per day (ALS Canada). According 
to the World Health Organization, neurodegenerative diseases, like ALS, are predicted to 
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surpass cancer as the second leading cause of death in Canada by 2040 (ALS Canada). Thus, new 
and more efficient diagnostic and therapeutic techniques are required in order to decrease the 
local and global incidence of neurodegenerative diseases, including ALS. 
ALS is a complex disorder involving multiple pathophysiological mechanisms that 
culminate in neurodegeneration. Notably, several genetic defects that affect protein function 
and metabolism have been identified as causative factors in ALS. Mutations in SOD1 gene were 
the first to be associated with this disease. SOD1 encodes the antioxidant enzyme Copper, Zinc – 
Superoxide Dismutase, mutation of which leads to an accumulation of oxygen free radicals 
inside cells and increased oxidative damage50. Recently, mutations in other genes, particularly 
TARDBP, have been implicated in ALS. The TARDBP gene encodes TAR DNA binding protein-43 
(TDP-43), which is a DNA and RNA binding protein involved in transcriptional regulation of many 
genes, as well as in RNA splicing50. Mutated forms of TDP-43 form cytosolic aggregates in 
neurons which are a hallmark of ALS47. Although mutant TDP-43 has the propensity to abrogate 
a wide array of cellular functions, it has been shown to exaggerate the neuroinflammatory 
response and lead to neuronal death51,52. Despite these advances, the exact pathological 
mechanisms involved in the onset and progression of ALS still largely remain obscure. 
Recently, the retroviral enzyme reverse transcriptase (RT) was identified in the serum 
and cerebrospinal fluid of ALS patients at levels equivalent to those found in individuals infected 
with HIV-136,53. In addition, the RT activity was also enhanced in the first degree relatives of 
these ALS patients, suggesting that this retroviral enzyme may originate from active proviruses 
present within the human genome35. Accordingly, the source of this enzyme was demonstrated 
to be active ERVK loci in the cortical neurons of these ALS patients31, suggesting a role for this 
endogenous retrovirus in the pathophysiology of ALS.  
A viral etiology of ALS has long been suspected, as some individuals infected with the 
exogenous retrovirus HIV-1 also develop HIV-associated neurocognitive disorder (HAND) – an 
ALS-like syndrome exhibiting motor neuron pathology54–56. However, HIV-1 is not known to 
infect neurons57; thus, neuronal damage in this case must result from indirect pathological 
effects. This includes the release of pro-inflammatory mediators called cytokines by HIV-1 
infected astrocytes, microglia, or infiltrating immune cells in the CNS, which can have cytotoxic 
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effects on neurons58. Interestingly HIV-1 infection has also been associated with enhanced ERVK 
expression in PBMCs and autopsy brain tissue obtained from infected individuals, as well as in 
astrocytic and T-lymphoma cell lines34,59,60. Thus, HIV-induced ERVK expression in neurons may 
alternatively serve as the link between this retroviral infection and the development of HAND. 
However, the role that ERVK re-activation plays in the neuropathology of ALS and HAND is yet 
obscure.   
Re-activation of ERVK may contribute to neurodegeneration through several 
mechanisms. ERVK transcripts and proteins may activate host anti-retroviral immune responses 
against the ERVK-expressing neurons, leading to inflammation, neuronal injury, and loss. This 
antiviral response may be mediated by innate immune sensors called pattern recognition 
receptors (PRRs) present in neurons and other resident cells of the CNS, particularly astrocytes 
and microglia. These PRRs detect a variety of pathogen associated molecular patterns (PAMPS), 
including viral proteins, RNA, and DNA. Retinoic acid inducible gene – I (RIG-I), which is known 
to detect HIV RNA61, is one of the key putative cytosolic ERVK sensors expressed in the cells of 
the CNS (The Human Protein Atlas). Interaction between viral ligands and their respective PRRs 
stimulates downstream signalling pathways, which drives both pro-inflammatory and anti-viral 
responses. The activation of key transcription factors, such as nuclear factor-kappa B (NF-κB), 
promotes the production of antiviral proteins (viral restriction factors) and pro-inflammatory 
cytokines. As an undesirable side effect, these inflammatory mediators provoke cytotoxic 
responses in the surrounding tissue.  Interestingly, astrocytic and microglial activation has been 
demonstrated to actively participate in ALS and HAND pathogenesis through release of toxic 
mediators, including cytokines such as Tumor Necrosis Factor α (TNFα)62,63,39. TNFα has been 
determined to be a major contributor to inflammation and neuronal loss in ALS as a result of 
excessive NF-κB activation64. We have preliminary evidence that astrocytes have the capacity to 
mount an innate anti-viral immune response against ERVK virions purified from a 
teratocarcinoma cell line (Raizman and Douville, unpublished). Thus, recognition of ERVK 
proteins and mRNA may activate astrocytes and microglia, which may trigger inflammatory 
responses to eliminate ERVK-expressing neurons, thereby contributing to neurodegeneration 
observed in ALS and ALS-like syndromes.  
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Similar to other retroviruses such as Human Immunodeficiency Virus-1 (HIV-1), ERVK 
may exploit the inflammatory proteins produced during an anti-retroviral innate immune 
response, particularly NF-κB and IRF165. Since these proteins have the potential to induce ERVK 
transcription (which will be discussed later), anti-ERVK immune response may culminate in a 
positive feedback loop favouring further ERVK expression and chronic inflammation. Thus, the 
inflammatory response initiated to restrict neuronal ERVK activity may actually be detrimental 
instead of being protective, leading to the progressive neurodegeneration.    
In addition, bioinformatics analysis has revealed that some ERVK proviruses may encode 
a neurotoxic protein homologous to omega-conotoxins (Fineblit, Jonasson, Ferguson-Parry, and 
Douville, unpublished). These toxins are known to inhibit voltage-gated calcium channels in 
neural and associated muscle tissues, which hinders neuro-muscular communication66,67. 
Similarly, the ERVK conotoxin-like protein (CTXLP) may inhibit communication between neurons 
and associated cells, resulting in typical ALS symptoms, such as paralysis and muscle wasting. 
Omega-conotoxins have also been demonstrated to cause neuronal death in animal models58. 
Thus, ERVK CTXLP may also directly cause neurodegeneration.   
Hence, ERVK re-activation may serve as a novel marker of ALS and define the 
pathophysiology of neuronal loss in this disease, as well as in HAND. However, the mode of 
ERVK re-activation during neuroinflammation in general, and in ALS and HAND, remains poorly 
understood. Through exploration into the ERVK proviral promoter and binding sites for cellular 
proteins68, as well as select inflammatory signalling pathways and protein functions deregulated 
in ALS and HAND, the sections hereafter will highlight the putative mechanisms by which ERVK 
activity may be augmented in these neurodegenerative conditions. 
 
1.4 | Transcriptional regulation of Human Endogenous Retrovirus -K 
 
1.4.1 | ERVK provirus: genomic structure and gene expression 
The structure of an ERVK provirus resembles that of a typical betaretrovirus. A full-
length ERVK provirus is approximately 9.5 Kb in size and consists of four overlapping retroviral 
genes –gag (group specific antigen), pro (protease), pol (polymerase), and env (envelope) – 
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flanked on each side by a Long Terminal Repeat (LTR)3 (Figure 2A). The gag, pro, pol, and env 
genes encode the retroviral capsid proteins, the enzyme protease (PR), retroviral polymerase 
(with reverse transcriptase (RT) and integrase (IN) subunits), and the viral envelope proteins, 
respectively 6. 
 
 
 
FIGURE 2. Structure of an intact ERVK provirus within the human genome and the ERVK 
transcripts produced . (A) The four ERVK genes – gag (group specific antigen) , pro (protease; PR), 
pol (polymerase; with Reverse Transcriptase (RT) and Integrase (IN) activities ),  and env 
(envelope) – are flanked by Long Terminal Repeats (LTRs) on each side. Each LTR has one U3, R , 
and U5 region in a 5ʹ to 3ʹ direction.  (B)  ERVK genes are expressed as gag -pro and gag -pro-pol 
polypeptides,  which are cleaved by protease (black arrowheads) to yield individual proteins.  The 
envelope transcript can be alternatively spliced to yield Rec (in Type II  ERVK) and Np9 (in Type I 
ERVK) accessory proteins. The red horizontal bar in env marks the 292 bp deletion in Type I ERVK. 
Adapted from Douville & Nath, Clinical Handbook of Neurology ,2014.  Artwork by M. Manghera.  
 
The transcriptional activity of ERVK proviruses is regulated by their Long Terminal 
Repeats (LTRs), which serve as the viral promoters. A promoter is a region of DNA located 
upstream of a particular gene from which the transcription of that gene is initiated. Each LTR 
consists of U3, R, and U5 regions in a 5ʹ to 3ʹ direction68 (Figure 2A). U3 region is perhaps the 
most important as it contains all the sequences – TATA independent promoter, enhancer 
elements, and transcription factor binding sites – necessary for initiation of transcription of the 
downstream ERVK genes. The 5ʹ LTR modulates the sense transcription of ERVK by interacting 
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with certain viral proteins and human transcription factors68. The role of 3ʹ LTR in the 
transcriptional regulation of ERVK remains obscure; however, it may modulate the antisense 
transcription of ERVK as observed for other retroviruses including HIV-1 and HTLV-169,70. 
Retroviral gag, pro, and pol genes are initially transcribed and translated into gag-pro 
and gag-pro-pol precursor polypeptides, which are cleaved by the viral protease into individual 
peptides to form each mature protein, including the RT enzyme (Figure 2B). This protease-
mediated processing of the gag-pro-pol polyprotein has been extensively described for 
exogenous retroviruses such as HIV-1, HTLV-1, and MMTV (Mouse Mammary Tumor Virus)71–75, 
but remains poorly studied for endogenous retroviruses including ERVK.  The exogenous 
retroviral gag-pro-pol polyprotein is known to be sequentially cleaved (Figure 3) to yield 
intermediate proteins, and finally a heterodimeric RT protein comprised of two subunits: a 
larger catalytic isoform with DNA polymerase activity and a ribonuclease H (RNase H) domain 
responsible for degrading the viral RNA genome template as viral DNA is synthesized, and a 
smaller isoform which serves a structural role72,76,77. In contrast, little work has been done to 
understand the synthesis and structure of ERVK RT, despite the fact that the augmented levels 
of this protein have been implicated in a variety of inflammatory and neurological diseases. For 
the first time, we have shown ERVK gag-pro-pol polyprotein cleavage leading to the production 
of intermediate RT-containing proteins, and ultimately the two distinct ERVK RT subunits, in 
human cell line models of neuroinflammatory disease (Publication 2). Thus, the ERVK gag-pro-
pol polyprotein is likely processed by the viral protease in a similar fashion as that seen with 
other retroviruses (Figure 3), culminating in the production of an active heterodimeric ERVK RT 
enzyme under select conditions. 
Finally, ERVK env is transcribed in a different reading frame than the gag-pro-pol 
polyprotein to yield a full length envelope protein. The envelope transcript can be alternatively 
spliced to yield an accessory protein called Rec in ERVK HML-2 proviruses termed Type II3 
(Figure 2B). Type I proviruses have a 292 base pair deletion in the env gene; as a result, the 
accessory protein Np9 is produced instead of Rec3 (Figure 2B). Rec is responsible for 
transporting ERVK mRNAs from the nucleus into the cytoplasm3. Np9 has no known 
physiological function in ERVK replication. However, Rec and Np9 may serve as ERVK 
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oncoproteins as they have been implicated in tumor development; they have been 
demonstrated to increase the levels of c-Myc protein, leading to enhanced cell growth and 
reduced apoptosis78. 
 
FIGURE 3. Protease-mediated sequential cleavage of the retroviral gag -pro-pol polyprotein to 
produce mature RT isoforms.  Here, HIV-1 is used as the model to il lustrate the sizes of each 
intermediate protein and the final RT subunits  produced: 66 KDa RT with RNase H and 51 KDa RT 
without RNase H. ERVK polyprotein cleavage is predicted to proceed in a  similar  fashion, leading 
to the generation of a h eterodimeric RT. However, the sizes of the ERVK intermediate cleavage 
products and RT subunits may be different in comparison to that of HIV -1. Adapted from7 2.  
 
1.4.2 |Transcriptional silencing of ERVK 
The transcription of the majority of ERVs, including ERVK, has been silenced over 
evolutionary time through accumulation of deleterious point mutations and deletions. In 
addition, several layers of epigenetic control restrict ERVK expression in various cell types and 
tissues. Cellular proteins, particularly APOBEC3G, partake in nucleotide deamination of ERVK 
sequences prior to their integration into host genome, introducing G to A and C to T mutations 
to prevent the binding of transcriptional activators recognizing that region of the ERVK 
promoter68. Methylation of CpG dinucleotides in the U3 region of the ERVK 5ʹ LTR may also 
repress transcription of ERVK genes by preventing the binding of crucial transcription factors to 
the methylated sites68. The methylated CpG dinucleotides can further be spontaneously 
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deaminated, which is a major source of abundant G to A and C to T mutations in many ERVK 
LTRs and renders them incapable of transcription68. Thus, epigenetic factors play a major role in 
restricting ERVK transcription in human cells.  
Other than epigenetic mechanisms, transcription factors are also crucial for regulating 
the activity of the ERVK promoter. Although there is accumulating evidence of ERVK 
transcriptional activators, human and viral transcription factors that repress ERVK gene 
expression largely remain unidentified. To date, a single report depicts that HIV-1 Tat (Trans-
activating) protein is able to repress the transcription of several ERVK HML-2 proviruses60, 
although it was previously shown to induce global ERVK transcription in the context of HIV 
infection59,79. The use of different types of cells in these studies may account for disparate 
results. Such a cell-type dependent inductive and repressive transcriptional activity of Tat has 
also been described for the HIV promoter. For instance, Tat is able to stimulate HIV 
transcription in macrophages, but represses it in monocytes80. Genetic variations within the HIV 
LTRs have been shown to further alter the course of viral transcription by modulating the 
interactions of Tat with the HIV promoter. Thus, whether Tat is an ERVK transcriptional 
repressor or activator is currently unclear; in reality, it may act as a bifunctional transcription 
regulator whose activity is dependent on both the ERVK promoter and the cellular context. In 
addition, only a single transcriptional corepressor called tripartite containing motif 28 (TRIM28) 
is known to silence the transcription of MMERVK10C (a beta-like ERV similar to ERVK HML-2) in 
neural progenitor cells derived from transgenic mice81. This is achieved via TRIM28-mediated 
repressive histone modifications of MMERVK10C followed by DNA methylation81. However, the 
influence of TRIM28 on ERVK transcription has not been determined in human cells. 
Several human transcription factors are known to restrict the expression of retroviral 
genes. These include the TAR-DNA binding protein-43 (TDP-43), which is a nuclear RNA/DNA 
binding protein involved in RNA metabolism and transcriptional regulation of a variety of genes 
50,82. TDP-43 was originally described to repress HIV-1 transcription by interacting with a TAR-
DNA element present within the HIV-1 LTR; this likely displaces essential transcriptional 
machinery required to initiate transcription from the viral promoter, thereby inhibiting its gene 
expression83. However, the influence of TDP-43 on the transcription of other retroviruses 
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including ERVK remains unexplored. Through bioinformatics analysis of ERVK (HML-2) 5ʹ LTRs, 
we have identified a putative conserved TAR-RNA encoding element within the ERVK promoter 
(Figure 4). Additional conserved putative TDP-43 binding sites are also present throughout the 
ERVK LTR, three of which lie within the predicted TAR-like encoding motif (Figure 4). Therefore, 
endogenous TDP-43 may be able to restrict ERVK gene expression in a manner similar to that 
identified in HIV-1. On the contrary, a recent report depicts that TDP-43 is capable of slightly 
enhancing HIV-1 transcription in T cells84. Likewise, whether TDP-43 will act as a repressor or an 
activator of ERVK remains to be determined empirically; in fact, it may differentially modulate 
ERVK transcription in a promoter and cell-type specific manner.  
Clearly, there is a lack of knowledge regarding cellular and viral proteins capable of 
inhibiting ERVK transcription. Only a few studies document the repressive effect of retroviral 
and cellular proteins on ERVK transcription. TDP-43 is potentially a novel cellular ERVK 
transcriptional repressor – an area of research which undoubtedly warrants further 
investigation.  
 
Figure 4.  Conserved putative TDP-43 binding sites (pink) and TAR-RNA encoding motif within 
the consensus ERVK HML-2 5’LTR. The sequences of the TDP-43 DNA binding sites were adapted 
from83,  and used to identify multiple putative conserved TDP -43 binding sites with in the 5ʹ LTRs 
of five prototypic  ERVK (HML-2) proviruses. Here, binding sites are shown on the consensus ERVK 
5 ʹ  LTR sequence constructed from the alignment of these prototypic promoters. The sequence of 
the HIV-1 TAR-RNA encoding element  was obtained from GenBank (accession number 
AM076891.1) and used to identi fy a conserved potential TAR -RNA encoding motif spanning the 
nucleotides 448 to 505 within the ERV K 5ʹ LTRs. Black and gray arrows indicate conventional and 
alternative transcription start sites, re spectively. All alignments and annotations were performed 
in Geneious (Kearse et al.  2012).   
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1.4.3 |Known Transcriptional activators of the ERVK LTR  
Unlike identifying transcriptional repressors of ERVK, a greater research focus has been 
placed on elucidating transcriptional activators of this endogenous retrovirus. To date, several 
human transcription factors have been experimentally shown to induce ERVK expression in 
human cells through their interactions with the ERVK promoter. These include Specificity 
protein 1 and 3 (Sp1, Sp3)85, Yin Yang 1 (YY1)86, Microphthalmia-associated transcription factor-
M (MITF-M)87, Octamer binding transcription factor-4 (Oct4)13, and hormonal receptors for 
progesterone88, estrogen88, and androgen89. In addition, exogenous viral proteins are also 
known to induce ERVK transcription. For instance, HIV-1 Tat and HTLV-1 Tax proteins are able 
to trans-activate the ERVK promoter68.Tat interacts with and enhances the binding of NF-κB and 
NFAT-1 (nuclear factor of activated T-cells 1) transcription factors to the ERVK LTR, which 
correlates with an increased ERVK gag transcription68. Similarly, Tax has been postulated to 
increase the affinity of transcription factors including Sp1 and NF-κB to their DNA binding sites 
on the ERVK LTR68. However, majority of the transcription factors shown to activate ERVK LTR 
are not specific to inflammatory conditions, which exhibit most notable increases in the 
expression of this endogenous retrovirus. Thus, the transcriptional regulation of ERVK is yet to 
be fully elucidated, especially in the context of neuroinflammation.    
1.4.4 |Pro-inflammatory transcription factors: Novel ERVK transcriptional inducers  
By utilizing extensive bioinformatics analyses, we have recently identified conserved 
putative binding sites for a plethora of other human transcription factors in the ERVK (HML-2) 5ʹ 
LTRs, in addition to those aforementioned68. The ERVK promoter is laden with potential binding 
sites for transcription factors involved in inflammatory signaling cascades. A striking feature of 
the ERVK promoter is the presence of two conserved Interferon-Stimulated Response Elements 
(ISREs), which bind the pro-inflammatory transcription factors Nuclear Factor-kappa B (NF-κB) 
and Interferon Regulatory Factor 1 (IRF1) (Figure 5). In addition, the 5ʹ LTR harbors many other 
conserved putative NF-κB binding sites (Figure 5). NF-κB and IRF1 are known to induce LTR-
dependent transcription of other retroviruses, notably HIV-1. IRF1 has been shown to interact 
with NF-κB, and is in fact required for full NF-κB mediated activation of the HIV-1 LTR65. 
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Accordingly, overlapping binding sites for NF-κB and IRF1 have been identified at the HIV-1 
promoter65. The ERVK 5ʹ LTR also contains overlapping binding sites for these pro-inflammatory 
transcription factors (Figure 5). Thus, increased NF-κB and IRF1 activity may synergistically 
augment ERVK transcription in the context of inflammation, including in neurological diseases. 
Overall, it is clear that the transcriptional signals which normally limit, as well as the 
signals that enhance ERVK expression in the associated inflammatory diseases, are not well 
understood. Through in-silico analyses of the ERVK promoter, we have determined that TDP-43, 
NF-κB, and IRF1 may be novel transcriptional regulators of ERVK. In the succeeding sections, a 
closer look at perturbed activity of these cellular transcription factors will aim to highlight 
potential mechanisms which may lead to ERVK re-activation in neuroinflammatory diseases, 
with a major focus on ALS. 
 
 
FIGURE 5. In silico examination of the conserved transcription factor binding sites and response 
elements within five prototypic human endogenous retrovirus -K (ERVK) 5′ -LTRs using ALGGEN-
PROMO software  (Messeguer et al. 2002).  This excerpt highlights two Interferon Stimulated 
Response elements (ISRE) that bind IRF1 and NF -κB, as well  as other NF -κB binding sites scattered 
throughout the LTR. The ERVK LTR consensus sequence was construc ted using individual ERVK 
LTRs in the following order (GenBank accession numbers in brackets): ERVK -10 (M12854.1),  ERVK -
109 (AF164615.1), ERVK -115 (AY037929.1), ERVK -108 (AF074086.2) and ERVK -113 (JF742069.1). 
Sequence alignment and annotations were perfor med using Geneious software (Kearse et al.  
2012). Adapted from68 .  
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1.5 | Putative cellular pathways involved in ERVK re-activation in ALS 
 
1.5.1 | Pro-inflammatory cytokines in ALS pathology 
Immune activation and inflammation of the central nervous system (CNS) is a 
pathological hallmark of ERVK-associated neurodegenerative diseases including ALS. 
Neuroinflammation in this disease is characterized by the activation of resident innate immune 
cells in the CNS – microglia and astrocytes – which is accompanied by progressive degeneration 
of surrounding neurons90–92. T lymphocytes, effector cells of the adaptive immune system, have 
been observed to accumulate at sites of neurodegeneration in ALS91. Interestingly, there is also 
evidence of an anti-viral immune response in ALS. For instance, antibodies against ERVK (HML-
2) gag proteins have been detected in the sera obtained from ALS patients56. In addition, the 
majority of infiltrating T cells in the CNS of ALS patients are CD8+ cytotoxic T lymphocytes, 
which are responsible for destroying virus-infected host cells91. Increased numbers of natural 
killer T cells, which also kill virus-infected host cells, have also been observed in the spinal cord 
of ALS patients93. Together, these findings are suggestive of a putative immunological reaction 
to endogenous viral PAMPs, potentially ERVK protein and/or nucleic acids accumulation. 
Parallel to immune cell activation and infiltration, significantly higher levels of pro-
inflammatory mediators called cytokines have been reported in the cerebrospinal fluid (CSF) 
and sera of ALS patients as compared to healthy controls94–96. These include cytokines 
belonging to the Tumor Necrosis Factor superfamily, LIGHT (homologous to lymphotoxin, 
exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry 
mediator, a receptor expressed by T lymphocytes) and Tumor Necrosis Factor alpha (TNFα), as 
well as Interferon gamma (IFNγ)94,97. Reactive microglia, astrocytes, and T cells are the major 
sources of these pro-inflammatory cytokines in the ALS brain98,99,91.  
There is growing recognition that TNFα, LIGHT, and IFNγ play critical roles in ALS 
neuropathology, as these cytokines are neurotoxic and have been associated with enhanced 
neuronal death. TNFα is a potent activator of the canonical nuclear factor kappa B (NF-кB) 
signaling pathway, culminating in the activation of p65 and p50 isoforms of this pro-
inflammatory transcription factor100. TNFα-induced NF-кB has been shown to cause motor 
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neuron death in vitro64. In addition, IFNγ has been demonstrated to synergize with TNFα to 
induce NF-кB, and enhance motor neuron death101. In line with this finding, anti-IFNγ therapy is 
protective and delays motor neuron damage in ALS mouse models102. Recently, elevated LIGHT 
signaling has been shown to selectively contribute to motor neuron death in ALS spinal 
cords97,103. IFNγ secreted by astrocytes is a key player in this process, as it leads to enhanced 
LIGHT production in spinal motor neurons97,103. Similar to TNFα, LIGHT is also a potent activator 
of the canonical, as well as the non-canonical, NF-кB pathways, leading to the activation of an 
alternate p52 NF-κB isoform100. Additionally, TNFα and IFNγ are known to synergistically 
activate interferon regulatory factor 1 (IRF1) expression95. But, the role of IRF1 activation in ALS 
pathology remains unexplored. Overall, the sum of these augmented cytokine signaling 
pathways likely results in excessive activation of NF-кB and IRF1 in the brain; these transcription 
factors may subsequently interact with the ERVK promoter and significantly enhance ERVK gene 
expression in CNS cells (Figure 6).   
 
 
FIGURE 6. Exacerbated pro-inflammatory cytokine signaling may re-activate ERVK in ALS by 
facilitating the binding of active NF-κB and IRF1 transcription factors with the ERVK 5′ LTR . 
Artwork by M. Manghera.  
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In support of this theory, pro-inflammatory cytokines have previously been shown to 
trigger endogenous retrovirus expression in several ERVK-associated inflammatory diseases. For 
instance, TNFα treatment has been demonstrated to enhance ERVK (HML-2) gag transcription 
in synoviocytes obtained from patients with rheumatoid arthritis20. TNFα and IFNγ are able to 
enhance ERVW expression in peripheral blood mononuclear cells (PBMCs) obtained from 
patients with Multiple Sclerosis104. TNFα has been shown to trigger ERVW syncytin protein 
expression by enhancing the binding of NF-κB subunit p65 to the ERVW promoter in a human 
astrocytic cell line105. Nonetheless, how pro-inflammatory cytokines trigger ERVK expression in 
human cells, particularly in the CNS, remains to be studied.   
 
1.5.2 | Deregulation of TDP-43 function in ALS 
TDP-43 is a nuclear RNA/DNA binding protein involved in RNA metabolism and 
transcriptional regulation of a variety of genes50,82. This protein consists of several domains 
exhibiting distinct functions (Figure 7A). These include a nuclear localization signal (NLS) at the 
N terminus, two RNA-recognition motifs (RRM1 and RRM2) that interact with both DNA and 
RNA, and a C-terminal glycine-rich domain responsible for regulating alternative splicing and 
transcriptional repression of several genes106,107.  
Aggregation of TDP-43 mutants is a striking feature of several neurological disorders, 
including ALS50. Over 40 mutations have been reported in TDP-43, majority of which occur in 
the carboxyl terminus of this protein (Figure 7A)50. These include the two most frequent TDP-43 
mutants associated with ALS – A382T and G348C108. The single nucleotide changes that may 
affect the RNA/DNA binding function of TDP-43 include the missense mutations N267S and 
K263E in RRM2 domain, and the mutation D169G in RRM1 domain50,82,108. The significance of 
these mutations in ALS pathology remains unknown; however, these variants may affect the 
interaction of TDP-43 with its target genes, such as ERVK, and alter their expression. In addition, 
truncated C-terminal fragments of TDP-43 often dominate in the aggregates formed within the 
neurons of ALS patients (Figure 7B)109. The loss of NLS redirects these TDP-43 fragments from 
the nucleus to the cytosol, abolishing the nuclear functions of this protein. It has been 
demonstrated that these fragments can also drive aggregation of normal TDP-43, and thus  
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Figure 7. (A) Structure of the TDP-43 protein including mutations that affect the function of 
each domain. Mutations in the RRM1, RRM2, and glycine rich domains that may play a role in 
ERVK re-activation in ALS are boxed in red. Adapted from  1 1 0.  (B)  Truncated forms of TDP-43 
known to form aggregates within neurons. The dotted red line indicates the missing domains.  
These fragments are mislocalized to the cytosol, and may abolish nuclear functions of TDP -43. 
Adapted from 10 9.  
 
reduce the levels of nuclear TDP-43109. If TDP-43 serves as an ERVK repressor, the loss of nuclear 
TDP-43 function may relieve TDP-43-dependent inhibition of ERVK expression, thus augmenting 
ERVK RNA and protein levels in ALS. 
In contrast, a strong correlation has been found between the overexpression of wild-
type TDP-43 and high levels of ERVK pol transcripts in neurons of ALS patients31, suggesting that 
TDP-43 may induce ERVK transcription. This effect may be mediated through enhanced 
interaction of TDP-43 with its putative binding sites on the ERVK promoter (Figure 4). 
Overexpression of TDP-43 has also been associated with increased levels of active NF-кB in 
neurons, astrocytes, and microglia from ALS spinal cord tissue111. Interestingly, TDP-43 has been 
shown to directly interact with p65 through its N terminus and RRM1 domain111. This 
interaction mediates activation of p65, causing its translocation to the nucleus111. Thus, TDP-43 
variants that lead to constitutive p65 activity may be responsible for inducing ERVK expression 
in ALS. In addition, overexpression of wild type and ALS-associated TDP-43 mutants in glial cells 
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causes hyperactive innate immune responses against bacterial lipopolysaccharides (LPS), 
significantly increasing TNFα production and microglia-mediated neurotoxicity111. Similarly, in 
the presence of TDP-43 mutants, detection of ERVK-associated molecular patterns by innate 
immune sensors may aggravate the inflammatory response and lead to neuronal damage in 
ALS. Although substantial progress has been made in elucidating the role of TDP-43 dysfunction 
in ALS, the underlying mechanisms by which it mediates neurodegeneration still remain unclear. 
Recently, it was demonstrated that the 25 KDa C-terminal fragment of TDP-43, known as 
TDP-25, leads to increased levels of this protein in the nucleus and the cytosol of neurons from 
transgenic TDP-25 homozygous mice112. TDP-25 aggregation is a consistent feature of ALS112. In 
this study, TDP-25 accumulation associated with severe memory deficits and poor motor 
performance as compared to TDP-25 heterozygous mice. Interestingly, increased TDP-25 levels 
were found to reduce the function of autophagic and proteasomal clearance pathways – 
dysfunction of both of these pathways has been implicated in ALS67. Autophagy and the 
proteasome system are responsible for clearing protein aggregates and pathogens, and 
 
 
FIGURE 8. TDP-43 aggregation, proteasome inhibition, or dysfunction of the autophagy system 
may lead to ERVK transcriptional r e-activation and protein accumulation  in ALS. Artwork by 
M.Manghera.  
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thus may also clear ERVK expression in human cells48. However, in the presence of high TDP-25 
levels, a blockade in protein turnover may lead to ERVK proteinopathy in ALS (Figure 8). Thus, 
not only do TDP-43 variants have the potential to alter ERVK gene transcription, but they may 
also inhibit ERVK protein turnover in the CNS, contributing towards enhanced ERVK activity in 
this disease. 
1.5.3 | The sum of deregulated pathways likely determines the ultimate  
                pathological outcome 
Overall, elevated pro-inflammatory cytokine signaling and simultaneous TDP-43 
dysfunction may cooperate to considerably enhance ERVK expression in ALS. Elevated levels of 
pro-inflammatory cytokines may contribute to enhanced levels of inflammatory transcription 
factors NF-кB and IRF1, which may synergize to promote ERVK re-activation in CNS cells. 
Simultaneously, TDP-43 overexpression may enhance NF-κB binding to the ERVK promoter. 
TDP-43 may itself bind to the ERVK promoter and stimulate ERVK transcription. Alternatively, 
TDP-43 mutations may relieve inhibition of ERVK expression, and thus enhance ERVK protein 
levels. In addition, TDP-43 variants may reduce ERVK protein turnover in cells, thus leading to 
ERVK protein aggregation. Together, the sum of these multiple events likely determines the 
level of ERVK proteinopathy in the CNS.    
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The goal of this article was to write a comprehensive review of ERVK-associated 
neuroinflammatory diseases, with the aim to reconcile the pathologic contribution of ERVK by 
providing evidence of altered molecular regulation of this endogenous retrovirus, detailed 
examples of ERVK-mediated pathological processes, and altered inter-individual differences in 
ERVK genotypes in disparate neurologic diseases.  
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Abstract 
A new appreciation of the microbiome is changing the way we perceive human health and 
disease.  The holobiontic nature of humans is even etched into our DNA in the form of viral 
symbionts.  Empirical evidence for the presence of endogenous retroviruses (ERVs) in the 
human genome and their activity in homeostatic and pathological states has accumulated; 
however, no causal relationship with human disease has been established to date.  In this 
review, we will focus on the role of endogenous retrovirus-K in neurological disease.  
Specifically, we will attempt to reconcile the pathological contribution of ERVK in disparate 
neurological diseases by providing evidence as to inter-individual differences in ERVK 
genotypes, addressing the molecular regulation of ERVK, and providing detailed examples of 
ERVK-mediated processes in nervous system diseases. 
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Sclerosis; Human Immunodeficiency Virus; Prion Disease; Anti-virals 
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Introduction 
The DNA provirus hypothesis – where viral DNA integrates into a host genome – was 
proposed by Nobel laureate Howard M. Temin in the 1960s 1.  Indeed, over 8% of human DNA is 
the result of retrovirus integrations scattered throughout the genome.  Among the 31 lineages 
of endogenous retroviruses (ERVs) within the human genome (which are spread among several 
Retroviridae subfamilies), the betaretrovirus ERVK (alias Human Endogenous Retrovirus-K, 
HERV-K) is the most recently endogenated ERV.  The ERVK (HML-2) clade is estimated to have 
been active as recently as 250,000 years ago 2, and is considered the most transcriptionally 
active ERV.  Several insertions in the human genome are relatively intact, permitting the 
expression of viral RNA and proteins.  Full-length ERVK elements retain a classical retroviral 
genome structure, with core genes gag (group-specific antigen), pr (protease), pol (polymerase) 
and env (envelope) flanked by long terminal repeats (LTRs) 3.  Regulatory proteins within ERVK 
have also been described 4,5.  There is even evidence of ERVK virion production in HIV infection 
6 and lymphoma 7.  Unlike canonical retroviruses, Dube et al. have recently proposed that ERVK 
virions can contain either infectious viral RNA or viral DNA genomes 8, thus changing how ERVK 
expression and replication should be viewed in the context of health and disease pathology.  
 
Genotypic inter-individual differences in ERVK 
There are approximately one thousand ERVK (HML-2) integrations in humans, based on 
the human reference genome.  Of these, all are considered replication-defective, with only 24 
fixed loci retaining the capacity to encode viral proteins from at least one of their genes 3,9.  
However, evidence suggests that this is a fraction of the entire ERVK presence within individual 
human genomes 2,10,11.   
Polymorphic ERVK insertions (unfixed proviruses) have been identified in several cohort 
studies 2,3,9,12,13, with considerable variation between ethnic groups, as well as distinct inter-
individual profiles.  These studies indicate that people carry a distinctive ERVK signature based 
on individual genotypes.  For a given loci, ERV polymorphism can occur as integration of a full-
length ERV (with varying degrees of coding capacity), a solitary LTR, or an unoccupied pre-
integration site 3,9,14.  Recently, Belshaw’s group has performed Next Generation Sequencing on 
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individual human genomes revealing that several unfixed ERVK (HML-2) loci are absent from 
the human reference genome annotation 2.  Moreover, the frequency of unfixed ERVK (HML-2) 
loci varied dramatically in the populations tested 2, further supporting the idea that specific 
ERVK signatures may be associated with inter-individual differences in ERVK expression, 
pathology and disease states. 
Sequence variation, resulting in ERV alleles, may also alter the function of viral proteins.  
For example, the ERVK-18 envelope protein is a superantigen that is encoded by three distinct 
alleles which can alter the amino acid sequence of the protein 15, with predicted but 
uncharacterized biological effects.  Among these three ERVK-18 env alleles, the K18.3 form is 
the minor allele with a frequency of 10.8% within the Caucasian population 15.  The ERVK-18 env 
polymorphism has been shown to be a risk factor for Multiple Sclerosis (MS); homozygous 
carriers of the K18.3 allele had a significantly increased risk of this disease, suggesting that 
ERVK-18 may influence the genetic susceptibility to MS 16,17.  ERVK-18 has also been associated 
with enhanced risk of Type 2 diabetes (T2D) in individuals with schizophrenia (SCZ) 18, with a 
risk haplotype comprised of two single nucleotide polymorphisms (SNPs) in the env region 
(rs558648 and rs1090799).  These results remain controversial, as several cohort studies 
disagree over whether ERVK-18 polymorphisms are risk factors in T2D and SCZ 18,19.  
 
Phenotypic variation in the expression of ERVK 
Current research indicates that not all ERVs remain silent passengers within our 
genomes; re-activation of ERVK is associated with many inflammatory diseases, such as cancers 
7, HIV infection 4, Rheumatoid Arthritis 20, Systemic Lupus Erythematosus 20 as well as 
neurological conditions including Multiple Sclerosis (MS) 21, Schizophrenia (SCZ) 22, Bipolar 
disorder (BD) 22, Amyotrophic Lateral Sclerosis (ALS) 23 and Creutzfeldt-Jakob disease (CJD) 24.  
While there is ubiquitous ERV expression in many tissues, regardless of health or disease, it has 
been shown that individuals largely exhibit distinct ERV expression signatures 22.  A difficulty in 
understanding these individual profiles and their association with disease states is a lack of 
appreciation for the biological control of ERVs.   
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At the molecular level, there is limited experimental evidence to indicate the cellular 
state or signals that are required to control the expression of ERVK.  Accumulating evidence 
points to the importance of epigenetic mechanisms in the control of transposable elements 
including ERVs, and has been reviewed elsewhere 25.  The transcription of ERVK is under the 
control of viral promoters called Long Terminal Repeats (LTRs), which flank either side of the 
provirus. To date, only transcription factors Sp1 26, Sp3 26, YY127, MITF-M28 and steroid hormone 
receptors 29,30 have been experimentally shown to induce ERVK activity in human cells. Our 
group has recently focused on examining the role of pro-inflammatory transcription factors in 
the induction of ERVK expression.  Using bioinformatics, we have revealed that the ERVK 
promoter contains multiple conserved putative binding sites for pro-inflammatory transcription 
factors, including Nuclear Factor Kappa B (NF-κB) and Interferon Response Factors (IRFs) 31.  
Specifically, the viral promoter harbors two conserved Interferon Stimulated Response 
Elements (ISREs) (Figure 1); thus, inflammatory stimuli may modulate ERVK transcription.  We 
have also generated substantial experimental evidence using human neuron and astrocyte in 
vitro models to support this claim (unpublished results).  Thus, ERVK can exploit anti-viral 
immune responses and perhaps certain disease backgrounds, as select transcription factors can 
promote ERVK expression. 
Additional evidence supports the importance of innate immune signaling in ERVK re-
activation, as select anti-viral and pro-inflammatory cytokines can enhance ERVK expression.  
Cytokines, notably Tumor Necrosis Factor α (TNFα) and Interferon γ (IFNγ), play critical roles in 
the pathology of many neurodegenerative diseases including ALS 32,33, SCZ 34, MS 35, and CJD 36.  
TNFα and IFNγ are potent activators of NF-κB and IRF1, respectively, and may thus enhance 
ERVK transcription in these neuroinflammatory diseases (Figure 1). We have recently generated 
evidence in human neuron and astrocyte in vitro models to support this claim (unpublished 
results). TNFα has previously been demonstrated to augment ERVK expression in rheumatoid 
arthritis – another inflammatory disease 37.  TNFα-mediated induction of ERVW env expression, 
following the binding of NF-κB with the ERVW promoter, has also been documented 35.  In 
addition, ERVK-18 expression can be enhanced upon IFNα treatment of peripheral blood 
lymphocytes 15.  Exogenous IFNα drives IRF9 activation and its translocation to the nucleus 
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where it binds to ISREs in target promoters (Figure 1).  These results are consistent with our 
observation that ISREs in the ERVK LTR serve as key promoter elements. The ERVK env may also 
confer a self-regulating capacity, as an immunosuppressive domain in the transmembrane (TM) 
protein alters cytokine release through its immunomodulatory effects 38.  Although 
recombinant ERVK transmembrane protein and ERVK virions induced substantial IL-10 secretion 
in peripheral blood mononuclear cells (PBMCs), reproducible inter-individual differences in the 
IL-10 response were observed 38.  Moreover, notable enhancement of pro-inflammatory 
cytokine expression and impairment of genes involved in innate immunity 38, further suggests 
that the ERVK TM protein will alter the regulation of ERVK, as well as host genes.  Additionally, 
ERVK encoded dUTPase can activate NF-κB and promote pro-inflammatory cytokine secretion39.  
Additional ERV proteins are suspected to influence protein-protein interactions in humans 40.  
Considering that signalling pathways are finely tuned based on the activity of interacting 
proteins, the genetic background of the host will play a significant role in ERVK expression and 
immunomodulation. These findings suggest that ongoing signaling cascades in neuro-
inflammatory disease may trigger ERVK re-activation, thus promoting the expression of viral 
RNA and proteins which may further modulate the pathological status.  
 
Putative protective and pathological roles of ERVK in neurological disease 
 
Amyotrophic Lateral Sclerosis (ALS) 
Retroviruses, such as Human Immunodeficiency Virus (HIV) and Human T-cell Leukemia 
virus (HTLV), have been associated with an increased incidence of ALS-like syndromes 41,42.  
Currently, a single study has demonstrated a direct association between ERVK and ALS 23, 
despite evidence for retroviral pathology stemming from the repeated measurement of reverse 
transcriptase (RT: the retroviral enzyme that transcribes viral RNA into DNA) activity in this 
disease 43-45.  Elevated levels of ERVK pol transcripts (derived from select HML-2 and HML-3 loci) 
are detectable in post-mortem brain tissues of patients with ALS, as compared to tissues from 
Parkinson’s disease, systemic disease and accidental death 23.  Not only was ERVK RNA 
expressed in ALS, immunohistological analysis revealed the presence of RT protein in the 
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cortical neurons of patients with ALS 23.  Clusters of neurons in the prefrontal and motor cortex 
of patients with ALS exhibited the strongest RT expression, coinciding with the affected brain 
areas in this disease.  An earlier report demonstrated that over half of ALS patients examined 
showed serum IgG reactivity against ERVK (HML-2) gag protein 46.  Patients with reactive anti-
HML-2 gag antibodies exhibited a 10-fold reduction of viral RNA in PBMCs, suggesting an 
effective and ongoing immune response against ERVK in these patients with ALS 46.  As 
discussed by Alfahad and Nath 47, these studies open new avenues of investigation into the 
treatment of ALS.  
 
Schizophrenia (SCZ) and bipolar disorder (BD) 
Several studies have documented aberrant expression of ERVs in patients with 
schizophrenia 22,48-53, and to a lesser extent, in patients with bipolar disorder 22,48.  ERVW gene 
expression has been discovered in blood samples 49-51, in cerebrospinal fluid (CSF) 52, and in 
post-mortem brain tissue 52,53 of patients with SCZ, and has been reviewed extensively 
elsewhere 54.  Specifically, only ERVK10 (HML-2) RNA was significantly over-expressed in both 
SCZ and BD compared with healthy post-mortem brain tissue 22.  The ERVK HML-7 clade is also 
significantly over-represented in SCZ compared to BD samples (but not in SCZ compared to 
healthy controls), and under-represented in samples from patients with BD compared to 
healthy-brain samples 22.  A study by Diem et al. further demonstrated that ERVK transcription 
was not affected by treatment with valproic acid (VPA; a medication used to treat SCZ) or any of 
the other medications tested, indicating that previous findings of an association between ERVK 
transcription and SCZ cannot be explained by patient treatment with any of the four 
medications analyzed in this study 55.  To date, this represents limited and loci-specific 
alterations in ERVK expression in these neuropsychiatric diseases. 
It has been postulated that it may not be mutations in genes associated with SCZ that 
result in a disease state, but rather mutations in the regulatory regions of these genes 56.  ERV 
LTRs are known to have promoter, enhancer and regulatory functions 57.  Approximately 50% of 
all human-specific ERVK (hsERVK – HML-2) elements show promoter activity in human tissues 
58. Epigenetic silencing of ERVs by DNA methylation is a known phenomenon, and is thought to 
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be a part of the anti-retroviral defense system 25. Therefore the silencing or down-regulation of 
genes with ERV sequences in their regulatory regions may be the consequence of the host’s 
attempts to stop the expression of these endogenous viruses. 
Recently, a full-length almost intact ERVK (HML-2) sequence that displays strong 
enhancer activity, was identified near the PRODH gene 59.  Mutations in PRODH, which encodes 
a mitochondrial enzyme, have been found to be associated with neuropsychiatric disorders, 
including SCZ 60.  Given this link between PRODH and schizophrenia, Suntsova et al. attempted 
to characterize this ERVK locus (referred to as hsERVPRODH) and its potential enhancer activity 
for PRODH 59. They showed that the enhancer activity of hsERVPRODH is regulated by methylation 
and it acts synergistically with the PRODH internal CpG island to activate the PRODH promoter.  
Transcriptional analysis showed that PRODH displays the highest expression level in the 
hippocampus, where hsERVPRODH is hypo-methylated 59.  The hippocampus is known to be one 
of the structures of the brain that is most affected in SCZ 61; if hyper-methylation of hsERVPRODH 
occurred, aberrant expression of PRODH in the hippocampus would likely result. 
Similarly, an ERVW LTR is located in the regulatory region of the GABA receptor B1 gene 
(GABBR1) 56, a gene located in region associated with risk for SCZ 62.  It is speculated that hyper-
methylation of this ERVW LTR may down-regulate GABBR1 in brains of patients with SCZ 56, 
thus accounting for its altered expression pattern 63,64.  As a result, Hegyi et al. propose that the 
over-expression of ERVs at the onset of disease leads to their subsequent silencing by hyper-
methylation, which may pathologically contribute to diseases such as SCZ 56.  This hypothesis 
also offers an explanation as to why ERVW transcripts are readily found in the CSF of patients 
with recent-onset SCZ, but rarely in chronic patients 49,52,65. It could be that the activation of 
ERVs occurs early in the etiopathology of schizophrenia or during highly symptomatic periods of 
disease, resulting in the up-regulation of some genes for which ERV elements act as promoters 
or enhancers. This may be followed by hyper-methylation of ERV sequences as a defense 
mechanism, leading to down-regulation of ERV-regulated genes. 
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Multiple Sclerosis (MS) 
Among ERVs associated with MS, ERVW has been the most extensively studied.  Many 
studies have reported significant up-regulation of ERVW RNA in brain samples from MS patients 
35,66.  ERVW env protein is highly expressed within astrocytes and microglia in MS plaques, and 
correlates with the extent of inflammation and active demyelination 35,66.  Augmented ERVW 
expression has also been observed in the CSF and blood of MS patients 67,68.  A recent study has 
also shown enhanced ERVW DNA copy number in the PBMCs of women with MS; this 
phenomenon correlated with disease severity scores 68.  In contrast, other studies depict a lack 
of association between enhanced ERVW expression and MS.  Using high-throughput amplicon 
sequencing, Schmitt et al. reported a lack of significant difference in ERVW transcripts between 
MS and control brain tissue samples, despite clear evidence of inter-individual variability 69.  
Similarly, enhanced ERVW expression in the CSF and blood of MS patients could not be 
detected in several studies 70,71.  Thus, a definitive association between ERVW activation and 
MS neuropathology remains to be established.    
Nonetheless, other human endogenous retroviruses, including ERVK, have been 
reported to be up-regulated in MS.  Elevated levels of ERVK RNA have been found in the brain 
tissue from MS patients 72.  As mentioned above, the ERVK-18.3 env allele has been determined 
to be a risk factor for MS. Interestingly, ERVK-18 env superantigen can be transactivated by 
Epstein Barr Virus (EBV) latent membrane protein LMP-2A 73,74, and EBV infection is considered 
to be one of the major risk factors for MS 75. Similarly, ERVW env protein also displays 
superantigenic properties, and can be transactivated by EBV infection of astrocytes in vitro 76.  
Together, these superantigens may promote the non-specific activation of T lymphocytes in the 
CNS, leading to extensive demyelination and neuronal injury 77.  Thus, ERV-derived 
superantigens may contribute to MS immuno-pathogenesis, particularly in the context of EBV 
infection. 
Activation of the host immune system has been implicated as the ultimate effector in 
MS pathogenesis. Re-activation of human endogenous retroviruses in the CNS may play an 
important role in this process, as the immune system may mount an anti-viral response against 
ERV elements in order to eliminate ERV-expressing cells. Anti-retroviral defense mechanisms 
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can be mediated by a variety of innate immune sensors including Pattern Recognition 
Receptors (PRRs) that detect retroviral RNA and proteins.  PRRs, including Tripartite motif 
containing 5 (TRIM5) and Toll like receptor 4 (TLR4), are known to recognize retroviral capsid 
and envelope proteins, respectively; engagement of these sensors with their viral ligands 
activates signaling cascades that stimulate innate immunity 78,79. The role of TRIM5 in detection 
of gag proteins encoded by MS-associated ERVs has not yet been studied. Nonetheless, single 
nucleotide polymorphisms (SNPs) in TRIM5 gene (as well as SNPs in other viral restriction 
factors) have been associated with the risk of MS 80. However, the functional outcomes of these 
SNPs remain unclear. 
Another mechanism by which ERV proteins may trigger MS immunopathology is through 
molecular mimicry. Recently, ERVW env proteins were predicted to share several T and B cell 
epitope regions with myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein 
(MBP) 81. This suggests that ERVW env over-expression in the CNS may break tolerance towards 
host MOG and MBP, generating an autoimmune response against these myelin proteins, which 
can explain extensive demyelination typically observed in MS. However, the cross-reactivity 
between ERVW env and myelin protein epitopes, and the resulting autoimmune reaction, 
needs to be validated experimentally. In addition, whether antigen mimicry is also employed by 
other MS-associated ERVs, such as ERVK, remains to be explored.          
 
HIV infection 
ERVK activity is well-documented in HIV infection 6,82 (reviewed in 4), including the 
nervous system (Douville and Nath, unpublished) 83.  Recently, Bhat et al. have provided 
evidence that enhanced ERVK (HML-2) env protein expression in the brains of HIV infected 
individuals may confer neuroprotective effects 83.  This is based on the observation that 
neuroblastoma cells transfected with an ERVK env expressing construct were protected from 
injury by staurosporine and the HIV-1 Vpr protein, as compared to the control vector alone.  
Moreover, the protection from HIV-1 Vpr toxicity was recapitulated in vpr/RAG1−/− mice which 
were adoptively transferred with neural stem cells expressing ERV-K Env into the striatum; 
these animals exhibited a significant reduction in TNFα expression as compared with controls. 
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Exaptation of ERVK Env may provide neurons a degree of protection in the context of chronic 
neurodegenerative diseases.   
Moreover, cellular cytotoxic responses and antibodies produced against ERVK can prove 
to be detrimental to HIV-infected cells 84,85.  During HIV infection, ERVK env peptides can be a 
target for cytotoxic T cells 84.  NK cells may also destroy HIV-infected cells via an antibody-
dependent cytotoxic mechanism, based on in vitro assays 85.  Additionally, it was observed that 
either the HIV strain or the host were important factors in determining the extent of ERVK env 
induction in HIV-infected cells 85,86, and thus may alter the degree of CNS tissue injury in HIV-
associated neurocognitive disorder (HAND).  
In addition, other ERVK proteins may promote changes in dendritic spine morphology in 
pyramidal neurons.  The ERVK regulatory protein Rec has been shown to interact with the 
mRNA binding protein Staufen-1, causing its accumulation in the nucleus 5.  This interaction 
may alter Staufen-1-mediated mRNA trafficking and turnover, functions that are essential for 
regulation of neuronal synapses during long-term plasticity in learning and memory 87.  The 
interaction with Staufen-1 also favoured Rec-dependent viral RNA transport 5, and thus may 
enhance ERVK protein expression.  Moreover, ERVK and HIV Gag proteins can both 
independently interact with Staufen-1 to enhance their respective production of virions 5,88, as 
well as ERVK Env expression within HIV-1 virions 89.  Together, these studies suggest that ERVK 
expression in the CNS may have both protective and pathological consequences. 
 
Prion Disease 
Prion diseases, such as Creutzfeldt-Jakob disease (CJD) in humans, are a group of rare 
but fatal neurodegenerative disorders.  The causative agent of these diseases is believed to be 
an infectious misfolded cellular protein called a prion protein (PrPSC), which is resistant to 
proteinase degradation and accumulates inside neurons, leading to neuronal toxicity and death 
24,90.  The disease propagates upon transmission of PrPSC to new cells, which further catalyzes 
the conversion of the normal cellular prion protein (PrpC) into its abnormal form; however, the 
mechanisms behind this conversion have not been clearly elucidated. 
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Recently, augmented expression of several ERVs has been observed in the CSF of CJD 
patients 24.  Although the frequency of ERVK transcripts was higher in CJD CSF samples as 
compared to the controls, this result did not reach statistical significance. Nonetheless, the 
increased expression of ERVs in CJD suggests that endogenous retroviruses may contribute to 
the pathogenesis of this prion disease. For instance, ERV viral RNA molecules may elicit the 
transformation of PrPC to PrPSC 90. In support of this hypothesis, small highly structured RNAs 
have been shown to interact with human recombinant PrPC and stimulate its conversion to a 
proteinase resistant isoform 91.  Interestingly, RNA molecules derived from ERVK elements have 
extremely conserved complex secondary structures resembling that of the small highly 
structured RNAs used in these studies 91(Carr and Douville, unpublished). Highly structured 
RNAs derived from HIV-1 have also been shown to interact with the human recombinant PrPC 
and impart proteinase resistance to it in vitro 92. Thus, increased levels of ERVK RNA in the CSF 
of CJD patients have the potential to drive the transformation of the normal human prion 
protein to its infectious misfolded isoform. 
In addition, ERVs may facilitate the spread of pathological prion agents intercellularly by 
recruiting prion proteins to virions as ERVs replicate. In fact, it was recently demonstrated that 
murine PrPSC associates with gag and env proteins on Moloney Murine Leukemia Virus (MMLV) 
particles, and infection with MMLV strongly enhances the extracellular release of murine PrPSC, 
thus augmenting the infectivity of this prion protein 90,93. Similarly, human PrPSC has also been 
shown to be recruited by HIV-1 virions 93. Human endogenous retroviruses, ERVW and ERVK, 
which are capable of producing virions 7,21, may also be able to recruit PrPSC either through 
interactions with surface gag and env proteins or with viral RNA, thereby transmitting prion 
proteins to new cells and facilitating the progression of human prion diseases.     
Moreover, CJD is neuroinflammatory and marked by augmented levels of pro-
inflammatory cytokines, including TNFα 36,94. Mice models of CJD also exhibit increased TNFα, 
as well as NF-κB activity 95.  Recently, the toxic domain of human prion protein has been shown 
to activate NF-κB, and lead to TNFα production in a macrophage cell line 96.  Based on our 
prediction of NF-κB responsive elements in the ERVK promoter 31 (Figure 1), it is possible that 
PrPSC-induced TNFα production and NF-κB activation may enhance ERVK transcription in CJD 
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brains. This may culminate in a positive feedback loop favouring further neuroinflammation, 
ERVK re-activation, and prion infection. 
 
 
Conclusion 
Although ERVK has not been shown to be a causative agent of nervous system disease, 
its expression can clearly influence both protective and pathological aspects of motor neuron, 
neuropsychiatric and neurodegenerative diseases (Table 1).  A common thread among ERVK-
associated disease appears to be the presence of inflammatory signals; but how this retrovirus 
fits into the complex interplay between infection, immunity, autoimmunity and environmental 
exposures is yet to be fully elucidated.  Activation of multiple ERVs may cooperatively stimulate 
a multitude of host anti-retroviral immune responses against ERV-expressing cells; and, ERVs 
may exploit this response, culminating in a positive feedback loop favouring further viral gene 
expression, excessive neuroinflammation, and subsequent neuronal injury and loss.  Moreover, 
it is important to consider that specific ERVK loci can confer select pathological contributions.  
Bulk measurement of ERVs (without consideration of the individual integrations and their 
genomic context) may be an insufficient methodology to address their role in distinct 
neurological diseases.  Examining an individual’s unique complement of ERVs may prove to be a 
better predictor of disease risk, once further inroads are made in understanding the protective 
and pathological roles of each integrated provirus.  It will be important for future studies to 
expand how we measure ERVK activity in the CNS; improved screening for ERVK expression in 
specific cell types, CNS regions and disease stages, as well as an expansion towards single-loci 
ERVK measurements will broaden our current knowledge in this area.  Current studies are 
limited by the availability of commercial ERV-specific reagents for molecular biology and the 
expense of high-throughput screening techniques – a possible solution for our field would be 
the development of an ERV resource bank, as has been accomplished with the NIH AIDS 
Reagent Program.    
Another benefit of ERV research in the context of nervous system disease is the 
possibility of improved therapeutics.  For example, patients with schizophrenia and bipolar 
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disorder are treated with a range of chemotherapeutics including antipsychotics and lithium. 
Lithium is protective against HIV neurotoxicity, and HIV patients treated with this medication 
show cognitive improvements 97. Clozapine is an antipsychotic drug, which actually inhibits HIV 
replication in vitro 98.  Since both of these drugs interact with exogenous retroviruses, it is 
possible that they may have some effect on ERVs as well.  In support of this notion, there is 
epidemiologic evidence that incidence of ALS is extremely rare among individuals with SCZ 
(much lower than predicted for the general population) 99.  Common medications for SCZ may 
convey prophylactic neuro-protection, inhibiting the development of ALS 99.  There is some 
evidence that medications routinely prescribed to schizophrenics may stop inflammation and 
support neuronal survival 100.  Abating inflammation may also decrease the expression of ERVK, 
which is up-regulated by inflammatory transcription factors 31.  With improved biomarkers for 
neurological disease risk, the use of currently vetted SCZ medications may be repurposed for 
the prevention or delay of ERVK-associated nervous system diseases. 
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Figure 1. Pro-inflammatory signaling cascades and the associated transcription factors that 
may stimulate ERVK gene expression in multiple neurodegenerative diseases. TNFα, IFNγ and 
IFNα signaling leads to the phosphorylation (P) and activation of NF-κB (isoforms p50 and p65), 
IRF1, and IRF9, respectively. These pro-inflammatory transcription factors then translocate to 
the nucleus, where they bind their respective sites in the target promoters. The ERVK promoter 
(5ʹ LTR) contains multiple conserved putative NF-κB binding sites, as well as two Interferon 
Stimulated Response Elements (ISREs) that bind IRFs including IRF1 and IRF9 31. Binding of 
nuclear NF-κB, IRF1, and/or IRF9 to the ERVK promoter may induce the expression of 
downstream proviral genes – gag (group specific antigen), pr (protease), pol (polymerase), and 
env (envelope).          
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Table 1: Summary of potential mechanisms of ERVK protection and pathogenesis in 
neurodegenerative diseases 
 
Neurological Disease 
 
Putative mechanisms of protection or pathogenesis 
 
Amyotrophic Lateral Sclerosis 
(ALS) 
 
ERVK RNA and proteins may stimulate a pro-inflammatory immune 
response against ERVK-expressing neurons 23, leading to neuronal 
injury and loss. ERVK may also exploit this inflammatory response 31, 
thus establishing a cycle of ERVK re-activation and excessive 
inflammation.  
Schizophrenia (SCZ) and 
Bipolar Disorder (BD) 
ERVK LTR sequences and Env protein may act as regulatory elements 
for genes associated with SCZ and BD 56,59.  Upon detection of ERVK 
over-expression (brought on by infection or inflammation), 
methylation of ERVK sequences may decrease the subsequent 
expression of SCZ and BD associated genes (necessary for normal 
neurological function), leading to a diseased state.   
 
 
Multiple Sclerosis  
(MS) 
 
 
ERVK-encoded superantigens may exacerbate neuroinflammation 
73,77, and thus lead to demyelination. Recognition of ERVK RNA and 
proteins by innate immune sensors may generate an anti-retroviral 
response against ERVK-expressing cells in the CNS 78,79, thus causing 
neuronal injury and loss. ERVK env may mimic myelin proteins, 
which may produce an autoimmune response and contribute to 
demyelination 81. 
 
HIV infection 
 
ERVK Env protein may confer protection against HIV-1 Vpr-induced 
toxicity 83.  Humoral and cytotoxic immune responses targeted at 
ERVK antigens may promote the killing of HIV-infected cells 84,85.  
ERVK Rec protein may promote changes in neuronal dendritic spine 
morphology by interacting with Staufen-1 5. 
 
Creutzfeldt-Jakob Disease 
(CJD) 
ERVK RNA may stimulate conversion of normal proteins to 
pathogenic prion proteins 91. ERVK virions may recruit and facilitate 
intercellular transmission of prion agents 92. ERVK RNA and proteins 
may exacerbate neuroinflammation. 
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2.  HYPOTHESES AND OBJECTIVES 
The first aim of this study was to elucidate the influence of augmented levels of pro-
inflammatory cytokines on ERVK re-activation in CNS cells. I hypothesized that pro-
inflammatory cytokines will enhance ERVK transcription and protein levels by facilitating NF-
κB and/or IRF1 interactions with the ERVK promoter in astrocytes and neurons. 
To test this premise, we derived the following experimental objectives: 
1) Determine whether TNFα, LIGHT, and IFNγ enhance ERVK transcription and 
polyprotein/RT levels in a dose-dependent manner. 
2) Evaluate the interactions of NF-κB and IRF1 at the ISREs on the ERVK promoter in 
untreated and cytokine-stimulated cells. 
3) To validate the in vitro findings, determine if the brain tissue from ALS patients 
exhibits increased levels of NF-κB and IRF1 in ERVK positive cells. 
Another key goal of this study was to evaluate the influence of wild-type and ALS-associated C-
terminal truncated forms of TDP-43, as well as TDP-43 turnover, on ERVK transcription and 
protein levels. We also aimed to determine whether TDP-43 is able to interact with the ERVK 
promoter, and how truncated TDP-43 fragments alter this interaction. I hypothesized that wild 
type and truncated TDP-43 fragments will modulate ERVK transcription and protein 
accumulation in astrocytes and neurons by altering TDP-43 binding to the ERVK promoter. I 
also hypothesized that decreased TDP-43 turnover will enhance ERVK transcription and ERVK 
proteinopathy in astrocytes and neurons.  
To test this premise, we derived the following experimental objectives: 
1) Determine whether overexpression and aggregation of wild-type and truncated TDP-
43 forms enhances ERVK transcription and polyprotein/RT levels. 
2) Determine whether proteasomal inhibition, and thus decreased TDP-43 turnover, 
increases ERVK transcription and polyprotein/RT aggregation.   
3) Evaluate the interactions of TDP-43 with the ERVK promoter under normal 
conditions, as well as during proteasomal blockade and in the presence of truncated 
TDP-43 fragments. 
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The goal of this study was to elucidate the influence of IFNγ on ERVK transcription, polyprotein 
cleavage, as well as RT expression and enzymatic activity in astrocytes and neurons. This is the 
first report to establish that inflammatory conditions, such as IFNγ exposure, markedly induce 
ERVK expression in CNS cells. We are the first to characterize sequential ERVK gag-pro-pol 
polyprotein cleavage, culminating in the production of active ERVK RT subunits in human 
astrocytic and neuronal cell lines, under inflammatory conditions. This study has also revealed 
distinct patterns of cytosolic, nuclear, and perinuclear ERVK polyprotein/RT localization in IFNγ-
stimulated cells. Overall, we have established new in-vitro models of inducible ERVK expression, 
which will serve as useful tools in exploring ERVK biology in the context of neuroinflammatory 
diseases. 
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Abstract: Enhanced expression of the reverse transcriptase (RT) protein encoded by human 
endogenous retrovirus-K (ERVK) is a promising biomarker for several inflammatory and 
neurological diseases. However, unlike RT enzymes encoded by exogenous retroviruses, little 
work has been done to identify ERVK RT isoforms, their expression patterns, and cellular 
localization. Using Western blot, we showcase the ERVK gag-pro-pol polyprotein processing 
leading to the production of several ERVK RT isoforms in human neuronal (ReNcell CX) and 
astrocytic (SVGA) models of neuroinflammatory disease. Since the pro-inflammatory cytokine 
IFNγ plays a key role in the pathology of several ERVK-associated neurological diseases, we 
sought to determine if IFNγ can drive ERVK RT expression. IFNγ signalling markedly enhanced ERVK 
polyprotein and RT expression in both human astrocytes and neurons. RT isoforms were 
expressed in a cell-type specific pattern and the RT-RNase H form was significantly increased 
with IFNγ treatment. Fluorescent imaging revealed distinct cytoplasmic, perinuclear and nuclear 
ERVK RT staining patterns upon IFNγ stimulation of astrocytes and neurons. These findings 
indicate that ERVK expression is inducible under inflammatory conditions such as IFNγ 
exposure—and thus, these newly established in vitro models may be useful in exploring ERVK 
biology in the context of neuroinflammatory disease. 
OPEN ACCESS 
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1. Introduction 
Reverse transcriptase (RT) is the signature protein of retroviruses; however, for 
endogenous retrovirus-K (ERVK; alias HERV-K) there is limited knowledge regarding its RT 
isoforms, expression patterns and cellular localization in human health and disease. Despite 
evidence of enhanced ERV expression (ERVW, ERVH, ERVK, etc.) associated with several 
inflammatory and neurological diseases [1–7], few studies have sought to specifically examine 
ERVK polymerase (pol) gene and RT protein expression [8–11]. Elevated levels of ERVK RT have 
been observed in the cortical neurons of patients with Amyotrophic Lateral Sclerosis (ALS) [8]. 
This observation is consistent with the measurement of RT activity in the CSF and serum of 
individuals with ALS, at levels similar to those found in Human Immunodeficiency Virus (HIV) 
positive individuals [12]. ERVK RT is emerging as a promising prognostic biomarker in breast 
cancer [13]. Clearly, improved detection assays for ERVK RT expression are likely to be useful in 
other ERVK-associated diseases, including cancers [13], HIV infection [14,15], ALS [8], 
schizophrenia [16], rheumatic disease [17] and human prion disease [18]. Despite no known 
causal relationship between ERVK and human disease, pathological contributions of ERVK 
proteins continue to shape our understanding of complex disease processes [1,15,19–21]. 
ERVK (HML-2) encodes a reverse transcriptase enzyme with RNase H activity of 
approximately 65 kDa [22]. It is currently unclear if the active form of ERVK RT acts as a 
heterodimer—one monomer with an RNase H domain and the other without—as seen with 
other RT enzymes [23]. As with typical RT proteins, this enzyme contains a conserved LPQG 
motif and the catalytic YIDD motif [22]. The expression of ERVK RT is dependent on protease 
processing of the Gag-Pro-Pol polyprotein. Protease cleavage of the ERVK Gag precursor has 
recently been examined using recombinant constructs [24,25]; however, there is little known 
regarding the proteolytic processing of the entire Gag-Pro-Pol polyprotein in situ. 
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ERVK expression often occurs in diseases with inflammatory underpinnings. For 
example, ERVK is concomitantly expressed during HIV infection, both in the periphery and the 
central nervous system [15,26]. ERVK-specific T cells have been shown to secrete IFNγ in 
response to their cognate ligands [27,28]. Enhanced IFNγ levels in the brains of HIV-infected 
individuals [29], are believed to contribute to HIV-associated neuropathology [30]. Indeed, IFNγ 
has been shown to enhance HIV replication in astrocytes [31,32]. Therefore, we sought to 
stimulate human astrocyte and neuronal cell cultures with IFNγ, as a potential mechanism to 
drive ERVK RT expression.  
2. Materials and Methods 
2.1. Cell Culture and Cytokine Treatment 
The SVGA cell line [33] (gifted by Dr. Avindra Nath, NIH) is derived from immortalized 
human foetal astrocytes, and was maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% Fetal Bovine Serum and 1% Penicillin/Streptomycin (HyClone, South 
Logan, UT, USA). ReNcell CX cells [34] (Millipore, Temecula, CA, USA) are immortalized human 
neural progenitor cells (HNPCs), and were maintained in a proprietary ReNcell neural stem cell 
medium (Millipore) supplemented with 20 ng/mL human epidermal growth factor (EGF; 
Peprotech, Rocky Hill, NJ, USA), 20 ng/mL human basic fibroblast growth factor (bFGF; 
Peprotech), and 1% Penicillin/Streptomycin. All cell lines were maintained in a humidified 
chamber containing 5% CO2 at 37 °C. 
SVGA cells were seeded into six-well plates and onto glass coverslips in twelve-well plates 
at a density of 300,000 cells/mL and 30,000 cells/mL, respectively, and grown for 24 h. To 
differentiate HNPCs into neurons, ReNcells were seeded in laminin (20 μg/mL; Millipore) coated 
six-well plates at a density of 50,000 cells/mL for 24 h. Adhered cells were rinsed with 1X PBS 
and allowed to differentiate in the presence of ReNcell medium lacking EGF and bFGF for two 
weeks. SVGAs and neurons were treated with 0.1, 0.5, 1, and 5 ng/mL doses of human IFNγ 
(PeproTech) for 24 h. Plated untreated cells were used as negative controls. 
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2.2. Quantitative Polymerase Chain Reaction (Q-PCR) 
Total RNA was extracted and purified from cells using an Aurum Total RNA Mini Kit (Bio-
Rad, Hercules, CA, USA). RNA concentration was measured with a NanoDrop 
spectrophotometer. The acceptable RNA purity was A260/A280 > 2.0. The iScript Reverse 
Transcription kit (Bio-Rad) was used to synthesize cDNA from extracted RNA. CFX Connect Real 
Time System (Bio-Rad) was employed to perform Q-PCR in order to measure alterations in ERVK 
gag and pol transcripts using SYBR Green detection method. The primers used to amplify ERVK 
gag were F: 5' TCGGGAAACGAGCAAAGG 3' and R: 5' GAATTGGGAATGCCCCAGTT 3', and for 
ERVK pol were F: 5' TGATCCCMAAAGAYTGGCCTT 3' and R: 5' TTAAGCATTCCCTGAGGYAACA 3'. 
18S rRNA was used as the endogenous control (Ambion kit #1718, Carlsbad, CA, USA). The data 
was analysed using the ΔΔCT (Livak) method. GraphPad Prism [51] was used to carry out 
statistical analyses including column statistics, One-way Anova Friedman test, and Dunn’s post-
test. 
2.3. Reverse Transcriptase (RT) Assay 
The activity of reverse transcriptase (RT) in protein fractions isolated from cells was 
measured using an EnzChek Reverse Transcriptase Assay Kit (Molecular Probes, Carlsbad, CA, 
USA), as per manufacturer’s instructions. Soluble and insoluble protein fractions were prepared 
at a fixed protein concentration, and pooled at a 1:1 ratio to perform each reaction. MMLV RT 
standards (Bio-Rad) were also run over a 4-log10 dilution series, and used to construct the 
standard curve. RT activity was quantitated by measuring the end point fluorescence of each 
reaction using CFX Connect Real Time System (Bio-Rad) and compared to that of the standard 
curve. GraphPad Prism [51] was used to carry out statistical analyses including column 
statistics, One-way Anova Friedman test, and Dunn’s post-test. 
2.4. Western Blotting 
Cells were lysed on ice with 50 μL of in-house lysis buffer (0.05 M Tris (pH 7.4), 0.15 M NaCl, 
0.002 M EDTA, 10% glycerol and 1% NP-40 in ultra-pure water) to extract the soluble proteins, 
followed by extraction of insoluble proteins in 50 μL of RIPA buffer (10% 1X TBS, 1% SDS, 1% 
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NP-40 and 0.5% DOC in ultra-pure water). Both buffers were supplemented with 1x HALT 
protease and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL, USA). BCA assay 
(Thermo Scientific) was used to determine the protein content of each sample as per 
manufacturer’s instructions. Cell lysates were prepared for SDS-PAGE and heated at 95 °C for 10 
min. Proteins (15 μg per lane) were separated by SDS-PAGE using a 10% polyacrylamide gel, and 
transferred onto a nitrocellulose membrane. The membrane was blocked in 5% skim milk 
solution for one hour and probed with mouse anti-human ERVK2 RT primary antibody (1:1000 
dilution; Abnova, Jhongli City, Taiwan, ROC) overnight at 4 °C, followed by incubation at room 
temperature for 3 h. The membrane was then probed with horseradish peroxidase-conjugated 
goat anti-mouse IgG secondary antibody (1:5000 dilution; Bio-Rad) for 2 h at room 
temperature. β-actin was detected using mouse anti-human β-actin primary (1:5000 dilution; 
Thermo Scientific) and goat anti-mouse secondary antibodies, and was used as the loading 
control. The membrane was developed with 2 mL of Luminata Crescendo Western HRP 
substrate (Millipore) and imaged using Bio-Rad ChemiDoc XRS+ chemiluminescent imager. 
Image Lab software [52] was used to determine the molecular weight of each band, as well as 
their density relative to that of the negative control. The identity of each band was predicted 
based on the molecular weight of each ERVK protein [35] and informed by the gag-pro-pol 
processing pattern of HIV [36,37], including HIV protein post-translational modifications [38]. 
2.5. Fluorescent Imaging 
Cells were fixed with methanol (Fisher Scientific, Fair Lawn, NJ, USA) for 1 min and 
rinsed with 1× PBS. Cells were permeabilised with 250 μL of PBS-T (PBS with 0.25% TritonX-100) 
and blocked with 250 μL of 3% BSA in TBS-T (TBS with 0.25% TritonX-100) for 30 min. Cells were 
incubated in primary antibodies (1:200 dilution) for one hour, followed by incubation in 
appropriate fluorophore-conjugated secondary antibodies (1:1500 dilution) for one hour. Mouse 
anti-human ERVK2 RT and rabbit anti-human α-tubulin (Abnova) were used as primary 
antibodies. Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes) and Alexa Fluor 594 goat 
anti-rabbit IgG (Molecular Probes) were the secondary antibodies. Nuclei were counter-stained 
with DAPI (1:50,000 dilution; Molecular Probes). Controls were prepared by immunostaining 
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without the primary antibodies. Coverslips with stained SVGAs were mounted onto slides using 
ProLong Gold anti-fade reagent (Molecular Probes). Confocal 2D images and 3-plane view 
images were acquired using an Olympus Fluoview FV1200 confocal microscope with the FV10-
ASW4.0 software suite. Six-well plates with stained neurons were imaged using an EVOS FL Cell 
Imaging System (Life Technologies, Carlsbad, CA, USA).  
3. Results and Discussion 
Augmented IFNγ signalling is a hallmark of several neurological diseases including ALS 
[39] and HIV-associated neuropathology [30]. Both exogenous (HIV) and endogenous (ERVW) 
retrovirus expression can be enhanced by IFNγ stimulation [7,31,32,40]. IFNγ is a potent 
activator of pro-inflammatory transcription factors Interferon Response Factor 1 (IRF1) and 
Nuclear Factor-kappa B (NF-κB), and can enhance HIV gene expression through interaction of 
these transcription factors with the HIV promoter [31,32,41]. Similarly, we have recently shown 
that the ERVK promoter also harbours multiple conserved putative binding sites for IRF1 and 
NF-κB [42], suggesting that IFNγ signalling may also enhance ERVK transcription and protein 
levels. In support of this evidence, Figure 1A shows that indeed ERVK transcription is enhanced 
upon IFNγ treatment of human astrocytes, perhaps through increased binding of NF-κB and 
IRF1 with the ERVK promoter. The levels of the ERVK gag-pol transcript were assessed by Q-PCR 
using gag and pol-specific primers. IFNγ treatment significantly enhanced ERVK transcription in 
a dose-dependent manner (5 ng/mL IFNγ, p < 0.05). In order to determine whether this 
transcriptional increase in ERVK expression was correlated with evidence of functional viral 
proteins, we also assessed overall RT activity in this model. Basal RT activity was observed in 
untreated SVGA cells; however, upon IFNγ treatment RT activity substantially increased (Figure 1B; 
5 ng/mL IFNγ, p < 0.05). This method is unable to identify the viral source of the RT activity; 
therefore, we employed an ERVK RT-specific antibody to address whether ERVK polyprotein 
processing occurred, producing active RT isoforms, under inflammatory conditions. Figure 1C 
demonstrates that IFNγ is capable of enhancing ERVK polyprotein (gag-pro-pol, 180 kDa) and RT 
(60 and 52 kDa forms) expression in astrocytes.  
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Similar to HIV polyprotein processing [36,37], multiple protease cleavage steps produce 
intermediate protein products, before each RT isoform is released from the polyprotein. Active RT 
enzymes are generally heterodimers comprised of a large catalytic RT isoform containing an 
RNase H domain and a smaller RT isoform without the RNase H domain, which plays a 
structural role [38,43,44]. Figure 1C shows the formation of two different sized ERVK RT 
isoforms. The short ERVK RT form of 52/54 kDa is expressed at basal levels in astrocytes, and dose-
dependently increases with IFNγ treatment (Table 1), with an optimal stimulating dose of 0.5 
ng/mL of IFNγ. Of note, ERVK RT bands appear as doublets, suggesting that they may be post-
translationally modified, as seen with HIV-1 RT phosphorylation [38]. The 60 kDa ERVK RT-
RNaseH isoform is expressed only upon IFNγ stimulation, suggesting that RT activity may 
optimally occur under inflammatory conditions, such as low-level chronic IFNγ exposure. 
Additionally, the appearance of active and structural ERVK RT isoforms leads us to propose that 
ERVK may be a cellular source of RT activity in inflammatory disease. Figure 1D demonstrates 
that the majority of the ERVK polyprotein (pro-pol form) is found in the insoluble fraction of the 
SVGA whole cell lysate, whereas the RT proteins were found within the soluble cytoplasmic 
fraction. 
The anti-ERVK RT antibody was also used to perform fluorescent immunocytochemistry 
on SVGA cells. Based on the Western blot data from Figure 1, we expect that the ERVK RT 
staining pattern represents the sum of intracellular polyprotein and RT isoforms. IFNγ-mediated 
ERVK RT expression was observed in the cytoplasm, with a non-uniform distribution (Figure 2A). 
ERVK proteins may act similarly to HIV, whereby the large subunit of RT or the polyprotein can 
interact with β-actin [46]. RT-actin interactions are known to be a fundamental and dynamic 
process in reverse transcription and localization of reverse transcription complexes (RTCs) [47]. 
ERVK RT expression also accumulated around the nucleus (Figure 2 A,B), as observed with HIV-1 
RTCs [48]. The formation of a perinuclear ring with a large RT protein aggregate proximal to the 
nucleus occurs concurrently with cellular swelling. Nuclear ERVK RT expression exhibited a 
speckled pattern (Figure 2B), and may reflect nuclear import of RTCs [48]. 
In ALS [8] and HIV infection [15], ERVK expression occurs in cortical neurons. We have 
employed ReNcell CX neural progenitor cell line [34] as a means to study ERVK expression in 
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human neurons. Figure 3A demonstrates that these progenitor cells exhibit enhanced ERVK 
polyprotein expression; however, differentiation of these neural progenitor cells through 
growth factor deprivation substantially reduces ERVK pro-pol polyprotein levels (>10-fold 
decrease) and promotes the expression of RT (10-fold increase) in the soluble fraction. ERVK RT 
isoforms in ReNcell cultures exhibited increased mass as compared to SVGAs (RT-RH 68 kDa 
versus 60 kDa and RT 56/58 kDa versus 52/54 kDa, Figure 3 versus Figure 1, respectively), and 
may represent cell-type specific post-translational modification of RT [38]. For example, HIV RT 
is phosphorylated at several sites [49], suggesting that our data also may depict several 
phosphorylated forms of ERVK RT. The cell-type specific differences in RT isoform mass may be 
related to differential capacity for phosphorylation patterns in neurons versus astrocytes [50]. 
Treatment of these neuronal cultures with IFNγ also enhances the expression of the 180 kDa 
ERVK polyprotein and 56 kDa RT from that of basal levels (2.6 fold and 2.4 fold, respectively) 
(Figure 3B). Figure 3C shows that within the differentiated ReNcell culture, IFNγ treatment 
promotes ERVK RT expression in neuronal cells, but not glial cells. Basal ERVK RT expression was 
evident in untreated neurons; however, ERVK RT expression was markedly enhanced in the cell 
body of IFNγ-treated neurons. This model of enhanced ERVK RT in the neuronal cell body is 
consistent with the immunoreactive staining pattern observed in the cortical brain tissue of 
patients with ALS [8]. 
 
For the first time, we show that the pro-inflammatory cytokine IFNγ can enhance ERVK 
polyprotein expression and promote its cleavage into heterodimeric RT isoforms. These 
working in vitro models of RT expression in astrocytes and neurons will permit the further 
examination of ERVK biology in the context of inflammatory neurological disease. 
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Figure 1. ERVK polyprotein and reverse transcriptase expression is inducible in  
IFNγ-treated astrocytes. The SVGA cell line was treated with increasing doses (0 to 5 ng/mL) of the 
cytokine IFNγ for 24 h. (A) IFNγ treatment enhances ERVK transcription, as measured by Q-PCR 
using gag and pol-specific primers (n = 5). * = p < 0.05; (B) IFNγ stimulation of astrocytes 
promotes elevated cellular RT activity (n = 4); * = p < 0.05 (C) Representative Western blot 
depicts proteins detected by a commercial anti-ERVK reverse transcriptase antibody (AbNova) 
or an anti-β-actin antibody control. IFNγ exposure enhances ERVK gag-pro-pol polyprotein (180 
kDa), as well as several protease-cleaved forms of this viral polyprotein (n = 4). The two 
expected heterodimeric forms [44] of the ERVK RT are present in IFNγ-treated astrocytes; a 60 
kDa form with an RNase H (RH) domain and a 52/54 kDa form without the RNase H domain. 
Several bands appear as doublets, such as the 52/54 kDa RT band, and likely represent post-
translational protein modifications [38]. Short forms of the ERVK RT (41 and 34 kDa bands) may 
be truncated forms or represent instability and degradation of the RT protein [45]; (D) In both 
untreated and IFNγ-stimulated SVGA cells, the majority of the pro-pol polyprotein exists in an 
insoluble form within cells (n = 3). In contrast, the RT isoforms are concentrated in the soluble 
cytoplasmic fraction of the cell. 
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Figure 2. IFNγ enhances ERVK RT expression in human astrocytes. The SVGA cell line was 
treated with 5 ng/mL of IFNγ for 24 h. Cells were immunostained using a commercial anti-ERVK 
reverse transcriptase primary antibody (Abnova) and fluorescently-labelled secondary antibody. 
Nuclei were stained with DAPI. Images were acquired using an Olympus FV1200 laser scanning 
confocal microscope. (A) Representative micrographs show basal ERVK RT staining in untreated 
astrocytes, while IFNγ-stimulated cells exhibit a substantial increase in ERVK RT staining as 
compared to the control. Magnification 200X; (B) Untreated and IFNγ treated astrocytes were 
evaluated using a 9 μm Z-stack (0.5 μm steps) which depicts ERVK RT expression throughout the 
entire cell. 3D projections (X, Y and Z planes of crosshair sections) confirm enhanced cytoplasmic, 
perinuclear and nuclear (arrows) ERVK RT staining in IFNγ treated astrocytes. Accumulation of 
ERVK RT in IFNγ treated cells is associated with cellular swelling (asterisk). Magnification 600X.  
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Figure 3. IFNγ enhances ERVK polyprotein and RT expression in human neurons. 
Representative Western blots depict proteins detected by a commercial anti-ERVK reverse 
transcriptase antibody (Abnova) and an anti-β-actin antibody control. (A) Soluble and insoluble cell 
fractions of ReNcell CX progenitors and ReNcell CX neurons differentiated by growth factor 
withdrawal. Differentiated neurons express enhanced ERVK gag-pro-pol polyprotein (180 kDa), 
RT-RH (68 kDa) and RT (56/58 kDa) isoforms as compared to ReNcell progenitors (n = 2); (B) 
ReNcell CX-derived neurons were treated with 5 ng/mL IFNγ for 24 h (n = 1). IFNγ exposure 
enhances ERVK gag-pro-pol polyprotein (180 kDa), as well as RT levels in soluble whole cell 
lysates; (C) ReNcell CX-derived neurons were treated with 5 ng/mL IFNγ for 24 h (n = 3). Cells 
were immunostained using anti-ERVK reverse transcriptase primary antibody (Abnova), anti α-
tubulin primary antibody (Abnova), and fluorescently-labelled secondary antibodies. Nuclei 
were stained with DAPI. Images were acquired using an EVOS FL microscope. Representative 
micrographs show basal ERVK RT staining in untreated neurons (asterisk) and glial cells, while 
IFNγ-stimulated neurons (but not glia) exhibit a substantial increase in ERVK RT staining in the 
cell body as compared to the control. Images acquired using a 40X objective. 
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Table 1. Fold change in ERVK polyprotein and RT band intensity normalized to β-
actin loading control for Western blot in Figure 1A. 
 
Band size 
(kDa) 
IFNγ dose (ng/ml) 
0 0.1 0.5 1 5 
180 1.0 0.7 2.6 2.6 2.6 
125 1.0 1.1 1.9 1.5 3.0 
100 1.0 1.1 2.4 1.8 2.0 
85 1.0 2.0 3.9 3.5 4.2 
72 1.0 1.8 2.7 2.4 2.6 
60 1.0 1.9 2.8 1.7 2.0 
54 1.0 1.2 1.5 1.1 1.2 
52 1.0 1.8 2.5 1.8 2.1 
41 1.0 1.4 2.2 2.4 2.8 
34 1.0 1.1 1.6 1.4 1.2 
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The goal of this study was to elucidate the influence of TNFα and LIGHT cytokines on ERVK 
transcription and polyprotein/RT expression in CNS cells. This is the first report to establish that 
TNFα and LIGHT can markedly induce ERVK expression in neurons and astrocytes, respectively, 
which correlates with increased levels of IRF1 and NF-κB transcription factors in these cells. For 
the first time, we have determined that TNFα and LIGHT enhance IRF1 and NF-κB p65/p50 
binding to the two Interferon Stimulated Response Elements (ISREs) in the ERVK 5ʹ LTR. We 
have also validated increased IRF1 and NF-κB expression in ERVK+ neurons in autopsy ALS brain 
tissue in comparison to neuro-normal controls. This study has revealed that ERVK re-activation 
in ALS probably stems from augmented levels of TNFα and LIGHT in the CNS – findings with 
significant implications for anti-inflammatory and anti-retroviral ALS therapeutics. 
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ABSTRACT 
 
Within the human genome reside thousands of endogenous retrovirus (ERV), viral fossils of 
ancient germ-line infections.  Evidence of ERV activity has been widely observed in health and 
disease.  Most often cited as a bystander effect of cell culture or disease states, it is unclear as 
to which signals control ERV transcription and whether their expression is relevant in cellular 
processes.  We have previously proposed that the viral promoter of endogenous retrovirus-K 
(ERVK) is responsive to inflammatory transcription factors.  Now, we have experimental 
evidence to show that the likely reason ERVK is upregulated in cancer, inflammatory, infectious 
and neurological diseases is because of functional interferon-stimulated response elements in 
the viral promoter.  To demonstrate that IRF1 and NF-κB isoforms drive ERVK expression, we 
employed over-expression assays which revealed independent and synergistic up-regulation of 
ERVK.  Through TNFα and LIGHT cytokine treatments of human astrocytes and neurons, we 
show that transcriptional enhancement (Q-PCR) is mediated by IRF1 and NF-κB binding to the 
ERVK promoter (ChIP), and that functional ERVK viral proteins are produced (Western blot and 
microscopy).  We further show that in ALS brain tissue, neuronal ERVK re-activation is 
associated with the nuclear translocation of IRF1 and NF-κB.  These findings present cell-type 
specific signaling mechanisms behind ERVK reactivation in ALS, which extends to the 
pathobiology of other ERVK-associated inflammatory diseases.  
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INTRODUCTION 
 
Within the human genome reside thousands of endogenous retroviruses (ERV), viral 
fossils of ancient germ-line infections.  Evidence of ERV activity has been widely observed health 
and disease.  Most often cited as a bystander effect of cell culture or disease states, it is unclear 
as to which signals control ERV transcription and whether their expression is relevant in cellular 
processes.  We have previously proposed that the viral promoter of endogenous retrovirus-K 
(ERVK) is responsive to inflammatory transcription factors [1], due to the presence of two 
conserved interferon-stimulated response elements (ISREs).   
The transcription of integrated retroviral sequences within the human genome is 
regulated by viral promoters called Long Terminal Repeats (LTRs) flanking either side of the core 
viral genome.  These LTRs contain transcriptional regulatory elements that are responsive to 
both viral and cellular transcription factors (TFs).  Interferon regulatory factors (IRFs) and 
nuclear factor kappa B (NF-кB) have been shown to be crucial in the transcription of Human 
Immunodeficiency Virus (HIV) proviruses [2,3], thus promoting HIV replication in the context of 
inflammation [4].  The human genome is already populated with numerous ERVK viral 
promoters containing IRF and NF-κB binding sites [1], however it remains unclear as to their 
propensity to drive ERVK transcription and expression. 
In support of this paradigm for ERVK re-activation, pro-inflammatory cytokines have 
previously been shown to trigger viral expression in several ERVK-associated inflammatory 
diseases. For instance, TNFα treatment has been demonstrated to enhance ERVK (HML-2) gag 
transcription in synoviocytes obtained from patients with rheumatoid arthritis [5]. TNFα and 
IFNγ are able to enhance ERVW expression in peripheral blood mononuclear cells (PBMCs) 
obtained from patients with Multiple Sclerosis [6]. TNFα has been shown to trigger ERVW 
syncytin protein expression by enhancing the binding of NF-κB subunit p65 to the ERVW 
promoter in a human astrocytic cell line [7]. Nonetheless, how pro-inflammatory cytokines 
trigger ERVK expression in human cells, particularly in the central nervous system (CNS), 
remains to be studied.   
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ERVK expression is strongly enhanced in the neurodegenerative disease amyotrophic 
lateral sclerosis (ALS) [8].  Parallel to immune cell activation and infiltration, significantly higher 
levels of pro-inflammatory mediators called cytokines have been reported in the cerebrospinal 
fluid (CSF) and sera of ALS patients as compared to healthy controls [9-11]. These include 
cytokines belonging to the Tumor Necrosis Factor superfamily. The pathogenic role of Tumor 
Necrosis Factor alpha (TNFα) in ALS is well documented and reviewed elsewhere [12,13].  In 
contrast, few studies have explored the contribution of LIGHT (homologous to lymphotoxin, 
exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry 
mediator, a receptor expressed by T lymphocytes) in ALS [14-16]. Reactive microglia, astrocytes, 
and T cells are the major sources of these pro-inflammatory cytokines in the ALS brain 
[10,17,18]. 
There is growing recognition that TNFα and LIGHT play critical, yet divergent, roles in ALS 
neuropathology.  Both cytokines are neurotoxic and have been associated with enhanced 
neuronal death. TNFα is a potent activator of the canonical nuclear factor kappa B (NF-кB) 
signaling pathway, culminating in the activation of p65 and p50 isoforms of this pro-
inflammatory transcription factor [19]. TNFα-induced NF-кB has been shown to cause motor 
neuron death in vitro64. In addition, IFNγ has been demonstrated to synergize with TNFα to 
induce NF-кB, and enhance motor neuron death [20,21]. In line with this finding, anti-IFNγ 
therapy is protective and delays motor neuron damage in ALS mouse models [16]. Recently, 
elevated LIGHT signaling has been shown to selectively contribute to motor neuron death in ALS 
spinal cords [14,15]. IFNγ secreted by astrocytes is a key player in this process, as it leads to 
enhanced LIGHT production in spinal motor neurons [14,15]. Similar to TNFα, LIGHT is also a 
potent activator of the canonical, as well as the non-canonical, NF-кB pathways, leading to the 
activation of an alternate p52 NF-κB isoform [19]. Additionally, TNFα and IFNγ are known to 
synergistically activate interferon regulatory factor 1 (IRF1) expression [21]. But, the role of IRF1 
activation in ALS pathology remains unexplored. Overall, the sum of these augmented cytokine 
signaling pathways likely results in excessive activation of NF-кB and IRF1 in the brain. 
Although exacerbated TNFα, LIGHT, and IFNγ signaling pathways in the CNS converge at 
NF-κB and/or IRF1 dependent neuronal damage [22], the exact mechanism by which these pro-
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inflammatory transcription factors promote neuronal death is unclear. ERVK re-activation in 
neurons triggered by NF-κB/IRF1 may serve as the link between exacerbated pro-inflammatory 
cytokine signaling and neuronal damage in ALS.  
 
 
METHODS 
 
Patient samples 
Autopsy ALS (n=5) and neuro-normal control (n=5) tissue specimens were obtained from 
the NIH NeuroBioBank (USA). Pathologic examination was used to confirm the clinical diagnosis 
of ALS.  The postmortem interval of all patients was <24 hours.  Table S1 indicates the 
individual patient diagnosis, location of brain tissue sampling, age, gender and post-mortem 
interval (PMI in hours) of the samples used in this study.  The brain regions analysed were 
prefrontal cortex (Brodmann area 9, BA9) and motor cortex (Brodmann area 6, BA6). 
 
Immunohistochemistry of autopsy tissue 
To determine the extent of ERVK RT, IRF1, and NF-κB expression patterns in the CNS of 
ALS patients, immunohistochemistry was performed to detect the levels and localization of 
these target proteins in autopsy human cortical brain tissue, as previously described [8]. 
Primary antibodies used were mouse anti-human ERVK RT (1:750; AbNova #H00002087-A01), 
rabbit anti-human IRF1 (1:100; Santa Cruz #SC497), rabbit anti-human NF-κB p65 (1:100; Abcam 
#ab7970), and rabbit anti-human NF-κB p50 (1:100; Abcam #ab7971). Primary antibodies were 
detected using 1:250 goat anti-mouse AF488 (Molecular Probes #A11017) or goat anti-rabbit 
AF594 (Molecular Probes #11072). Neurons were identified using a fluorescent Nissl stain 
(1:100; Molecular Probes # N21483). Tissues were also counterstained with 1:50,000 DAPI. 
Free-floating tissues were mounted onto slides and stained in a 0.1% solution of Sudan Black B.  
Slides were rinsed and coverslips mounted using ProLong Gold anti-fade reagent (Molecular 
Probes). Controls were prepared by immunostaining without the primary antibodies. 
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Immunostained tissues were imaged with Olympus FV1200 laser scanning confocal microscope 
fitted with the Olympus Fluoview version 4.0B software suite.  
 
Cell Culture  
The SVGA cell line is derived from immortalized human fetal astrocytes [23], and was 
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% Fetal Bovine Serum 
(HyClone). ReNcell CX cells (Millipore #SCC007) are immortalized human neural progenitor cells 
(HNPCs) [24], and were maintained in a proprietary ReNcell neural stem cell medium (Millipore) 
supplemented with 20 ng/ml human epidermal growth factor (EGF; PeproTech #AF10015) and 
20 ng/ml human basic fibroblast growth factor (bFGF; PeproTech #AF10018B). All cell lines 
were maintained in a 37oC incubator containing 5% CO2.  SVGA cells were seeded into six-well 
plates and onto glass coverslips at a density of 300,000 cells/ml and 30,000 cells/ml, 
respectively, for 24 hours. To differentiate HNPCs into neurons, ReNcells were seeded in 
laminin (20 μg/ml; Millipore #CC095) coated six-well plates at a density of 50,000 cells/ml for 
24 hours. Adhered cells were rinsed with 1X PBS and allowed to differentiate in the presence of 
ReNcell medium lacking growth factors for 10 days.  For imaging experiments, ReNcell CX cells 
were cultured and differentiated into neurons in Alvetex scaffolds. Alvetex membranes 
(Reinnervate #AVP002) were treated with 70% Ethanol for 1 minute, rinsed with 1X PBS, and 
coated with 20 μg/ml laminin for 6 hours. ReNcell CX cells were seeded onto each scaffold at a 
density of 5 x 105 cells/well for 1 hour at 37oC and 5% CO2, as per manufacturer's instructions. 
The wells were then flooded with 2 ml of ReNcell media supplemented with EGF and FGF 
growth factors. Twenty-four hours post-seeding, the cell culture media was replaced with that 
lacking growth factors. Cells were allowed to differentiate for 10 days, with partial media 
changes performed every 3 days.   
 
Transient transfection of cells with constitutively active NF-κB and IRF1 constructs 
IRF1-pCMVBL, NF-κB p65-pCMVBL, NF-κB p50-pCMVBL, and pCMVBL empty vector were 
generously provided by Dr. Rongtuan Lin (McGill University). To determine whether IRF1 and 
NF-κB isoforms synergize to induce ERVK transcription, SVGA cells were transfected with 1 µg of 
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these plasmids individually or in combinations using 6 µl of Turbofect Reagent, as per 
manufacturer’s instructions (Thermo Scientific #R0531). Cells were transfected in serum-free 
culture media for 4 hours, followed by addition of complete media. Cells were harvested 48 
hours post-transfection. Untransfected cells and those transfected with the empty vector were 
used as the negative controls. 
 
Quantitative Polymerase Chain Reaction (Q-PCR) 
Total RNA was extracted and purified from cells using an Aurum Total RNA Mini Kit (Bio-
Rad #732-6820). RNA concentration was measured with a NanoDrop spectrophotometer. The 
acceptable RNA purity was A260/A280 1.95 to 2.05. The iScript Reverse Transcription kit (Bio-Rad 
#170-8840) was used to synthesize cDNA from the extracted RNA. CFX Connect Real Time 
System (Bio-Rad) was utilized to perform Q-PCR in order to measure alterations in ERVK pol 
transcripts using SYBR Green detection method. The primers used were: ERVK pol F: 5ʹ 
TGATCCCMAAAGAYTGGCCTT 3ʹ and R: 5ʹ TTAAGCATTCCCTGAGGYAACA 3ʹ. 18S rRNA was used 
as the endogenous control (Ambion kit #1718). The data were analysed using the ΔΔCT (Livak) 
method, and normalized relative to the appropriate negative control. All data were graphed as 
mean ± standard error of measurement. GraphPad Prism was used to carry out statistical 
analyses including column statistics, One-way Anova test and Bonferroni post-test. 
 
Western Blotting 
SVGAs and ReNcell CX-derived neurons were treated with 0, 0.1, 0.5, 1, 5, and 10 ng/ml 
doses of human TNFα (PeproTech #AF-300-01A) or human LIGHT (PeproTech #AF-310-09B). 
Twenty four hours post-treatment, cells were harvested and lysed on ice with 50 μl of in-house 
lysis buffer (0.05M Tris (pH 7.4), 0.15M NaCl, 0.002M EDTA, 10% glycerol and 1% NP-40 in ultra-
pure water) to extract proteins. The lysis buffer was supplemented with 1x HALT protease and 
phosphatase inhibitor cocktail (Thermo Scientific). BCA assay (Thermo Scientific #PI23227) was 
used to determine the protein content of each sample as per manufacturer’s instructions. Cell 
lysates were prepared for SDS-PAGE and heated at 95oC for 10 minutes. Proteins (15 μg per 
lane) were separated by SDS-PAGE using a 10% polyacrylamide gel, and transferred onto a 
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nitrocellulose membrane. The membrane was blocked in 5% skim milk solution for one hour 
and probed with the desired primary antibody (1:1000 dilution) overnight at 4oC, followed by 
incubation at room temperature for 3 hours.  Primary antibodies used were:  mouse anti-
human ERVK2 RT (Abnova #H00002087-A01), rabbit anti-human IRF1 (Santa Cruz #SC497), 
rabbit anti-human NF-κB p65 (Abcam #ab7970), rabbit anti-human NF-κB p50 (Abcam 
#ab32360), rabbit anti-human NF-κB p52 (Cell Signaling #4882S), and mouse anti-human β-actin 
(Thermo Pierce #MA5-15739; loading control).  The membrane was then probed with 
horseradish peroxidase-conjugated goat anti-mouse or rabbit IgG secondary antibody (1:5000 
dilution; Bio-Rad, #170-6516 and #170-6515) for 2 hours at room temperature. The membrane 
was developed with 2 ml of Luminata Crescendo Western HRP substrate (Millipore 
#WBLUR0500) and imaged using Bio-Rad ChemiDoc XRS+ or Protein Simple FluorChem M 
chemiluminescent imager. Image Lab software was used to determine the molecular weight of 
each band. The identity of each band was based on gag-pro-pol processing, as previously 
described [25]. 
 
Chromatin immunoprecipitation (ChIP) 
SVGAs were seeded in 10cm dishes at an approximate density of 3 x 106 cells/dish for 24 
hours at 37oC and 5% CO2. Laminin-coated dishes were used to seed ReNcell CX cells at a 
density of 3 x 105 cells/dish for 24 hours at 37oC and 5% CO2. The culture media on adhered 
ReNcell CX cells was then replaced with that lacking EGF and bFGF growth factors, and cells 
were allowed to differentiate into neurons for 10 days. SVGAs and neurons were treated with 
10ng/ml human TNFα (PeproTech) or human LIGHT (PeproTech) for 8 hours, fixed with 4% 
paraformaldehyde, and harvested. Untreated cells were used as the negative control. 
Chromatin Immunoprecipitation (ChIP) was performed using Pierce Magnetic ChIP kit (Thermo 
Scientific #26157) as per manufacturer’s instructions. IRF1 and NF-κB bound DNA segments 
were isolated using 3 µg of rabbit anti-human IRF1 (Santa Cruz #SC497), rabbit anti-human NF-
κB p65 (Abcam #ab7970), rabbit anti-human NF-κB p50 (Abcam #ab32360), or rabbit anti-
human NF-κB p52 (Cell Signaling #4882S) antibodies. Immunoprecipitation with IgG antibody 
was used as the negative control. QPCR was performed on the immunoprecipitated DNA using 
87 
 
SYBR Green detection to amplify the ISREs in the ERVK 5ʹ LTR. Primers for the first ISRE (nt. 380 
- 392) were F: 5ʹ-TCACCACTCCCTAATCTCAAGT-3ʹ and R: 5ʹ-TCAGCACAGACCCTTTACGG-3ʹ and 
for second ISRE (nt. 563 - 575) were F: 5ʹ- CTGAGATAGGAGAAAAACCGCCT-3ʹ and R: 5ʹ-
GGAGAGGGTCAGCAGACAAA-3ʹ. Data were analyzed using the ΔΔ Ct method and normalized 
relative to the input and IgG controls for each condition. All data were graphed as mean ± 
standard error of measurement. Statistical analyses were performed in GraphPad PRISM using 
Two-Way Anova and Tukey’s multiple comparisons test. 
 
Fluorescent microscopy 
SVGA cells and ReNcell CX-derived neurons in Alvetex scaffolds were treated with 10 
ng/ml human TNFα (PeproTech) or human LIGHT (PeproTech). Untreated cells were used as the 
negative control. Twenty-four hours post-treatment, cells were fixed with methanol for 40 
seconds, and rinsed with 1X PBS. Cells were permeabilized with 250 μl of PBS-T (PBS with 0.25% 
TritonX-100) and blocked with 250 μl of 3% BSA in TBS-T (TBS with 0.25% TritonX-100) for 30 
minutes. Immunocytochemistry was performed using 1:750 mouse anti-human ERVK RT 
(Abnova #H00002087A01) primary antibody for 3 hours and 1:1000 goat anti-mouse AF488 
(Molecular Probes #A11017) secondary antibody for 2 hours. Nuclei were counterstained with 
1:50,000 DAPI. ReNcells were also stained with fluorescent Nissl to detect neurons (Molecular 
Probes #N21483).  Coverslips or Alvetex membranes were mounted onto slides using ProLong 
Gold anti-fade reagent (Molecular Probes), and dried overnight. Controls were prepared by 
immunostaining without the primary antibodies. Confocal microscopy was performed using an 
Olympus FV1200 laser scanning confocal microscope. 
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RESULTS 
 
TNFα and LIGHT enhance ERVK polyprotein and RT expression in a cell-type specific manner 
Augmented levels of pro-inflammatory cytokines TNFα and LIGHT play a crucial role in 
ALS neuropathology [14-16,26]. Considering that ERVK re-activation coincides with pro-
inflammatory signatures in ALS, we sought to determine whether these cytokines can enhance 
ERVK expression in human astrocytes and neurons. The treatment of human astrocytic SVGA 
cell line and human neurons derived from ReNcell CX cell line with TNFα or LIGHT dose-
dependently enhanced ERVK polyprotein and RT levels, albeit in a cell-type specific manner. 
LIGHT increased ERVK protein levels most prominently in astrocytes, whereas TNFα was best 
able to induce ERVK expression in neurons (Figures 1A and 2A). We also observed enhanced 
ERVK polyprotein processing in these cytokine stimulated cells, which culminated in the 
production of the catalytic RT subunit containing an RNase H domain and the structural RT 
subunit without the RNase H domain (Figures 1A and 2A). These observations are in line with 
our previous finding of IFNγ-mediated ERVK polyprotein cleavage to produce a heterodimeric 
mature and active ERVK RT [25]. Interestingly, TNFα-treated neurons exhibited marked 
cleavage of the ERVK polyprotein to generate the RT-RH catalytic subunit (Figure 2A), 
suggesting that neuronal ERVK RT activity detected in ALS may optimally occur in the context of 
chronic TNFα exposure.  
Confocal microscopy revealed that under optimal stimulating conditions, LIGHT-treated 
astrocytes and TNFα-treated neurons exhibited marked ERVK RT protein accumulation (Figures 
1B and 2B). In astrocytes, ERVK polyprotein/RT formed a perinuclear ring and a large aggregate 
proximal to the nucleus (Figure 1B). Nuclear ERVK RT expression also increased and exhibited a 
speckled pattern (Figure 1B). We have previously observed similar ERVK RT staining patterns in 
IFNγ-treated cells [25], suggesting that ERVK polyprotein/RT aggregation is a common cellular 
feature occurring in the context of  CNS inflammation. In addition, enhanced ERVK protein 
expression occurred concomitantly with the up-regulation of IRF1 and NF-κB p65, p50, and/or 
p52 transcription factors in astrocytes and neurons (Figures 1A and 2A). This finding suggests 
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that IRF1 and NF-κB isoforms likely play a crucial role in ERVK re-activation in astrocytes and 
neurons, and thus, we sought to explore the mechanism behind this process.  
 
IRF1 and NF-κB synergize to markedly enhance ERVK transcription  
Previously, in silico analysis revealed that two Interferon Stimulated Response Elements 
(ISREs) are a conserved feature of ERVK promoters called 5’ Long Terminal Repeats (5ʹ LTR; 
Figure 3A) [1]. ISREs are known to bind Interferon Regulatory Factors, such as IRF1 [27]. The 
ERVK 5ʹ LTR also harbours numerous conserved putative NF-κB binding sites, including those 
that partially overlap and are adjacent to IRF1 binding sites (Figure 3A). The binding of IRF1 and 
NF-κB to their cognate sites is required for optimal transcriptional activation from the HIV-1 5ʹ 
TLR [28]. Similarly, these pro-inflammatory transcription factors may be crucial for enhancing 
ERVK transcription in neuroinflammatory diseases such as ALS. 
To determine whether IRF1 and NF-κB cooperatively enhance ERVK transcription, we 
transiently transfected astrocytes with plasmids expressing constitutively active NF-κB 
(isoforms p65 and p50) and IRF1, individually or in combinations. The overexpression of IRF1 
and NF-κB p65 alone was sufficient to significantly enhance ERVK pol transcription in astrocytes 
(Figure 3B). We did not observe a perceivable effect with overexpression of NF-κB p50 alone on 
ERVK pol RNA levels. However, co-expression of IRF1 and NF-κB p65 and p50 in astrocytes 
produced a marked 70 fold increase in ERVK pol RNA levels. These findings support the notion 
that IRF1 and the NF-κB p65/p50 heterodimer synergize to drive optimal transcriptional re-
activation of ERVK in astrocytes.  Enhanced expression of Sp1 and Sp3 transcription factors can 
also regulate ERVK expression (Figure S1), but not nearly as to the same extent as pro-
inflammatory TFs. 
 
TNFα and LIGHT enhance the binding of IRF1 and NF-κB to Interferon Stimulated Response 
Elements in the ERVK 5′ LTR 
Pro-inflammatory cytokines, such as TNFα and LIGHT, are generally potent activators of 
NF-κB and also lead to IRF1 activity [19,21]. Therefore, we sought to determine whether TNFα 
and LIGHT-mediated induction of ERVK expression is facilitated by enhanced interactions of NF-
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κB and IRF1 with their cognate binding sites on the ERVK 5ʹ LTR. For the first time, we showcase 
the biological functionality of ISREs in the ERVK 5ʹ LTR, as they can interact with IRF1 and NF-κB 
isoforms. Both astrocytes and neurons exhibited basal IRF1 and NF-κB binding to both ISREs 
(Figure 3 C-F), which alludes to the basal ERVK expression observed in these cells. However, 
under optimal stimulating conditions, LIGHT-treated astrocytes (Figure 3 C and D) and TNFα-
treated neurons (Figure 3 E and F) exhibited markedly enhanced NF-κB p65 and p50 binding to 
each ISRE in the ERVK promoter. We did not observe any perceivable change in the binding of 
NF-κB p52 isoform to the ISREs.   This suggests that the canonical NF-κB p65/p50 complex, or 
p50 homodimers, predominantly bind the ERVK promoter and partake in proviral 
transcriptional re-activation. Furthermore, ChIP data did not support a role for the non-
canonical p50/p52 NF-κB complex in ERVK transcription.  Although the binding of IRF1 to the 
ISREs considerably increased with cytokine stimulation 9 and 7 fold in SVGAs and neurons, 
respectively, it did not reach statistical significance. Overall, these findings support the notion 
that TNFα or LIGHT-induced IRF1, NF-κB p65 and p50 binding to the ERVK promoter re-activates 
this endogenous retrovirus in the context of inflammation. 
Interestingly, cytokine-mediated IRF1 and NF-κB binding to the ERVK promoter occurred 
in a cell-type specific manner. LIGHT, but not TNFα, significantly enhanced NF-κB p65 and p50 
binding to the ISREs in astrocytes (Figure 3 C and D). In stark contrast, TNFα, but not LIGHT, 
significantly increased NF-κB p65 and p50 protein levels as well as their interaction with the 
ISREs on the ERVK promoter in neurons (Figure 3 E and F). Consistently, these results were 
associated with increased ERVK polyprotein/RT expression in LIGHT-treated astrocytes and 
TNFα-treated neurons.  
The ERVK pol gene was used as the negative control for ChIP Q-PCR (Figure S2); 
however, transcription factor binding was detected to the ERVK pol region.  This can be 
explained by extensive binding by NF-κB and IRF1 to regions other than promoters throughout 
the human genome [27].  Cytokine treatment did not result in notably enhanced NF-κB and 
IRF1 binding to the ERVK pol gene, which confirms that transcription factor enrichment to the 
ERVK promoter region is not a random event under conditions of inflammation. 
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IRF1 and NF-κB expression is markedly increased in ERVK+ cortical neurons in ALS 
We have previously demonstrated that ERVK RT expression is specifically increased in 
the cortical neurons of patients with ALS as compared to neuro-normal controls [8]. However, 
the signals that lead to neuronal ERVK RT accumulation have remained unidentified. The 
augmented levels of TNFα and LIGHT in the CNS is a hallmark of ALS [10,12-16]. We are the first 
to demonstrate that that these pro-inflammatory cytokines lead to ERVK expression in human 
astrocytic and neuronal cell lines. In order to validate our in vitro findings, we sought to 
determine whether cortical brain tissue from patients with ALS exhibits increased NF-κB and 
IRF1 nuclear localization in ERVK+ neurons as compared to neuro-normal controls. 
Here, we highlight that ERVK RT expression predominantly accumulated in large 
pyramidal neurons in the third and fifth cortical layer of prefrontal and motor cortex tissue, and 
associated with loss of cortical tissue organization in ALS (Figure 4).  Weak basal ERVK 
expression was observed in neuro-normal cortex.  Yet, a striking enhancement and expanded 
distribution of ERVK expression occurred in ALS cortical tissues.  Inter-individual differences in 
ERVK expression levels were maintained when comparing prefrontal and motor cortex samples, 
suggesting that either genetic background (polymorphisms in proteins of key cellular pathways) 
or disease severity (degree of inflammation) account for differential ERVK expression.  We 
showcase that in comparison to neuro-normal controls, motor cortex neurons in patients with 
ALS exhibited clear nuclear translocation of pro-inflammatory transcription factors IRF1 and NF-
κB p50, and to a lesser degree p65 (Figure 5). Nuclear translocation of these TFs correlated with 
enhanced ERVK RT expression in cortical neurons. Overall, our findings strongly support the 
premise that ERVK re-activation in the motor cortex of patients with ALS stems from enhanced 
interactions of cytokine-induced IRF1 and NF-κB transcription factors with the ERVK promoter.    
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DISCUSSION 
 
Several lines of evidence suggest that augmented levels of TNFα and LIGHT cytokines 
drive enhanced activity of pro-inflammatory transcription factors (TFs) in neurological diseases 
[14,15,26]. These signalling pathways may be important triggers of ERVK transcription in the 
CNS. Herein, we show that TNFα and LIGHT are potent inducers of ERVK polyprotein and RT 
expression in neurons and astrocytes, respectively. Confocal microscopy revealed a unique 
pattern of ERVK RT expression in cells, consisting of punctuated structures that accumulated in 
the perinuclear region along with the formation of a large aggregate proximal to the nucleus. 
This type of staining is typically seen for specialized inclusion bodies called viroplasms, which 
comprise the viral replication machinery [55,56]. This suggests the formation of putative ERVK 
viral factories in cytokine-stimulated cells. The morphology of these viroplasms also resembles 
that of the aggresomes, which are compartments that sequester unwanted proteins in 
specialized inclusions and facilitate their clearance by autophagy, thereby dissipating the 
cytotoxic effects of protein aggregates [57,58]. Likewise, formation of ERVK RT aggresomes may 
be a cellular response to protect against toxic ERVK protein accumulation. Unfortunately, the 
appearance of aggresomes and inclusion bodies can impair vital cellular functions, including 
inactivation of the proteasomal pathway responsible for clearing protein aggregates [58]. 
Interestingly, protein clearance pathways, such as the proteasome system and autophagy, are 
dysregulated in ERVK-associated neurological diseases including ALS [59]. In the absence of 
functional protein degradation pathways, inflammation-induced ERVK viroplasms or 
aggresomes may persist and propagate chronic neuronal damage.    
To delineate the mechanism behind cytokine-induced ERVK re-activation, we have 
utilized ChIP and confirmed that the ISREs in the ERVK promoter are functional, and that 
enhanced binding of IRF1 and NF-κB to these elements synergistically augments ERVK gene 
expression in response to pro-inflammatory stimuli. The cooperative binding of IRF1 and NF-κB 
to their cognate sites is a conserved feature of many IRF1 and NF-κB-responsive gene 
promoters. For instance, synergy between IRF1 and NF-κB is required to induce the 
transcription from human inducible nitric oxide synthase, interleukin-15, major 
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histocompatibility complex class I, vascular cell adhesion molecule I, and interferon β 
promoters [29-33]. Accordingly, overlapping or adjacent IRF1 and NF-κB binding sites have been 
described at these promoters, similar to that observed in the ERVK promoter [1]. IRF1 and NF-
κB also synergistically activate transcription from the HIV-1 promoter, although IRF1 binding 
sites are not found adjacent to or overlapping with NF-κB sites [28]. In line with these findings, 
we have added the ERVK promoter to the growing list of IRF1 and NF-κB responsive enhancer 
elements.  
It is interesting to note that TNFα and LIGHT enhance ERVK expression in a cell-type 
dependent manner. TNFα increased ERVK protein levels most prominently in neurons, whereas 
LIGHT was best able to induce ERVK in astrocytes. This effect can be explained by differential 
enrichment of NF-κB at the ERVK promoter during TNFα or LIGHT stimulation of astrocytes and 
neurons. TNFα, but not LIGHT, significantly increased the interaction of NF-κB p65 and p50 with 
the ISREs on the ERVK promoter in neurons. In contrast, LIGHT, but not TNFα, significantly 
enhanced NF-κB p65 and p50 binding to the ISREs in astrocytes.  
Cell-type specificity of TNFα and LIGHT may also be explained by differential expression 
of their cognate cell surface receptors, as well as downstream signaling molecules in astrocytes 
and neurons. TNFα is known to be biologically active in both transmembrane as well as soluble 
forms [13,34]. Soluble TNFα mainly signals through TNF receptor 1 (TNFR1) [13], which is found 
at a lower level in astrocytes as compared to neurons (The Human Protein Atlas). 
Overproduction of soluble TNFα has been shown to cause neurodegeneration in the CNS [34]. 
Trans-membrane TNFα on the other hand mainly signals through TNFR2, which is primarily 
found in microglial cells [13,15]. Since, we utilized soluble TNFα in our cell line models, it is not 
surprising that neurons, but not astrocytes, were more responsive to this cytokine. Adaptor 
molecules that associate with TNF receptors, known as TRAFs, exert a second layer of control 
over cell-specific TNFα and LIGHT signaling. TRAF3 is basally expressed in neurons, but not in 
glial cells (The Human Protein Atlas), and has been shown to be much more inducible in 
neurons as compared to astrocytes [35]. TRAF3 is a negative regulator of LIGHT signaling as it 
inhibits the function of LTβ receptor, which results in NF-κB inactivity [35]. In contrast, TRAF3 
has no effect on TNFα-induced NF-κB signaling [35]. Neuronal expression of TRAF3 may have 
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inhibited LIGHT-induced NF-κB signaling, leading to a lack of any perceivable effect on ERVK 
expression in our neuronal models. 
The NF-κB class of transcription factors function as heterodimers or homodimers 
comprised of various combinations of subunits p65, Rel B, c-Rel, p50, and p52 [36]. The most 
common NF-κB species found in human neurons are the canonical p65/p50 and the non-
canonical p50/p50 complexes [37]. Different NF-κB dimers recognize slightly different binding 
sequences with high affinity [38]. For instance, p50 homodimers bind the consensus decamer 
GGGGATYCCC, where Y is a pyrimidine base, while p65/p50 heterodimers have high affinity for 
NF-κB sites with AT rich centres [38]. Since, majority of the NF-κB binding sites on the ERVK 5ʹ 
LTR are GC rich (60 to 80% GC content) [1], the ERVK promoter is likely most responsive to p50 
homodimers. Indeed, ChIP experiments revealed the most dramatic enrichment in the binding 
of NF-κB p50 at the ISREs in the ERVK promoter in both astrocytes and neurons. Nevertheless, 
p50 may be present in homodimeric or heterodimeric complexes with p65 at the ERVK 
promoter. 
Our findings suggests that the canonical p65/p50 complex most likely activates ERVK in 
astrocytes. This is because we observed a marked increase in ERVK pol RNA levels only with the 
co-overexpression of IRF1 and NF-κB p65 and p50 in astrocytes, and not with IRF1 and p65 or 
IRF1 and p50 combinations. In addition, enhanced ERVK RT expression associated with 
increased levels of all of these TFs in astrocytes. In contrast, our findings support the role of 
non-canonical p50 homodimers, rather than p65/p50 heterodimers, in ERVK re-activation in 
neurons. In support of this claim, enhanced levels of mature ERVK RT were observed despite 
the lack of any significant increase in NF-κB p65 protein levels upon TNFα stimulation of 
neurons. Further support emanates from the finding that the cortical neurons in ALS tissues 
exhibited enhanced nuclear translocation of p50 rather than p65, concomitantly with ERVK RT 
accumulation. 
Previous studies have demonstrated that p50 homodimers are global transcriptional 
repressors, as p50 lacks a transcriptional activation domain (TAD) [36]. Accordingly, p50 
homodimers repress the expression of a variety of human genes including TNFα and IL-6 [39]. 
NF-κB p50 homodimers are also known to repress HIV-1 transcription, leading to retroviral 
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latency [39]. In stark contrast, our findings argue for an activating role of p50 homodimers on 
ERVK transcription. Interestingly, this may account for enhanced ERVK expression which 
precedes rebounds of HIV-1 re-activation in cells latently infected with this exogenous 
retrovirus [40]. Since p50 lacks a TAD, it can only stimulate transcription when complexed with 
other NF-κB subunits containing a TAD, or alternatively with other co-activators such as Bcl-3, 
C/EBP, Sp1, or TFII-I that bridge the p50 homodimers to the transcriptome by recruiting 
transcription initiation machinery [41-43]. Thus, NF-κB p50 must be present in a complex with 
other transcriptional co-activators at the ERVK 5ʹ LTR. Indeed, ERVK promoter harbors binding 
sites for co-activators such as Sp1 and TFII-I in the vicinity of NF-κB sites [1], suggesting that 
transcription factors other than NF-κB p65 and p50 and IRF1 likely partake in the complexity of 
LTR-driven ERVK re-activation.  
Moreover, in a study by Zhou et al., NF-κB p50 was demonstrated to play a much more 
prominent role in neuronal survival as compared to p65 [37]. In the presence of glutamate 
toxicity, marked increase in p50 nuclear levels was required to enhance neuronal survival [37]. 
Spinal cord neurons were also determined to be more vulnerable to apoptosis upon the 
inhibition of nuclear p50 translocation in vitro [44]. Neuronal survival in these studies can be 
accounted for by homodimeric p50-mediated induction of bcl-2 transcription, as well as 
blockade of caspase 3 cleavage – both of which decrease the propensity of cells to apoptotic 
cell death [44,45]. Thus, under conditions of cellular stress, p50 homodimers elicit a protective 
survival response in neurons; unfortunately, this may inadvertently cause neuronal ERVK 
transcriptional re-activation mediated by p50, as well as accumulation of ERVK proteins which 
are normally cleaved and degraded by caspase activation [46].  
As compared to neuro-normal controls, ERVK RT expression was markedly enhanced in 
large pyramidal neurons in BA9 prefrontal and BA6 motor cortex of ALS tissues. Pyramidal 
neurons in the motor cortex normally exhibit constitutive basal NF-κB activity, which is required 
to maintain neuronal plasticity [47]. In the presence of already active NF-κB, pro-inflammatory 
stimuli including TNFα and LIGHT, which culminate in IRF1 activation, may be sufficient to drive 
ERVK re-activation in pyramidal neurons. IRF1 activation in cortical neurons has previously been 
demonstrated in the context of neurotropic viral infections, and serves as a protective 
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mechanism limiting viral replication and spread within the CNS [48]. Acute and chronic viral 
infections have been associated with the etiology of several ERVK-associated neurological 
diseases, including schizophrenia, multiple sclerosis and ALS [49-52]. However, a causative link 
between these viral infections and the pathology of neurodegenerative diseases is a highly 
debated topic. Viruses may cause transient infections, leading to anti-viral immune activation 
which eventually culminates in the clearance of the infectious agent. However, based on our 
findings, IRF1 and NF-κB may trigger ERVK re-activation. Anti-viral response against ERVK may 
create a feed forward loop, generating repetitive cycles of NF-кB/IRF1-induced ERVK expression 
and inflammatory response against ERVK-expressing neurons, leading to neuronal injury. 
Previously, the envelope protein of ERVW has been demonstrated to trigger innate immune 
signaling and the secretion of pro-inflammatory cytokines, thereby driving NF-κB activation 
[53]. This TF further activated LTR-driven transcription of ERVW, generating a vicious cycle of 
latent ERV re-activation and uncontrolled inflammation [6,7]. Likewise, ERVK re-activation in 
cortical neurons may perpetuate chronic tissue damage. 
In addition to immune-mediated neuronal damage, multiple retroviral proteins have 
been shown to exert direct neurotoxic effects. For instance, the overexpression of ERVW 
envelope protein induces endoplasmic reticulum stress, leading to neuroinflammation and 
production of free radicals with ensuing demyelination and axonal injury in multiple sclerosis 
[54]. Similarly, the expression of ERVK proteins may also prove to be toxic for neurons. 
However, whether ERVK re-activation in neurological diseases is responsible for 
neuroinflammation and cell death is yet to be elucidated.  
It is now well established that exacerbated TNFα and LIGHT signaling pathways in ALS 
converge at NF-κB and possibly IRF1 dependent neuronal damage [22]; however, the exact 
mechanism by which these pro-inflammatory transcription factors promote neuronal death has 
remained obscure. Our findings suggest that neuronal ERVK protein expression and aggregation 
triggered by the synergistic action of NF-κB and IRF1 may serve as the link between 
exacerbated pro-inflammatory cytokine signaling and tissue damage. Consequently, squelching 
ERVK activity through antiretroviral or immunomodulatory regimens may hinder virus-
mediated neuropathology and improve the symptoms of ALS.  
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Figure 1. LIGHT, but not TNFα, markedly enhances ERVK polyprotein and RT expression in 
astrocytes. SVGA cells were treated with various doses of TNFα or LIGHT for 24 hours. Western 
blot and confocal microscopy were used to detect alterations in ERVK RT, IRF1, and NF-κB p65, 
p50, or p52 protein levels. (A) Western blot depicts that LIGHT strongly induced ERVK 
polyprotein expression and cleavage to produce the small 52/54 kDa RT without RNase H and 
the larger 60 kDa RT with RNase H, concomitantly with up-regulation of IRF1 and NF-κB protein 
levels. In comparison, TNFα slightly enhanced ERVK polyprotein and RT subunit expression. β-
actin was used as the loading control (n=3). (B) Representative confocal micrographs depicting 
marked LIGHT-mediated induction of ERVK RT expression. ERVK RT aggregates deposited 
proximal to the nucleus and formed a perinuclear ring (n=3). 
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Figure 2. TNFα, but not LIGHT, markedly enhances ERVK polyprotein and RT expression in 
neurons. ReNcell CX-derived neurons were treated with various doses of TNFα or LIGHT for 24 
hours. Western blot and confocal microscopy were used to detect alterations in ERVK RT, IRF1, 
and NF-κB p65, p50, or p52 protein levels. (A) Western blot depicts that TNFα strongly induced 
ERVK polyprotein expression and cleavage to produce the small 56/58 kDa RT without RNase H 
and the larger 68 kDa RT with RNase H, concomitantly with up-regulation of IRF1 and NF-κB 
protein levels. In comparison, LIGHT enhanced the expression of RT subunit without RNase H, 
but not RT with RNaseH domain, suggesting that optimal RT activity may occur during exposure 
of neurons to TNFα. β-actin was used as the loading control (n=3). (B) Representative confocal 
micrographs depicting TNFα-mediated induction of ERVK RT expression in neurons. Fluorescent 
Nissl stain was used to identify neurons (n=3). 
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Figure 3. NF-κB and IRF1 interact with the ISREs in the ERVK 5′ LTR, and synergize to enhance 
ERVK gene transcription. (A) In silico-predicted IRF1 and NF-κB binding sites, including two 
Interferon Stimulated Response elements (ISREs) in the ERVK 5ʹ LTR. Adapted from [1]. (B) IRF1 
and NF-κB p65 and p50 synergize to significantly enhance ERVK pol transcription in astrocytes. 
SVGA cells were transfected with 10 µg of empty vector (negative control), as well as plasmids 
encoding IRF1 and NF-κB isoforms individually and in combinations, for 48 hours. The 
modulation in ERVK pol RNA levels was measured by using SYBR Green detection through Q-
PCR, and data were normalized relative to the negative control (*p<0.05 ***p<0.001; n=3). 
18sRNA was used as the endogenous control. Although IRF1 and NF-κB p65 alone were 
sufficient to significantly induce ERVK pol transcription, IRF1 and NF-κB p65 and p50 synergized 
to further enhance ERVK pol RNA levels up to 70 fold. (C-F) TNFα and LIGHT markedly enhance 
the binding of IRF1 and NF-κB p65 and p50 to both ISREs in the ERVK 5ʹ LTR in a cell-type 
specific manner. Chromatin was extracted from SVGAs and ReNcell CX-derived neurons treated 
with TNFα (10 ng/ml) or LIGHT (10 ng/ml) for 8 hours. Chromatin Immunoprecipitation (ChIP) 
was performed with anti-human IRF1, or NF-κB p65, p50, or p52 antibodies. Q-PCR was used to 
amplify immunoprecipitated ISRE sequences within the ERVK 5ʹ LTR using SYBR Green 
detection. Fold enrichment of transcription factors at each ISRE was first normalized to the 
input control and then to the IgG negative control. All transcription factors were bound to the 
ISREs at basal levels. However, the binding of NF-κB p65 and p50 was significantly enhanced 
with LIGHT treatment, but not with TNFα treatment in astrocytes (C-D) (n=3; *p<0.05, 
****p<0.0001). In contrast, the binding of NF-κB p65 and p50 was significantly enhanced with 
TNFα treatment, but not with LIGHT treatment in neurons (E-F) (n=2; *p<0.05, ***p<0.001).  
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Figure 4. Representative images of ERVK reverse transcriptase (RT) in cortical brain tissue.  
Prefrontal cortex autopsy tissues (Brodmann area 9, NIH NeuroBioBank) of an individual with 
cancer (neuro-normal) and a patient with ALS were immunostained for ERVK RT expression 
(green).  Mosaic tiling (left panel, 10X magnification) reveals enhanced ERVK RT expression in 
deep cortical tissue (V) and upper cortical tissue (III) layers in ALS tissue.  Nissl stained cells 
reveal ERVK RT staining in large pyramidal neurons.  Nuclear DAPI staining (blue).  Scale bar on 
40X magnified images (right) is 10μm.   
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Figure 5. The expression of ERVK RT is markedly enhanced in cortical neurons of patients with 
ALS and associates with increased levels of and enhanced nuclear translocation of IRF1 and 
NF-κB. Representative confocal micrographs of ERVK RT, IRF1 and NF-κB p50 protein detection 
in Brodmann area 6 motor cortex tissue from an ALS patient and from a neuro-normal control 
(n=5). ERVK RT expression increased in the perinuclear region and in the axons of large 
pyramidal neurons in ALS motor cortex. This occurred concomitantly with increased expression 
of (A) IRF1, (B) NF-κB p50 and (C) NF-κB p65 nuclear translocation in cortical neurons. 
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Figure S1. Sp1 and Sp3 enhance ERVK transcription and protein expression.  (A) Reduced ERVK 
pol expression 24 hours after Mithramycin-A (MTM-A) treatment of chronically ERVK-
expressing NCCIT cells. MTM-A is known to abrogate Sp1 activity. ERVK expression was 
measured by Q-PCR and data were normalized relative to the untreated cells. 500nM MTM-A 
inhibited ERVK expression in NCCIT cells by 90%. Statistical analysis was performed using One-
way Anova and Bonferroni post-test (n=3; *p<0.05).  (B)  SVGAs were transfected with 1 ug of 
Sp1 and/or Sp3 plasmids for 48 hours using Turbofect reagent. ERVK pol expression was 
measured by Q-PCR using SYBR Green detection, and data were normalized relative to the 
untreated cells. 18s rRNA was used as the endogenous control. Sp1 alone did not significantly 
up-regulate ERVK pol transcription. Sp3 alone induced ERVK pol RNA levels by 3 fold. In the 
presence of both Sp1 and Sp3, ERVK expression was increased 6 fold. Statistical analysis was 
performed using One-Way Anova and Bonferroni post-test (n=3; *p<0.05 ***p<0.005). (C) 
Western blot depicting the sequential cleavage of the gag-pro-pol polyprotein, culminating in 
the production of prototypical ERVK RT isoforms. ERVK RT protein levels increased in the 
presence of Sp1 and Sp3 individually and in combination. β-actin was used as the loading 
control (n=3).  
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Figure S2. Chromatin was extracted from SVGAs treated with TNFα (10 ng/ml) or LIGHT (10 
ng/ml) for 8 hours. Chromatin Immunoprecipitation (ChIP) was performed with anti-human 
IRF1, or NF-κB p65, p50, or p52 antibodies. Q-PCR was used to amplify immunoprecipitated 
ERVK pol (negative control) using SYBR Green detection. Fold enrichment of transcription 
factors at ERVK pol was first normalized to the input control and then to the IgG negative 
control. IRF1 as well as NF-κB p65 and p50 were bound to the ERVK pol region at basal levels.  
NF-κB p65 binding increased with TNFα treatment.  All transcription factor binding decreased 
with LIGHT treatment (n=2). 
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Table S1. Cortical Brain Tissue Specimens 
Case Diagnosis Cause of Death Tissue 
Age 
(yrs) 
Gender PMI 
2776 ALS 
ALS  
(progressive bulbar palsy) 
BA6, BA9 76 F 8.6 
5215 ALS ALS BA6, BA9 59 M 12.5 
5187 ALS 
ALS, Hypertension, Chronic 
urinary tract infection 
BA6, BA9 69 M 13.2 
5212 ALS ALS BA6, BA9 50 M 21 
5216 ALS ALS BA6, BA9 53 M 16.8 
4660 Normal 
Pancreatic cancer, Diabetes, 
Hypertension 
BA6, BA9 73 F 18.5 
3371 Normal Lung Cancer BA6, BA9 52 M 16 
4514 Normal 
Lung Cancer, 
Chronic obstructive 
pulmonary disease 
BA6, BA9 66 M 17.3 
3565 Normal Cardiomyopathy BA6, BA9 76 M 11 
3221 Normal 
Chronic obstructive 
pulmonary disease 
BA6, BA9 90 M 17.8 
BA6: Brodmann area 6 motor cortex 
BA9: Brodmann area 9 prefrontal cortex 
PMI: post-mortem interval 
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The goal of this study was to evaluate the influence of altered TDP-43 activity on ERVK 
transcription and proteinopathy in astrocytes and neurons. We have shown that neurons 
exhibiting TDP-43 accumulation have a marked increase in ERVK protein levels in autopsy brain 
tissue from HIV-infected individuals and those with ALS. We also determined that 
overexpression of wild-type, but not truncated forms of TDP-43 induced ERVK transcription. 
Aggregating forms of TDP-43 however promoted the cytoplasmic accumulation and aggregation 
of ERVK proteins. TDP-43 was found to bind the ERVK promoter, and increased binding in the 
context of inflammation or proteasome inhibition enhanced ERVK transcription. Thus, 
enhanced ERVK transcription and protein accumulation likely stems from TDP-43 dysregulation 
in ALS and HIV associated neurocognitive disorder. 
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ABSTRACT 
The involvement of TDP-43 in retrovirus replication, and specifically HIV infection, remains 
controversial.  We evaluated whether TDP-43 exerts an effect on endogenous retrovirus-K 
(ERVK) expression.   Using autopsy tissue from HIV+ individuals and patients with amyotrophic 
lateral sclerosis (ALS), we show marked enhancement of ERVK in TDP-43+ neurons.  Human 
astrocytes and neurons further demonstrated cell-type specific differences in their ability to 
express and clear ERVK proteins during inflammation and proteasome inhibition.  Astrocytes, 
but not neurons, were able to clear excess ERVK proteins through an autophagic response.  
Overexpression of wild-type, but not ALS-associated aggregating forms of TDP-43 induced ERVK 
transcription.  TDP-43 bound the ERVK promoter in the context of inflammation or proteasome 
inhibition.  However, only aggregating forms of TDP-43 promoted the cytoplasmic accumulation 
and aggregation of ERVK proteins.  Our findings support the paradigm that TDP-43 
heterozygosity enhances neuropathology, and that ERVK proteinopathy is a novel aspect of 
TDP-43 misregulation in neurodegenerative diseases. 
 
 
Keywords:  Human Immunodeficiency virus (HIV); Endogenous retrovirus (ERVK); TAR DNA-
binding protein 43 (TDP-43); HIV-associated neurocognitive disorders (HAND); Amyotrophic 
Lateral Sclerosis (ALS) 
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INTRODUCTION 
Human retroviruses are neurotrophic, causing clinically silent central nervous system 
(CNS) lesions long before diagnosis 1.  Despite antiretroviral therapy, neurocognitive disorders 
continue to complicate the clinical treatment of Human immunodeficiency virus (HIV) 
infection2.  More severe forms of HIV-associated neurocognitive disorders (HAND) are now less 
frequent, but the prevalence of mild neurocognitive deficits – those affecting daily living 
activities – have increased among HIV+ populations 1.  Both HIV and human T-cell leukemia virus 
(HTLV) have also been associated with an increased incidence of ALS-like syndromes 3, 4.   Anti-
retroviral therapy in HIV-infected patients has been reported to reverse the symptoms of ALS-
syndrome 5, 6.  A pathological link between HAND and ALS is the re-activation of neuron-
expressed human endogenous retrovirus-K (ERVK) 7, 8. 
The human genome is actually a composite of human and viral genes, with over 8% of 
our DNA occupied by endogenous retroviruses (ERVs) 9, 10.  ERVK is one of the most recent 
entrants into the human genome 11, and its expression has been linked to inflammatory, 
infectious and neurological diseases 12.  Inflammatory signals and cell-specific transcription 
factors are crucial for driving differential ERVK expression in tissues 13, 14.  Infectious agents, 
such as HIV, can also trigger ERVK expression 8, 15, 16.  Once re-activated, ERVK virions can 
transfer viral genomes to neighbouring cells 17, but unlike HIV, there is no evidence of viral 
replication cycles that could lead to human-to-human transmission of ERVK.   
HIV enters the CNS shortly after initial infection, yet it remains unknown whether slow 
progressive pathological changes or abrupt alterations following systemic immunosuppression 
trigger neurodegeneration.  Microglia, macrophages and astrocytes can support productive HIV 
infection and promote chronic pro-inflammatory responses (reviewed in 18).  HIV infection is 
known to re-activate ERVK expression in proliferating peripheral blood mononuclear cells 19.  A 
longitudinal study by Contreras-Galindo et al. indicates that increased ERVK expression in HIV-
infected patients precedes spikes of HIV replication 20.  Clinically, patients who fail to respond to 
HAART therapy or receive sub-optimal therapeutic doses also exhibit higher ERVK expression 20, 
21.  However, ERVK re-activation is not limited to the periphery, as it is also a hallmark of HIV 
121 
 
neuroinvasion8.  Cortical neurons of HIV+ individuals exhibit enhanced ERVK (HML-2) envelope 
protein expression as compared to HIV- controls, which is postulated to be neuroprotective 8.   
We are now only beginning to recognize the pathological contributions of ERVs in 
neurological disease.  ERV expression was commonly cited as a bystander effect of disease 
processes, but it is now becoming evident that transfer of ERVK RNA and proteins within the 
host may trigger innate immune responses 17, 22.  Another unexplored facet of ERVK re-
activation is what cells do with excess viral protein accumulation.  Protein deposition is 
characteristic of several neurological diseases, where a failure to clear excess and aggregating 
cellular proteins is associated with neuronal dysfunction and a lack of structural connectivity 
correlating with clinical symptom severity 23, 24.   
Several gene mutations within different pathways converge into the common feature of 
TDP-43 positive neuropathology in ALS 25, 26.  Only 5-10% of familial and 1% of sporadic ALS 
cases carry TDP-43 mutations 27, 28, eluding to the fact that wild-type TDP-43 is incorrectly 
processed in the majority of patients with ALS26.  An important aspect contributing to altered 
proteostasis and TDP-43 proteinopathy is impairment of both the ubiquitin proteasome system 
(UPS), autophagy and stress granule pathways, which are disrupted in ALS 26, 29.  TDP-43 is 
known to tightly auto-regulate its expression, in order to maintain the homeostatic RNA-protein 
complex formation 25.  Yet, studies have documented enhanced TDP-43 expression in ex vivo 
patient tissues and fluids 7, 30-33.  Our previous findings demonstrate that enhanced nuclear TDP-
43 protein expression co-localizes and correlates with the extent of ERVK+ neurons in ALS 
patients 7.  Several studies have shown that cell stress and pathogenic ALS mutations can 
contribute to elevated TDP-43 levels, thus promoting neurodegeneration (reviewed in 34, 35).  
Conversely, in the context of glutamate accumulation, elevation of nuclear TDP-43 lends 
protection against cortical neuronal death 36. 
One challenge of understanding how TDP-43 fits into the pathways involved in 
neurodegeneration is its multiple cellular functions.  TDP-43 is a global regulator of RNA 
metabolism with defined roles in transcription, splicing, stability, transport, translation, 
microRNA maturation, as well as protein homeostasis. In addition to the role of TDP-43 in RNA 
regulation 37, its DNA binding capacity has been shown to repress HIV transcription by binding 
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to specific sequences within proviral DNA 38.  Recently, this finding was put into question, as 
TDP-43 over-expression had no effect on HIV levels in human immune cells and could even 
weakly enhance Tat-dependent HIV replication in HeLa cells 39.  Both articles examining the role 
of TDP-43 on HIV replication did not address cell-specific TDP-43 proteinopathy, nor validate 
their findings in ex vivo tissues.  Moreover, the influence of TDP-43 on ERVK expression remains 
unexplored. 
 
 
METHODS 
 
Patient samples 
Tissue specimens were obtained from the California NeuroAIDS Tissue Consortium 
(CNTC), the Texas Repository for AIDS Neuropathogenesis Research (TRANR), the National 
NeuroAIDS Tissue Consortium (NNTC), the Human Brain and Spinal Fluid Resource Center 
(HBSFRC), the Rocky Mountain MS Center (RMMSC) and the Johns Hopkins School of Medicine 
Brain Bank (JHSMBB).  Table S1 indicates the individual patient diagnosis, location of brain 
tissue sampling, age, gender and post-mortem interval (PMI in hours) of the samples used in 
this study.  Among confirmed cases with HIV infection (as indicated by CD4 count, plasma and 
cerebral spinal fluid viral loads), brain tissue samples were further classified as having HIV-
encephalitis based of neuropathological examination.   
 
Immunohistochemistry and immunoblotting of autopsy tissue 
To determine the extent of ERVK expression patterns in the CNS of HIV-infected 
patients, we used a previously described immunohistochemistry technique to detect RT protein 
levels and localization in autopsy tissue from human cortical brain tissue 41.  Density of 
immunostaining was quantified using ImageJ software.  Antibodies against the ERVK reverse 
transcriptase protein (AbNova #H00002087-A01) and human TDP-43 (Protein Tech #10782-2-
AP) were used for immunohistochemistry, and the same TDP-43 antibody for western blotting.  
For immunoblot sample preparation, small pieces of brain tissue were disrupted with a pestel 
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and whole cell extracts were prepared using RIPA buffer (50mM Tris, 100mM NaCl, 100 mM 
EDTA, 1% SDS, 0.5% sodium deoxycholate, 1% NP40 and protease inhibitor cocktail).  Whole cell 
extracts were cleared by centrifugation at 13,000 rpm for 10 minutes at 4°C before use in 
western blot.  Primary antibodies were detected using IRDye secondary antibodies and 
immunoblot visualised with an Odyssey scanner (LI-COR Biosciences).  Odyssey software was 
used to measuring the optical density of the TDP-43-specific bands versus the β-actin control of 
each sample.  Comparisons between patient groups were performed using the nonparametric 
Mann–Whitney U-test.  Evaluation of correlation was performed by calculating the Spearman’s 
rank correlation coefﬁcient.  P-values less than 0.05 were considered statistically significant.  
Analyses were performed with GraphPad Prism version 5 (GraphPad Software, La Jolla, 
California, USA). 
 
Cell Culture  
The SVGA cell line is derived from immortalized human fetal astrocytes73, and was 
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% Fetal Bovine Serum 
(HyClone). ReNcell CX cells (Millipore, #SCC007) are immortalized human neural progenitor cells 
(HNPCs) 74, and were maintained in a proprietary ReNcell neural stem cell medium (Millipore) 
supplemented with 20 ng/ml human epidermal growth factor (EGF; Peprotech #AF10015), 20 
ng/ml human basic fibroblast growth factor (bFGF; Peprotech #AF10018B). All cell lines were 
maintained in a 37oC incubator containing 5% CO2.  SVGA cells were seeded into six-well plates 
and onto glass coverslips in twelve-well plates at a density of 300,000 cells/ml and 30,000 
cells/ml, respectively, and grown for 24 hours. To differentiate HNPCs into neurons, ReNcells 
were seeded in laminin (20 μg/ml; Millipore #CC095) coated six-well plates at a density of 
50,000 cells/ml for 24 hours. Adhered cells were rinsed with 1X PBS and allowed to 
differentiate in the presence of ReNcell medium lacking EGF and bFGF for 10 days.  For imaging 
experiments, ReNcell CX cells were cultured and differentiated into neurons in Alvetex 
scaffolds. Alvetex membranes (Reinnervate #AVP002) were treated with 70% Ethanol for 1 
minute, rinsed with 1X PBS, and coated with 20 μg/ml laminin for 6 hours. ReNcell CX cells were 
seeded onto each scaffold at a density of 5 x 105 cells/well for 1 hour at 37oC and 5% CO2, as 
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per manufacturer's instructions. The wells were then flooded with 2 ml of ReNcell media 
supplemented with EGF and FGF growth factors. Twenty-four hours post-seeding, the cell 
culture media was replaced with that lacking growth factors.  Cells were allowed to 
differentiate for 10 days, with partial media changes performed every 3 days.  SVGAs and 
neurons were treated with 10 ng/ml dose of human TNFα (PeproTech, #AF300-02) and/or 3μM 
MG132 (Sigma) for 24 hours.  Plated untreated cells were used as negative controls. 
 
Transient transfection of wild-type and mutant TDP-43 constructs 
For transcript and total protein quantification, 4 µl of Lipofectamine LTX with 4 µl of Plus 
Reagent was used to transfect cells with 0.5, 1, 2, and 4 µg doses of TDP-43 Notag 1 or Notag 6 
constructs (Addgene), as per manufacturer’s instructions (Life Technologies).   For imaging 
experiments, cells were transfected with 0.5 µg of TDP-43 tomato alone or in combination with 
1.0 µg of TDP-43 Notag 1, 2, 3, or 6 constructs (Addgene), using 2 µl of Lipofectamine LTX with 1 
µl of Plus Reagent.  Cells were transfected in serum-free culture media for 4 hours, followed by 
addition of complete media for a total incubation of 24 hours. Untransfected cells and those 
transfected with LTX and Plus Reagent only were used as negative controls. 
 
Chromatin immunoprecipitation (ChIP) 
SVGAs were seeded in dishes at an approximate density of 3 x 106 cells/dish for 24 hours 
at 37oC and 5% CO2. Dishes were coated with 130 µg of laminin (Millipore) overnight. ReNcell 
CX cells were seeded at a density of 3 x 105 cells/dish for 24 hours at 37oC and 5% CO2, and then 
allowed to differentiate into neurons in media lacking FGF and EGF growth factors (Peprotech) 
for 10 days. Cells were treated with 10ng/ml TNFα (Peprotech) and/or 3µM MG132 (Sigma 
Aldrich) for 18 hours, fixed with 4% paraformaldehyde, and harvested. Chromatin 
Immunoprecipitation (ChIP) was performed using Pierce Magnetic ChIP kit (Thermo Scientific) 
as per manufacturer’s instructions. TDP-43 bound DNA segments were isolated using 3 µg of 
ChIP-validated rabbit anti-human TDP-43 (Proteintech #I2892-I-AP) antibody. IgG antibody was 
used as the negative control. QPCR was performed on the immunoprecipitated DNA using SYBR 
Green detection to amplify the ERVK 5ʹ LTR (nt. 800 - 968). Primers used were F: 5ʹ- 
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TACTAAGGGAACTCAGAGGCCG-3ʹ and R: 5ʹ-TAGACACCAGTGAAGGGGTGG-3ʹ. Data were 
analyzed using the ΔΔ Ct method and normalized relative to the input and IgG controls for each 
condition. All data were graphed as mean ± standard error of measurement. Statistical analyses 
were performed in GraphPad PRISM using One-Way Anova and Tukey’s multiple comparisons 
test. 
 
Quantitative Polymerase Chain Reaction (Q-PCR) 
Total RNA was extracted and purified from cells using an Aurum Total RNA Mini Kit (Bio-
Rad, #732-6820). RNA concentration was measured with a NanoDrop spectrophotometer. The 
acceptable RNA purity was A260/A280 > 2.0. The iScript Reverse Transcription kit (Bio-Rad, #170-
8840) was used to synthesize cDNA from extracted RNA. CFX Connect Real Time System (Bio-
Rad) was employed to perform Q-PCR in order to measure alterations in TARDBP, ERVK gag and 
pol transcripts using SYBR Green detection method. The primers used were: TDP-43   F: 5ʹ-
GTACGGGGATGTGATGGATG-3ʹ and R: 5ʹ-CTGCGCAATCTGATCATCTG-3ʹ, ERVK gag F: 5ʹ 
TCGGGAAACGAGCAAAGG 3ʹ and R: 5ʹ GAATTGGGAATGCCCCAGTT 3ʹ, and ERVK pol F: 5ʹ 
TGATCCCMAAAGAYTGGCCTT 3ʹ and R: 5ʹ TTAAGCATTCCCTGAGGYAACA 3ʹ. 18S rRNA was used 
as the endogenous control (Ambion kit #1718). The data were analysed using the ΔΔCT (Livak) 
method. All data were graphed as mean ± standard error of measurement. GraphPad Prism was 
used to carry out statistical analyses including column statistics, One-way Anova Friedman test, 
and Dunn’s post-test. 
 
Western Blotting 
Cells were lysed on ice with 50 μl of in-house lysis buffer (0.05M Tris (pH 7.4), 0.15M 
NaCl, 0.002M EDTA, 10% glycerol and 1% NP-40 in ultra-pure water) to extract the soluble 
proteins, followed by extraction of insoluble proteins in 50 μl of RIPA buffer (10% 1X TBS, 1% 
SDS, 1% NP-40 and 0.5% DOC in ultra-pure water). Both buffers were supplemented with 1x 
HALT protease and phosphatase inhibitor cocktail (Thermo Scientific). BCA assay (Thermo 
Scientific, #PI23227) was used to determine the protein content of each sample as per 
manufacturer’s instructions. Cell lysates were prepared for SDS-PAGE and heated at 95oC for 10 
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minutes. Proteins (15 μg per lane) were separated by SDS-PAGE using a 10% polyacrylamide gel, 
and transferred onto a nitrocellulose membrane. The membrane was blocked in 5% skim milk 
solution for one hour and probed with primary antibody overnight at 4oC, followed by 
incubation at room temperature for 3 hours.  Primary antibodies were:  mouse anti-human 
ERVK2 RT primary antibody (1:1000 dilution; Abnova, #H00002087-A01), rabbit anti-human 
TDP-43 (Thermo Scientific #PA5-17011), G3BP1, mouse-anti-human LC3B (MBL, #M1523), 
mouse anti-human β-actin (Thermo Pierce, #MA5-15739; loading control).  The membrane was 
then probed with horseradish peroxidase-conjugated goat anti-mouse or rabbit IgG secondary 
antibody (1:5000 dilution; Bio-Rad, #170-6516 and #170-6515) for 2 hours at room 
temperature. The membrane was developed with 2 ml of Luminata Crescendo Western HRP 
substrate (Millipore; #WBLUR0500) and imaged using Bio-Rad ChemiDoc XRS+ or Protein 
Simple FluorChem M chemiluminescent imager. Image Lab software was used to determine the 
molecular weight of each band, as well as their density relative to that of the negative control. 
Band densities were normalized relative to the β-actin loading control. The identity of each 
band was based on gag-pro-pol processing, as previously described 13. 
 
Fluorescent microscopy 
 Twenty-four hours post-transfection or treatment, cells were fixed with methanol for 40 
seconds, and rinsed with PBS. Cells were permeabilized with 250 μl of PBS-T (PBS with 0.25% 
TritonX-100) and blocked with 250 μl of 3% BSA in TBS-T (TBS with 0.25% TritonX-100) for 30 
minutes. Immunocytochemistry was performed using 1:1000 mouse anti-human ERVK RT 
(Abnova #H00002087A01), rabbit anti-human TDP-43 (Thermo Scientific #PA5-17011) and/or 
G3BP1 primary antibodies for 3 hours and 1:1500 goat anti-mouse AF488 and goat anti-rabbit 
AF594 (Molecular Probes #A11017 and #A11072) secondary antibodies for 2 hours. Nuclei were 
counterstained with 1:25000 DAPI. ReNcells were also stained with fluorescent Nissl (Molecular 
Probes #N21483).  Coverslips were mounted onto slides using Prolong gold anti-fade reagent 
(Molecular Probes), and dried overnight. Controls were prepared by immunostaining without 
the primary antibodies. Confocal microscopy was performed using Olympus FV1200 confocal 
microscope. For each image acquired, number of cells with aggregates and total number of cells 
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were counted in order to calculate percent aggregation under each condition using ASW4.0 
software suite. In each image, the boundaries of cells with and without aggregates were also 
outlined. The mean intensity of ERVK RT and DAPI staining was then recorded for these cells. 
The ratio of these intensities was calculated to give an indication of overall change in ERVK RT 
levels with the overexpression of wild-type and truncated TDP-43. Statistical analyses were 
performed in GraphPad PRISM using One-Way Anova and Dunn’s multiple comparisons test. 
 
 
RESULTS 
 
ERVK reverse transcriptase and TDP-43 are strongly upregulated in HIV infection 
We have previously demonstrated that ERVK reverse transcriptase (RT) expression is 
elevated in neurons of patients with Amyotrophic Lateral Sclerosis (ALS) 7.  Here, we sought to 
determine the extent of ERVK expression in the CNS of HIV-infected patients by detecting RT 
protein levels and localization pattern in autopsy tissue from parietal cortical tissue of HIV 
patients with encephalitis (HIV-E/HAND, n=6,), HIV patients without encephalitis (HIV, n=9) and 
chronic systemic illness (Controls, n=7) (Table 1).   
As HIV-E is a focal disease, different regions may have varying levels of HIV replication.  
Yet, in both HIV-infected groups, increased ERVK RT protein was detectable, but surprisingly 
expressed at similar levels (Figure 1A).  A caveat of using excised brain specimens is sampling 
bias, as not every tissue sample may be representative of the brain pathology as a whole; 
therefore, we sought to determine the extent of HIV replication in each tissue specimen 
examined and stratified the tissues from HIV infected individuals based on the presence or 
absence of HIV Gag p24 positive cells.  ERVK RT expression was significantly up-regulated in 
brain tissue with p24 reactivity (Figures 1B and 1C).  This result is consistent with previous 
findings in peripheral blood mononuclear cells demonstrating that ERVK expression is triggered 
by productive HIV infection 19, 40.  Moreover, ERVK titers are known to be elevated in HIV+ 
patients who failed to respond to HAART therapy 20, suggesting that ERVK expression in the CNS 
may also reflect inadequate response to antiretroviral treatment.  Interestingly, plasma viral 
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loads were related to ERVK RT measurements in cortical tissue of HIV-infected patients 
(Spearman’s correlation p=0.052), supporting the idea that systemic HIV replication favours 
ERVK expression in both brain and PBMC.  Neocortical productive HIV infection is characteristic 
of HIV encephalitis / HAND1, and may also be a significant factor in milder neurocognitive 
disorders.  As robust ERVK expression was found in several HIV+ patients not clinically 
diagnosed with HIV-E/HAND, pathological but modest HIV replication could drive ERVK activity 
in the CNS, which may precede overt clinical symptoms of neurological impairment.    
Our study of ERVK RT expression in ALS patients revealed that the degree of ERVK re-
activation was strongly correlated with TDP-43 in vivo41.  Aberrant cytoplasmic aggregates of 
ubiquitin-associated and hyper-phosphorylated TDP-43 are a common event in ALS cortical 
tissues42, 43.  Measurement of TDP-43 protein expression by immunohistochemistry (Figure 1D) 
or western blot (Figure S1) analysis revealed increased levels in HIV+ specimens compared to 
controls.  Furthermore, TDP-43 and ERVK RT proteins were co-expressed in the majority of 
neuronal cells (Figure 1D).  To quantitatively examine the expression pattern, co-labeled 
counting and density measurements of ERVK versus TDP-43 staining in neurons was evaluated.  
Figures 1E and 1F demonstrate that there is a significant positive correlation between TDP-43 
expression and ERVK expression in tissue (Spearman’s correlation p<0.0001, n=22) and within 
individual neurons (Spearman’s correlation p<0.0001, n=40).  Enhanced nuclear TDP-43 
expression in cortical neurons (6-fold) was also associated with increased TDP-43 
phosphorylation (4-fold) (Figure S1).  This data suggests that specific posttranslational 
modifications may alter TDP-43 protein turnover in the nucleus, as well as the formation of 
TDP-43 aggregates 42-44.    
 
Astrocytes and neurons differentially clear ERVK protein accumulation 
We observed neuronal ERVK expression in both HIV infection and ALS.  Intriguingly, no 
other brain cells appeared to accumulate ERVK proteins, as opposed to cortical neurons.  To 
address how astrocytes and neurons cope with ERVK re-activation, we designed an induction 
protocol based on inflammation and proteasome inhibition, two components of ALS 26, 45, 46 and 
HAND 47-49 neuropathology.  In both diseases, chronic inflammation and alterations in protein 
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ubiquitination culminates in a defect of proteasome function, decreased protein turnover and 
synaptic dysfunction in neurons.  TNFα treatment of human astrocytic cells (SVGAs) had no 
perceivable effect on the induction or cleavage of ERVK polyprotein into prototypic active 
subunits 13 (Figure 2A).  Proteasome inhibition by MG132 dramatically enhanced ERVK 
polyprotein levels in astrocytes.  In conjunction, TNFα and MG132 caused the degradation of 
ERVK proteins, as well as cleavage of TDP-43 into insoluble 35 and 25 kDa forms.  This 
degradative process in astrocytes appeared to be mediated through the autophagic pathway, 
as evidenced by LC3B cleavage.  Conversely, the same treatments in human ReNcell CX 
differentiated neurons yielded disparate results, with no evidence of effective autophagic 
clearance of ERVK proteins with dual TNFα and MG132 treatment (Figure 2B).  This was despite 
the fact that MG132 treatments resulted in TDP-43 and LC3B cleavage, indicating the initiation 
of autophagy. Moreover, co-treatment with TNFα and MG132 enhanced the prototypic 
cleavage of ERVK polyprotein into functional RT subunits.   
To validate that these observations were associated with protein aggregation or protein 
clearance, cells were visualized for ERVK RT and TDP-43 by confocal microscopy.  SVGA cells 
treated with TNFα exhibited slightly enhanced ERVK expression, which was not evident using 
western blot analysis (Figure 2C).  Deposition of ERVK polyprotein/RT occurred proximal to the 
nucleus in an asymmetric fashion.  MG132 treatment caused both the nuclear and cytoplasmic 
aggregation of TDP-43, in conjunction with substantially greater ERVK RT expression.  
Cytoplasmic ERVK RT and TDP-43 co-localized in aggregates adjacent to the cell nucleus.  SVGA 
cells given dual TNFα and MG132 treatment had less ERVK RT protein than MG132 treatment 
alone, suggesting inflammatory signals helped drive an effective protein degradation pathway 
in the context of proteasome inhibition.  Differentiated neurons exhibited more robust 
expression of ERVK RT at basal levels and when stimulated by either TNFα and/or MG132 
(Figure 2D).  However, MG132 treatment of ReNcell CX neurons resulted in ERVK protein 
aggregation and colocalization with TDP-43 aggregates, most markedly with TNFα and MG132 
co-treatment. 
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TDP-43 is a transcriptional activator of ERVK 
The ERVK LTR contains numerous putative TDP-43 binding sites (Figures 3A and S3), 
similar to those identified on the HIV-1 LTR 38.  Considering the enhanced expression of nuclear 
TDP-43 in cortical neurons of individuals with ALS and HIV infection, we sought to determine 
whether TDP-43 played a transcriptional role in the re-activation of ERVK.  To address this 
question, SVGAs and differentiated ReNcells were transfected with wild-type and C-terminal 
mutant TDP-43 constructs50.  Over-expression of a full-length TDP-43 construct (Notag 150) 
dose-dependently enhanced ERVK transcription in both astrocytes and neurons, independently 
of additional stimuli (Figure 3B).  Neuronal cultures were more susceptible to wild-type TDP-43-
mediated transcriptional activation, with a stronger ERVK gag and pol enhancement at 10-100-
fold lower levels of TDP-43 over-expression as compared to astrocytic cultures.  In stark 
contrast, N-terminal truncated TDP-43 (Notag 650) failed to enhance ERVK transcription (Figure 
3C).  This indicates that wild-type TDP-43 is a transcriptional activator of ERVK expression and 
may complex with other transcription factors to drive ERVK expression under inflammatory 
conditions.  TPD-43 is known to trigger pathogenic NF-κB mediated pathways in neurons 51, 52, 
and our data support this paradigm, extending it to include ERVK-driven pathology. 
TDP-43 is known to be both an RNA and DNA binding protein.  The ERVK promoter 
contains numerous putative TDP-43 binding sites, primarily in the U5 799-968 bp region (Figure 
4A and S2).  To confirm that TDP-43 bound the ERVK LTR, chromatin immunoprecipitation 
(ChIP) was performed (Figure 4 and S3).  Figure 4E reveals that TDP-43 binds the U5 region of 
the ERVK promoter, with enhanced binding during TNFα stimulation or proteasome inhibition 
(p<0.05) in astrocytes.  With simultaneous TNFα and MG132 treatment of SVGA cells, TDP-43 
undergoes cleavage into the 35 and 25 kDa forms (Figure 2A), and fails to bind the ERVK LTR.  
TDP-43 cleavage coincided with a reduction in inflammation-driven ERVK transcription (Figure 
4A and 4C), suggesting that TDP-43 co-activates the ERVK LTR along with NF-κB.  In contrast, 
enhanced TDP-43 binding to the ERVK LTR was not observed in TNFα stimulated neurons 
(Figure 4F), with no evidence of enhanced ERVK transcription in an inflammatory context 
(Figure 4B and 4D).  With MG132 treatment, TDP-43 was enriched on the ERVK LTR (Figure 4F), 
without evidence of an effect on transcription (Figure 4B and 4D).  With simultaneous TNFα 
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and MG132 treatment of neurons, partial TDP-43 cleavage occurs (Figure 2C), and there is less 
TDP-43 bound to the ERVK promoter despite exposure to MG132 (Figure 4F).  Under all 
treatment conditions in neurons, there was no effect on TDP-43 mRNA expression (data not 
shown).  This suggests that TDP-43 can only induce ERVK expression in neurons when it is 
expressed significantly above physiological levels.     
 
Mutant forms of TDP-43 promote cytoplasmic ERVK RT protein aggregation  
In ALS, the majority of TDP-43 mutations occur in the C-terminal glycine-rich domain.  
However, both N-terminal and C-terminal TDP-43 mutants can precipitate TDP-43 aggregation 
50, 53.  Transient transfection of SVGA cells with a fluorescently-tagged TDP-43 construct resulted 
in predominantly nuclear and to a lesser degree diffuse cytoplasmic TDP-43 localization (Figure 
5).  When this indicator protein was expressed in conjunction with wild-type (Notag 1) or 
domain-deletion aggregating forms of TDP-43 (Notag 2,3,6), we observed a marked 
enhancement of ERVK expression and aggregation with mutant TDP-43, as compared to wild-
type TDP-43.  Cytoplasmic TDP-43 aggregates co-localized with ERVK RT aggregation, although 
the extent of ERVK protein aggregates exceeded beyond the boundaries of TDP-43 foci.  
Quantification of ERVK protein expression was normalized against DAPI staining, revealing that 
only mutant forms of TDP-43 induced ERVK RT expression in cells.  Wild-type TDP-43 could 
promote protein aggregate formation in 14.6% of transfected cells, but was ineffectual at 
increasing ERVK RT protein levels.  In contrast, N-terminal and C-terminal truncated TDP-43 
constructs resulted in 24-31% of cells displaying protein aggregation, with a notable 
enhancement of ERVK RT expression in the majority of cells containing aggregates.  Deletion of 
the N-terminus of TDP-43 conferred the greatest effect on ERVK accumulation (Notags 2 & 3).  
This suggests that although both C and N-terminal truncated forms of TDP-43 can precipitate 
proteinopathy, the 35 kDa form of TDP-43 may be the most effective in promoting viral protein 
accumulation.  These findings further support the notion that ERVK proteinopathy may occur in 
neurological disease characterized by TDP-43 deregulation, such as ALS, HAND and 
frontotemporal dementia (FTLD).   
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ERVK RT localizes to stress granules 
ERVK RT co-localized with TDP-43 aggregates in our TDP-43 overexpression models in 
astrocytes (Figure 5). The ERVK RT and TDP-43 staining pattern in cells overexpressing these 
proteins resembled that of stress granules (SGs) 54.  Therefore, we immunostained astrocytes for 
the stress granule marker G3BP1 55.  In astrocytes, large G3BP1+ stress granules are formed in 
cells treated with TNFα and MG132 (Figure 6A).  In this case, the ERVK RT/polyprotein 
colocalizes with G3BP1, suggesting that this viral RNA binding protein is present in association 
with stress granules.  When ERVK RT expression is compared with the autophagosome marker 
LC3B (Figure 6B), there is some evidence of colocalization, but not to the same extent as with 
G3BP1.  Interestingly, in human autopsy tissue from ALS patients (Figure 6C), we observed a 
substantial increase in G3BP1.  G3BP1 levels may be supported by the enhanced TDP-43 
expression 54, as seen in ERVK+ cortical neurons in ALS 7.  Yet, in these cortical neurons, there 
was no clear colocalization of G3BP1 and ERVK RT; we propose that this segregation of SGs and 
viroplasm may underlie enhanced ERVK viral protein expression in ALS.  Together, our data 
point to the fact that stress granule formation may regulate ERVK expression, in conjunction 
with autophagic and proteasomal degradation of ERVK proteins.  Deregulation of stress granule 
formation is now considered a potential mechanism for disruption of neuronal homeostasis and 
motor neuron death in ALS.  Our data suggest that ERVK proteinopathy may be a crucial player 
in this degenerative process. 
 
DISCUSSION 
 
The expression of ERVs in the CNS has been associated with neurodegenerative 
diseases, such as ALS, Multiple Sclerosis and Schizophrenia, and is proposed to mediate specific 
pathological contributions to these diseases 56-58.  Our findings clearly suggest that the neuronal 
ERVK expression in HIV-infected individuals may also promote a unique pathological 
component of HIV-associated neurological disorders.  Enhanced ERVK expression in neurons 
occurred in the majority of HIV+ individuals, and more strongly within brain tissue exhibiting HIV 
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replication.  Our results support previous observations in PBMC from patients with HIV 
infection 20, 21, that a failure to respond to HAART therapy or receiving sub-optimal therapy may 
be associated with increased ERVK expression – both in the periphery and as our data suggest, 
in the CNS.  Thus, the development of antivirals suppressing HIV replication in the brain may 
also be indirectly neuroprotective by limiting ERV-mediated pathology.  
Inhibition of the ubiquitin-proteasome system, as seen in ALS, encourages the formation 
of stress granules 59.  Many viruses manipulate the cellular stress response by disrupting the 
formation of RNA granules 55.  Usurping key RNA binding proteins or degrading stress granules 
can facilitate viral replication.  TDP-43 is known to interact with the HIV Gag-pol polyprotein, as 
part of Staufen1 ribonucleoprotein (RNP) complexes 60.  The expression of TDP-43 in RNPs 
overlaps with both HIV viral RNA and Gag expression.  Both RNP and protein aggregates are 
subject to autophagic clearance. Overlapping aggregation of TDP-43 and ERVK polyprotein in 
both astrocytes and neurons suggests that inflammatory signals and/or proteasome 
impairment promote ERVK protein accumulation.  Both translated viral RNA and ERVK RT-RNA 
interaction could promote the formation of protein and RNP aggregates in the cytoplasm.  
Recruitment of TDP-43 to ERVK RNPs is consistent with a viral evasion strategy to promote 
ERVK replication.  Whereas astrocytes were able to clear the build-up of viral protein 
accumulation by unconventional ERVK polyprotein cleavage, neuronal cultures showed an 
inability to clear ERVK proteins.  In fact, dual inflammation and proteasome inhibition promoted 
the prototypic cleavage of functional ERVK RT isoforms.  The abundance of ERVK proteins 
within neurons may reflect cell-type specific differences in the selectivity and speed of 
autophagic mechanisms.  This may increase the vulnerability of human neurons to viral protein 
inclusion formation during ERVK reactivation.  Due to neuronal longevity and cytoarchitecture 
in the cerebral cortex, any genetic or functional impairment in protein or RNP clearance 
pathways may promote the maintenance of ERVK activity during and after the resolution of 
neuroinflammation.  
Stress granules (SG) and processing bodies (PB) are two forms of cytoplasmic RNA-
protein complexes, which regulate gene expression by translational arrest and RNA 
degradation, respectively 55.  Large SGs dock with PBs, facilitating RNA degradation 61.  Virus 
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tend to disrupt RNA granules as a mechanism to promote replication 55. Formation of stress 
granules has also increasingly been implicated in ALS pathology 29. The stress granule protein 
G3BP1 is regulated by TDP-43 54, 62 and is essential for SG-PB docking 61.  TDP-43 has previously 
been shown to colocalize with stress granule markers, and overexpression of wild type as well 
as mutant TDP-43 can enhance the formation of stress granules, although TDP-43 mutants 
result in more stress granules formed per cell 63. But, the localization of ERVK proteins to stress 
granules has not been examined. Herein, we have demonstrated that ERVK RT also co-localizes 
with the stress granule marker G3BP1 in response to TNFα and MG132 stimulation of 
astrocytes, suggesting that ERVK proteins can be recruited to stress granules. G3BP1 expression 
was also significantly enhanced in ERVK+ cortical neurons of patients with ALS as compared to 
neuro-normal controls, but no co-localization between ERVK RT and G3BP1 was observed. 
Exclusion of ERVK RT from stress granules in neurons may reflect a viral evasion strategy to 
escape degradative processes. As TDP-43 is an RNA binding protein, it may bind ERVK nucleic 
acids and shuttle them to SGs as an antiviral mechanism, to impede viral RNA translation. 
Despite the fact that TDP-43 mutants have an increased SG association, they may not be able to 
interact with ERVK RNA. In ALS, TDP-43 mutations or cleavage may result in a failure to traffic 
viral RNA to SGs, allowing the translation of ERVK polyprotein in neurons. 
We also postulate that TDP-43 cleavage may be enhanced by ERVK protease activity in 
neurons, as prototypic polyprotein cleavage events occurred concomitantly with the generation 
of a 35 kDa TDP-43 fragment.  Coxsakievirus B3 protease has been shown to mediate TDP-43 
cleavage at position Q327 resulting in an N-terminal 35 kDa product and an 8 kDa C-terminal 
fragment 64.  Protease cleavage of RNP-associated proteins, such as TDP-43, is a characteristic 
immune evasion strategy of many positive-stranded RNA viruses, as early induction and 
subsequent disassembly of stress granules limits innate antiviral response 55.   In contrast, here 
we have shown that human astrocytes displayed evidence of both prototypic ERVK polyprotein 
cleavage mediated by the viral protease, but under conditions of inflammation and proteasome 
inhibition, non-prototypic cleavage of the polyprotein occurred, suggesting that cellular 
proteases can also digest ERVK viral proteins.  A robust cleavage of all soluble and insoluble 
TDP-43 into the 35 kDa TDP-43 fragment in astrocytes during TNFα and MG132 treatment is 
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likely indicative of a caspase, calpain or cathepsin-mediated TDP-43 cleavage event 65-67, which 
may have also generated non-prototypic ERVK polyprotein cleavage.  This may represent an 
intrinsic cellular mechanism to protect astrocytes from the accumulation of endogenous 
retrovirus proteins.  It appears that neurons fail to initiate this digestive pathway, both in in 
vitro culture and as evidenced by the accumulation of ERVK RT in neurons of HIV+ individuals 
and patients with ALS. Viral protease activity may further explain the predictable spread of 
misfolded TDP-43 down the axon and across synapses through interconnected neural networks, 
as the transfer may involve the activity of virion-associated protease 68. 
TDP-43 heterozygous missense mutations have been identified in familial and sporadic 
ALS 69-71. Our data suggest that intact TDP-43 can transcriptionally activate the ERVK LTR, and 
that mutant TDP-43 can promote the aggregation of ERVK RT proteins.  This TDP-43-mediated 
enhancement of viral protein production in conjunction with the aggregating effects of 
truncated forms of TDP-43 may promote viral proteinopathy in individuals carrying select 
heterozygous TDP-43 alleles.  This effect may be further precipitated by the enhancement of 
ERVK expression by inflammatory signalling in ALS and cerebral HIV infection.  In support of 
these observations, it has been recently shown that human wild-type TDP-43 potentiates 
Q331K-mutant TDP-43 driven motor neuron loss in a humanized mouse model 72.  The 
aggressive phenotype of dual wild-type and mutant TDP-43 expression in this model resulted in 
the loss of both spinal and layer V neurons of the cortex.  In addition, TDP-43(WTxQ331K) mice 
exhibited enhanced nuclear clearance of TDP-43.    
In contrast with previous evidence of TDP-43-mediated transcriptional repression of 
HIV-1 promoter, here we showcase that TDP-43 is a transcriptional activator of ERVK.  TDP-43 
over-expression, specifically aggregating forms, promotes ERVK proteinopathy in human 
astrocytes and neurons.  These findings significantly challenge the perspective on protein 
deposition in the neuropathogenesis of HAND and ALS, by including ERVK proteinopathy as a 
novel mechanism of neuronal damage in these diseases. Consequently, quenching ERVK activity 
in these conditions may improve disease symptoms, and reverse viral-mediated pathology. This 
may be achieved through the use of anti-retroviral drugs, immunomodulatory regimens, and/or 
drugs that enhance autophagy. 
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Figure 1:  Human endogenous retrovirus-K reverse transcriptase is induced in cortical tissue 
during HIV infection.  HIV-infected individuals, with HAND/HIV-encephalitis (HIV-E) or without 
HIV-E (HIV) expressed greater levels of human endogenous retrovirus-K (HERV-K) reverse 
transcriptase protein in their cortical tissue, as compared to patients deceased with chronic 
systemic disease (Control) (A).  HIV replication in cortical tissue, as measured by HIV p24 
protein immunostaining, is associated with significantly higher HERV-K reverse transcriptase 
expression (B and C).  Mann-Whitney derived t-test, * p<0.05. Significant correlation of 
neuronal HERV-K reverse transcriptase and TDP-43 protein levels in HIV+ patients.  
Representative immunohistochemistry images of TDP-43 protein, human endogenous 
retrovirus-K reverse transcriptase (HERV-K RT), nucleic as measured by DAPI staining and 
neurons as measured by Nissl staining in the cortical brain tissue of HIV infected patients (HIV+) 
versus patients with systemic disease (Control) (D).  ImageJ analysis was used to quantify the 
density of HERV-K RT and TDP-43 staining within individual tissue samples (E) and within 
individual neurons (F) of HIV infected and controls cortical brain specimens.   
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Figure 2:  Astrocytes and neurons differentially clear ERVK protein accumulation. SVGA and 
ReNcell CX-derived neurons were treated with TNFα and MG132 individually or in combination 
for 24 hours (n=3). Western blot was performed on the soluble and insoluble protein fractions 
to detect alterations in ERVK RT, TDP-43, and LC3B protein levels relative to untreated cells. β-
actin was used as the loading control. (A) In SVGA cells, TNFα had no discernible effect on ERVK 
RT expression. MG132-mediated proteasome inhibition dramatically enhanced ERVK 
polyprotein/RT levels. SVGA cells were able to clear ERVK and TDP-43 protein accumulation 
through autophagy, as indicated by enhanced LC3B-I cleavage into LC3B-II with TNFα and 
MG132 combination treatment. (B) Representative confocal micrographs of SVGAs treated with 
TNFα and/or MG132 (n=3), recapitulating MG132-mediated ERVK polyprotein/RT and TDP-43 
aggregation. ERVK protein aggregates deposited proximal to the nucleus. TNFα slightly 
enhanced ERVK deposition, which was not evident in western blot. SVGA cells treated with a 
combination of TNFα and MG132 exhibited less ERVK polyprotein/RT expression and 
aggregation. (C) Unlike SVGAs, TNFα, but not MG132 treatment of neurons, enhanced ERVK RT 
expression. Neurons were also unable to degrade ERVK polyprotein/RT through autophagy, 
although LC3B cleavage was observed (n=3). (D) These findings were also confirmed using 
confocal microscopy, as ERVK polyprotein/RT aggregation persisted in neurons regardless of 
TNFα and MG132 dual treatment (n=3). 
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Figure 3. TDP-43 is a transcriptional activator of ERVK. Depiction of TDP-43 (pink) and κB 
(purple) binding sites on a consensus ERVK LTR, as predicted by Promo software (A).  The 
sequence of the HIV-1 TAR-DNA element was used to identify a potential TAR-like encoding 
motif spanning the nucleotides 448 to 505 within the consensus ERVK 5ʹ LTR. Conventional and 
three alternative transcriptional start sites are depicted by black and grey arrows, respectively. 
Wild-type TDP-43 drives ERVK expression to a greater extent in neurons than in astrocytes (B 
and C).  SVGA and ReNcell CX-derived neurons were transfected with various doses of plasmids 
encoding wild-type (Notag 1 construct) or truncated TDP-43 (Notag 6 construct) for 24 hours 
(n=3). Q-PCR was performed on RNA extracts using SYBR green detection. ΔΔCt method was 
used to calculate fold change in TARDPBP (TDP-43 gene), ERVK pol and ERVK gag transcription 
relative to untransfected negative control. 18s rRNA was used as the endogenous control. 
Western blot was also performed on the soluble and insoluble protein fractions to detect 
alterations in ERVK RT and TDP-43 levels relative to untreated cells. Over-expression of wild-
type TDP-43 dose-dependently enhanced ERVK gag and pol transcription in both astrocytes 
(*p<0.05 **p<0.01; n=3) (B) and neurons (n=2) (C). In contrast, mutated TDP-43 failed to 
significantly enhance ERVK transcription in astrocytes (*p<0.05 **p<0.01; n=3) (B) and in 
neurons (n=2) (C). 
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Figure 4. TDP-43 binds the ERVK LTR. Q-PCR was also performed on whole cell RNA extracts to 
determine alterations in ERVK gag and pol transcription relative to untreated cells using ΔΔCt 
method. 18s rRNA was used as the endogenous control. Decreased binding of TDP-43 to the 
ERVK promoter coincided with a reduction in ERVK transcription in astrocytes (*p<0.05; n=3) (A, 
C, E) and neurons (p values; n=1) (B, D, F).   Chromatin isolated from TNFα and/or MG132 
treated SVGAs and ReNcell CX-derived neurons was subjected to chromatin 
immunoprecipitation with anti-human TDP-43 antibody or IgG antibody control (E and F). QPCR 
was performed on immunoprecipitated DNA to amplify ERVK 5ʹLTR using SYBR Green detection. 
For each condition, fold Enrichment in TDP-43 binding was calculated relative to the input first 
and then IgG control. TNFα as well as MG132 treatment of SVGAs (E) and MG132 treatment of 
neurons (F) led to enhanced binding of TDP-43 to the ERVK promoter, which was abolished with 
TDP-43 cleavage during dual treatment of cells with TNFα and MG132 (*p<0.05 **p<0.01; n=3). 
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Figure 5. Wild-type and mutant forms of TDP-43 significantly differ in their capacity to 
enhance ERVK RT protein aggregation.  SVGAs (A and B) and ReNcells (C and D) were 
transfected with either wild-type (Notag 1) (A and C) or mutant TDP-43 (Notag 6) constructs (B 
and D). Western blot was performed on the soluble (left) and insoluble (right) protein fractions 
to detect alterations in ERVK RT and TDP-43 protein levels relative to untreated and 
untransfected cells. β-actin was used as the loading control. (A, B) In SVGA cells, overexpression 
of wild-type TDP-43 enhanced ERVK polyprotein expression, whereas overexpression the C-
terminal truncated TDP-43 mutant reduced ERVK expression. (C, D)  In stark contrast, wild-type 
TDP-43 promoted insoluble ERVK polyprotein expression, and the Notag6 construct enhanced 
the cytoplasmic availability of the ERVK polyprotein.  (E,F) SVGA cells were transfected with a 
combination of fluorescently-tagged wild-type TDP-43 indicator plasmid (TDP-43 tomato) and 
constructs encoding wild-type (Notag 1) or mutant forms of TDP-43 (Notag 2, Notag 3, or Notag 
6). 24 hours post-transfection, cells were fixed with methanol and immunostained using anti-
human ERVK RT antibody. Cells were counterstained with DAPI. Confocal micrographs were 
acquired using Olympus Fluoview confocal microscopy suite. Untransfected cells or those 
transfected with TDP-43 tomato only were used as negative controls. (E) Representative 
micrographs depict that over-expression of mutant TDP-43 markedly enhanced ERVK RT 
expression and aggregation, as compared to wild-type TDP-43. Cytosolic TDP-43 aggregates co-
localized with ERVK RT aggregates (n=3). (F) ERVK RT expression was also quantified in these 
cells and normalized to DAPI staining. Only mutant forms of TDP-43 were found to significantly 
enhance ERVK RT expression and aggregation, with N-terminal truncated TDP-43 fragments 
(Notag 2 and 3) conferring the greatest effect on ERVK accumulation (****p<0.0001; n=3). 
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Figure 6. ERVK is localized to G3BP1+ stress granules. SVGA cells were treated with TNFα (10 
ng/ml) and/or MG132 (3uM) for 24 hours, methanol-fixed, and immunostained for ERVK 
RT, G3BP1, or LC3B (n=1).  (A) Representative confocal micrographs depict markedly enhanced 
co-localization of ERVK RT and G3BP1 in astrocytes treated with a combination of TNFα and 
MG132. (B) In comparison, ERVK RT did not co-localize as strongly with the autophagy marker 
LC3B, suggesting specific shuttling of ERVK RT to stress granules. (C) Representative confocal 
micrographs of Brodmann's area 6 motor cortex from a patient with ALS and a neuro-normal 
control. Cortical neurons in ALS tissues exhibited marked increase in G3BP1 levels 
concomitantly with enhanced ERVK RT levels. However, a lack of co-localization between ERVK 
RT and G3BP1 was evident, and may represent viral evasion strategy to escape degradative 
processes.  
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Figure S1:  Neuronal TDP-43 is over-expressed and phosphorylated during HIV infection.  
Western blot analysis of whole cell lysates from cortical brain tissue reveals increased native 
and phosphorylated TDP-43 expression in HIV infected patient samples (1-4) as compared to 
controls (1-3) (A).  Densitometry measurements of the immunoblot bands confirm that both 
native and phosphorylated TDP-43 levels are enhanced in cortical tissue specimens from HIV 
positive individuals as compared to chronic systemic disease controls (B). 
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Figure S2:  TDP-43 and κB sites within the ERVK LTR, as predicted by Promo software.  In silico 
examination of the conserved TDP-43 binding sites within five prototypic ERVK 5ʹ LTRs. The 
ERVK 5ʹ LTR consensus sequence was constructed using individual ERVK LTRs in the following 
order (GenBank accession numbers in brackets): ERVK-10 (M12854.1), ERVK-9 (former HERV-
K109) (AF164615.1), ERVK-8 (former HERV-K115) (AY037929.1), ERVK-6 (former HERV-K108) 
(AF074086.2) and ERVK-113 (JF742069.1). The sequences of the TDP-43 DNA binding sites were 
obtained from 38. The sequence of the HIV-1 TAR-DNA element was obtained from GenBank 
(accession number AM076891.1) and used to identify a potential TAR-like encoding motif 
spanning the nucleotides 448 to 505 within the consensus ERVK 5ʹ LTR. Conventional (793bp) 
and three alternative (460, 570, and 826 bp) transcriptional start sites are depicted by black and 
grey arrows, respectively 14. Sequence alignment and annotation were performed using 
Geneious software 75.    
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Figure S3. No perceivable change was observed in TDP-43 binding to the RIG-I promoter. 
Chromatin isolated from TNFα and/or MG132 treated SVGAs (A) and ReNcell CX-derived 
neurons (B) was subjected to chromatin immunoprecipitation with anti-human TDP-43 
antibody or IgG antibody control. QPCR was performed on immunoprecipitated DNA to amplify 
the RIG-I promoter (negative control) using SYBR Green detection. For each condition, fold 
enrichment in TDP-43 binding was calculated relative to the input first and then IgG control.  
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Table 1:  Cortical Brain Tissue Specimens 
Case Brain 
Bank 
Diagnosis Tissue Age 
(yrs) 
Gender PMI CD4 Plasma viral 
load 
CSF viral 
load 
CB164 CNTC HIV+ Parietal lobe 35 M 5 211 2827 78 
CC128 CNTC HIV+ Parietal lobe 47 M 12 306 4953 ND 
CE132  CNTC HIV+/HIV-E Parietal lobe 39 M 7 26 ND 0 
7101868276 TRANR HIV+/HIV-E Parietal cortex 41 M 7.6 37 >500000 >55695 
7100616568 TRANR HIV+/HIV-E Parietal cortex 32 M 16.2 77 489796 3041500 
7101847783 TRANR HIV+ Parietal cortex 59 M 11.3 8 54439 735 
7101997784 TRANR HIV+ Parietal cortex 41 M 15.3 76 711 644 
7100928374 TRANR HIV+ Parietal cortex 38 F 10.8 3 104358 93 
7100598287 TRANR HIV+ Parietal cortex 50 M 13 121 <50 <10 
1093 NNTC HIV+/possible HAD Parietal cortex 56 M 6 365 25669 ND 
2005 NNTC HIV+ Parietal cortex 44 F 3 66 >75000 249 
2012 NNTC HIV+/HIV-E Parietal cortex 49 M 16 273 ND <50 
5007 NNTC HIV+/possible 
HAD/HIV-E 
Parietal cortex 37 F 3 91 >75000 ND 
5008 NNTC HIV+/possible 
HAD/HIV-E 
Parietal cortex 53 M 7 128 8641 54061 
6081 NNTC HIV+/probable HAD Parietal cortex 35 M 2 ND ND ND 
3565 HBSFRC Cardiomyopathy Cortex 76 M 11    
27 RMMSC Coronary artery 
disease 
Cortex 69 M 6.5    
712 JHSMBB Unknown Prefrontal cortex 44 F 20    
23895 JHSMBB Unknown Occipital cortex ND ND ND    
000 JHSMBB Unknown Motor cortex ND ND ND    
33 RMMSC Pulmonary disease Cortex 69 M 4.5    
795 JHSMBB Huntington's disease Sensory Cortex 48 F 9    
2776 NBB ALS BA6 Motor Cortex 76 F 8.6    
5215 NBB ALS BA6 Motor Cortex 59 M 12.5    
5187 NBB ALS BA6 Motor Cortex 69 M 13.2    
4660 NBB Cancer BA6 Motor Cortex 73 F 18.5    
3371 NBB Cancer BA6 Motor Cortex 52 M 16    
4514 NBB Cancer BA6 Motor Cortex 66 M 17.3    
 
Tissue specimens were obtained from the California NeuroAIDS Tissue Consortium (CNTC), the Texas Repository 
for AIDS Neuropathogenesis Research (TRANR), the National NeuroAIDS Tissue Consortium (NNTC), the Human 
Brain and Spinal Fluid Resource Center (HBSFRC), the Rocky Mountain MS Center (RMMSC), the Johns Hopkins 
School of Medicine Brain Bank (JHSMBB) and the NIH Neurobiobank (NBB). Post-mortem interval (PMI) is indicated 
in hours.  Brodmann’s area 6 (BA6).  No data (ND). 
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4.  DISCUSSION 
Aberrant ERVK transcription and protein expression in the CNS has been implicated in 
the pathogenesis of several neuroinflammatory diseases, including ALS and HAND. However, 
the mechanisms that promote ERVK transcription and viral protein accumulation in the context 
of neuroinflammation have not been comprehensively analyzed. Thus, the overarching goal of 
this work was to elucidate the cellular pathways responsible for ERVK re-activation in these 
associated neurological diseases, as well as to validate findings from our in vitro models by 
examining biomarkers in ex vivo human autopsy tissues. 
 
4.1 | Transcriptional regulation of ERVK  
 
4.1.1 | ERVK promoter contains functional ISREs, which bind NF -κB and IRF1 to  
             enhance ERVK gene transcription during neuroinflammation  
Several lines of evidence suggest that augmented levels of TNFα, LIGHT, and IFNγ 
cytokines drive enhanced activity of pro-inflammatory transcription factors (TFs) in neurological 
diseases, which may be important triggers of ERVK transcription in the CNS19,59,68. We have 
previously examined ERVK (HML-2) 5ʹ LTRs in silico and identified conserved putative binding 
sites for IRF1 and NF-κB, including two Interferon Stimulated Response Elements (ISREs)68. 
However, the biological functionality of these predicted ISREs has not been elucidated. We 
therefore set out to determine whether the aforementioned cytokines can enhance ERVK gene 
transcription and protein expression in astrocytes and neurons, and whether this effect is 
mediated by increased interactions of NF-κB and/or IRF1 with the ERVK 5ʹ LTR. 
For the first time, we have utilized chromatin immunoprecipitation (ChIP) to showcase 
that the ERVK 5ʹ LTR harbors two conserved functional ISREs which can interact with pro-
inflammatory TFs NF-κB and IRF1. Both astrocytes and ReNcell CX-derived neurons exhibited 
basal NF-κB and IRF1 binding to the ISREs in ERVK 5ʹ LTRs, which alludes to the basal ERVK 
expression in these cells (Publication 3; Figure 3). Under optimal stimulating conditions, LIGHT-
treated astrocytes and TNFα-treated neurons exhibited markedly enhanced NF-κB p50 and p65 
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binding to each ISRE in the ERVK promoter (Publication 3; Figure 3). Transcription factor 
binding was associated with increased ERVK polyprotein and RT expression in these cells 
(Publication 3; Figures 1 and 2). Although the binding of IRF1 to the ISREs considerably 
increased with cytokine stimulation (9 and 7 fold in SVGAs and neurons, respectively), it did not 
reach statistical significance with three experimental replicates. Together, these findings 
suggest that NF-κB and IRF1 binding to the ERVK 5ʹ LTR has an important role in transcriptional 
re-activation of this provirus in the context of neuroinflammation.  
A caveat of our ChIP experiments was the lack of a promoter deficient in IRF1 and/or 
NF-κB binding sequences to serve as the negative control. This is because the human genome is 
extensively laden with binding sites for these TFs113,114. For instance, there are 14,000 
estimated NF-κB binding sites in the human genome114. There are also numerous NF-κB 
responsive genes in a single cell type; for example, human pancreatic cells alone contain over 
500 genes targeted by this TF115. Additionally, NF-κB binding is not restricted to promoter 
regions, as a significant level of binding has been detected in intronic regions with ChIP 
experiments116. Likewise, we also observed enrichment of NF-κB and IRF1 proteins in DNA 
regions other than promoters, such as the ERVK pol gene (Publication 3, Figure S2). Thus, it is 
inherently difficult to identify IRF1 and/or NF-κB deficient regions of the human genome that 
may be used as negative controls in ChIP Q-PCR. 
Moreover, the interaction of transcription factors with their cognate sites on DNA is a 
very complex and a dynamic process, and not all binding events lead to functional outcomes117–
119. For instance, cooperativity between TFs is one of the crucial determinants of a successful 
transcriptional output at a given promoter117–119. IRF1 and NF-κB-responsive human and viral 
gene promoters are no exception, as synergy between IRF-1 and NF-κB is required to induce the 
transcription from human inducible nitric oxide synthase, interleukin-15, and interferon β 
promoters, as well as from the HIV-1 5ʹ LTR65. Accordingly, partially overlapping or adjacent 
IRF1 and NF-κB binding sites have been described at these promoters65,120. The ERVK 5ʹ LTR also 
harbours similar binding sequence arrangement for these TFs (Publication 3, Figure 3A). 
Cooperativity between TFs can activate a given promoter because co-bound TFs can recruit 
common cofactors, such as p300/CBP and TFIID, leading to the formation of transcription 
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initiation complexes117. The protein-protein interactions between transcription factors can 
further stabilize transcription initiation complexes, leading to an optimal effect on target gene 
expression117–119. IRF1 and NF-κB binding to their respective sites in the interferon β promoter 
is known to form a stable nucleoprotein complex, called an enhanceosome121. IRF1 and NF-κB 
cooperatively recruit p300/CBP to the enhanceosome, which leads to synergistic transcriptional 
activation of the interferon β gene. In line with these findings, herein we show that the binding 
of NF-κB p65/p50 and IRF1 to the ERVK promoter is simultaneously required to synergistically 
enhance proviral transcription. This is because transient transfections of astrocytes with 
plasmids encoding active NF-κB isoforms and IRF1 produced a significant 70 fold increase in 
ERVK pol RNA levels only when these transcription factors were co-expressed, and not when 
overexpressed individually (Publication 3, Figure 3B). This data supports the notion that a 
combination of NF-κB p65/p50 and IRF1 transcription factors can work in concert on the ERVK 
5ʹ LTR to optimally drive the transcriptional re-activation of ERVK. 
Pro-inflammatory cytokine-mediated induction of ERVK also translates to the protein 
level in astrocytes and neurons, as TNFα, LIGHT, and IFNγ dose-dependently enhance ERVK 
polyprotein/RT levels, albeit in a cell-type specific manner. IFNγ was able to induce ERVK 
polyprotein/RT expression equally well in both astrocytes and neurons (Publication 2, Figures 
1, 2, and 3). TNFα increased ERVK protein levels most prominently in neurons (Publication 3, 
Figure 2), whereas LIGHT was best able to induce ERVK in astrocytes (Publication 3, Figure 1). 
This effect can be explained by differential enrichment of NF-κB at the ISREs in the ERVK 
promoter during TNFα or LIGHT stimulation of astrocytes and neurons. TNFα, but not LIGHT, 
significantly increased NF-κB p65 and p50 protein levels as well as their interaction with the 
ISREs on the ERVK promoter in neurons (Publication 3, Figures 2 and 3 E-F). In stark contrast, 
LIGHT, but not TNFα, significantly enhanced NF-κB p65 and p50 binding to the ISREs in 
astrocytes (Publication 3, Figure 3 C-D).  
Such cell-type specificity of TNF superfamily cytokines, TNFα and LIGHT, may also be 
explained by differential expression of their cognate cell surface receptors, as well as 
downstream signaling molecules in astrocytes and neurons. TNFα is known to be biologically 
active in both transmembrane as well as soluble forms122,123. Soluble TNFα mainly signals 
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through TNF receptor 1 (TNFR1)122, which is found at a lower level in astrocytes as compared to 
neurons (The Human Protein Atlas). Overproduction of soluble TNFα has been shown to cause 
neurodegeneration in the CNS123. Trans-membrane TNFα on the other hand mainly signals 
through TNFR2, which is primarily found in microglial cells122,101. Since, we utilized soluble TNFα 
in our cell line models, it is not surprising that neurons, but not astrocytes, were more 
responsive to this cytokine. Adaptor molecules that associate with TNF receptors, known as 
TRAFs, exert a second layer of control over cell-specific TNFα and LIGHT signaling. TRAF3 is 
basally expressed in neurons, but not in glial cells (The Human Protein Atlas), and has been 
shown to be much more inducible in neurons as compared to astrocytes124. TRAF3 is a negative 
regulator of LIGHT signaling as it inhibits the function of LTβ receptor, which results in NF-κB 
inactivity124. In contrast, TRAF3 has no effect on TNFα-induced NF-κB signaling124. Neuronal 
expression of TRAF3 may have inhibited LIGHT-induced NF-κB signaling, leading to a lack of any 
perceivable effect on ERVK expression in our neuronal models.    
In order to further validate our in vitro findings, we have utilized fluorescent confocal 
microscopy to determine whether the cortical brain tissue from patients with ALS exhibits 
increased IRF1/NF-κB nuclear localization in ERVK+ neurons as compared to neuro-normal 
controls. The cortical neurons in ALS brain tissues indeed show enhanced nuclear translocation 
of IRF1 and NF-κB p50, and to a lesser extent p65, as compared to the controls (Publication 3, 
Figure 5). Nuclear translocation of these TFs correlated with enhanced ERVK RT expression in 
cortical neurons. Overall, ALS-associated pro-inflammatory cytokines are likely responsible for 
ERVK re-activation in the cortical neurons of patients with this neurodegenerative disorder. 
It is now well established that exacerbated TNFα, LIGHT, and IFNγ signaling pathways in 
the CNS converge at NF-κB and/or IRF1 dependent neuronal damage51; however, the exact 
mechanism by which these pro-inflammatory transcription factors promote neuronal death 
remains unclear. Our findings suggest that ERVK re-activation in neurons triggered by the 
synergistic action of NF-κB and IRF1 may serve as the link between exacerbated pro-
inflammatory cytokine signaling and neuronal damage. The detection of ERVK nucleic acids and 
proteins by innate immune sensors may drive anti-retroviral responses and further NF-кB/IRF1 
activation, culminating in the production of pro-inflammatory cytokines by astrocytes, glial cells, 
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and infiltrating T cells. This may create a feed forward loop, generating repetitive cycles of NF-
кB/IRF1-induced ERVK expression and inflammatory response against ERVK-expressing neurons, 
leading to neuronal injury. Previously, the envelope protein of ERVW has been demonstrated to 
trigger innate immune signaling and the secretion of pro-inflammatory cytokines, driving NF-κB 
activation125. This TF further activated LTR-driven transcription of ERVW, generating a vicious 
cycle of latent ERV re-activation and uncontrolled inflammation104,105. In addition, multiple 
retroviral proteins have been shown to exert neurotoxic effects. For instance, the 
overexpression of ERVW envelope protein induces endoplasmic reticulum stress, leading to 
neuroinflammation and production of free radicals with ensuing demyelination and axonal 
injury126. HIV-1 proteins gp120 and Tat can lead to the activation of neuronal proteases, which 
cleave post-synaptic density proteins and cause synaptic dysfunction39. Similarly, the expression 
of ERVK proteins may also prove to be toxic for neurons. However, whether ERVK re-activation 
in neurological diseases is responsible for neuroinflammation and cell death is yet to be 
elucidated. 
4.1.2 | TDP-43 interacts with the ERVK promoter and acts as a transcriptional  
            activator of ERVK 
 In addition to NF-κB and IRF1, other transcription factors may also play an important role 
in regulating ERVK transcription. TDP-43 is a global transcriptional regulator, and has previously 
been shown to modulate HIV gene expression83,84. The overexpression of endogenous TDP-43 
has been strongly co-related with higher levels of ERVK pol transcripts in the neurons of ALS 
patients31, suggesting that TDP-43 may influence ERVK transcription. Indeed, in silico analysis of 
ERVK 5ʹ LTRs has revealed conserved putative TDP-43 bindings sites throughout this proviral 
promoter, although the functionality of these sites remains to be verified empirically. Therefore, 
we sought to determine whether accumulation of TDP-43 enhances its interactions with the 
ERVK 5ʹ LTR, and leads to up-regulation of ERVK gene transcription and protein levels in 
astrocytes and neurons. 
 For the first time, we have shown that TDP-43 binds the ERVK promoter and acts as a 
transcriptional activator of ERVK. In support of this claim, overexpression of the wild-type TDP-
43, but not a mutated form, significantly enhanced ERVK gag and pol transcription in a dose 
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dependent manner in astrocytes and neurons (Publication 4, Figure 3). In addition, TDP-43 
accumulation, achieved through proteasome blockade via MG132 treatment of cells, associated 
with increased nuclear localization of TDP-43 and its interaction with the ERVK 5ʹ LTR in 
astrocytes and neurons (Publication 4, Figures 2B, 2D, and 4). This coincided with enhanced 
levels of ERVK polyprotein/RT in astrocytes but not in neurons (Publication 4, Figure 2). It is 
important to note that transcription factor binding on a promoter does not necessarily imply a 
gene expression output, as many other factors govern the outcome of transcription factor 
binding to DNA. This includes, but is not limited to, the presence or absence of other 
transcriptional co-modulators, ability of transcription factors to interact and dimerize, 
appropriate spatiotemporal organization of their binding sites, as well as the length of time they 
are bound to their cognate sites on a promoter117,118,119. A lack of effect on ERVK transcription in 
neurons despite enhanced TDP-43 binding to the ERVK promoter may be explained by these 
factors. Moreover, TDP-43 cleavage stimulated by TNFα and MG132 treatment diminished the 
binding of TDP-43 to the ERVK promoter, leading to a dramatic decrease in ERVK transcripts and 
polyprotein/RT levels in astrocytes (Publication 4, Figure 4). Although this effect was also 
observed in neurons, it was much less prominent as compared to that observed in astrocytes 
(Publication 4, Figure 4).  
Cell-type dependent regulation of host as well as viral gene expression is a common 
feature of many cellular transcription factors80. Thus, it is not surprising that TDP-43 was able to 
enhance ERVK expression in the astrocytic cell line much more strongly as compared to ReNcell 
CX-derived neurons. In addition, a given transcription factor can also exert a differential 
influence on the expression of its target gene depending on the promoter context, including 
where it binds on the promoter when multiple binding sites are present and its interactions 
with other transcription factors80,127,128. Likewise, TDP-43 may differentially bind to its 
respective sites in the ERVK promoter in astrocytes versus neurons. It may also differentially 
interact with other transcription factors, such as NF-κB p65111, and influence its binding to the 
ERVK promoter in these cells. Astrocytic cells used in these experiments expressed higher basal 
levels of IRF1 and NF-κB p65 proteins in comparison to neurons. A comparatively greater 
number of TDP-43 – NF-κB p65 interactions in astrocytes may enhance the levels of active NF-
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κB p65 above the required threshold, leading to ERVK transcriptional activation in the presence 
of IRF1. Consequently, these factors may account for the ability of TDP-43 to serve as a strong 
ERVK transcriptional activator in astrocytes but only a weak one in neurons.  
Furthermore, the genetic background of cell lines has previously been shown to cause 
transcriptional heterogeneity129. Likewise, the genetic background of the ReNcell CX cell line 
used to derive neurons may also influence the ability of endogenous TDP-43 to enhance ERVK 
transcription in these cells. For instance, there may be variations in ERVK LTRs or alternatively 
functional single nucleotide polymorphisms in transcription factors (for example NF-κB) 
between SVGAs and ReNcell CX cells, which may influence the level of TDP-43-mediated 
transcription of ERVK. A potential solution to this issue would be the use of additional astrocytic 
and neuronal cell lines to evaluate the influence of TDP-43 accumulation on ERVK transcription. 
Unfortunately, there is a lack of human astrocytic and neuronal cell lines with normal human 
karyotype; thus, alternative cell lines cannot be employed to study ERVK, as abnormalities in 
chromosome structure and number are known to significantly influence ERVK biology. 
 Overall, these studies have allowed us to expand our understanding of the mechanisms 
behind transcriptional re-activation of ERVK in ALS. We have demonstrated that augmented 
activity of ALS-associated transcription factors – NF-κB, IRF1, and TDP-43 – can enhance ERVK 
expression in astrocytes and neurons through their increased interactions with the ERVK 
promoter. Although enhanced NF-κB and IRF1 activity is a common feature of many 
inflammatory diseases, ERVK re-activation may proceed through different transcriptional 
mechanisms in other ERVK-associated diseases. Yet unexplored transcription factors and cellular 
signaling pathways may play a crucial role in this process, as the ERVK promoter is laden with 
binding sites for numerous other transcriptional regulators, such as activating protein-1 (AP-1), 
Signal Transducer and activator of transcription (STAT proteins), and other interferon regualtory 
factors (IRF3, IRF7)68. The influence of these host factors and disease-specific proteins on ERVK 
transcription was not in the scope of the current studies and will have to be tested empirically 
in the future.  
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4.2 | Processing of the ERVK polyprotein culminates in the production  
            of active heterodimeric RT under neuroinflammatory conditions  
Enhanced expression and activity of the ERVK reverse transcriptase (RT) protein has 
been implicated in several inflammatory and neurodegenerative diseases. Most importantly, 
elevated levels of ERVK RT have been observed in the cortical neurons of patients with ALS31. 
This observation is consistent with the detection of increased RT activity in the CSF and serum 
of individuals with ALS35,53. Thus, augmented ERVK RT expression is a promising biomarker for 
diseases associated with ERVK re-activation, including ALS. However, little work has been done 
to identify ERVK RT isoforms, their production resulting from ERVK polyprotein cleavage, and 
their functionality in health and disease. 
Using gag-pro-pol polyprotein processing in exogenous retroviruses (HIV) as a model 
(Figure 3), we are the first to describe enhanced ERVK polyprotein cleavage culminating in the 
generation of conventional RT subunits under inflammatory conditions in neurons and 
astrocytes. Similar to HIV polyprotein processing, multiple protease cleavage steps produced 
intermediate protein products before ERVK RT subunits were finally released. As with 
exogenous retroviral RT enzymes72,76,77, the formation of two different sized ERVK RT isoforms 
was detected in astrocytes and neurons. Astrocyte-derived ERVK RT consisted of a 52 or 54 kDa 
structural isoform without RNase H and a 60 kDa catalytic isoform containing an RNase H 
domain (Publication 2, Figure 1C; Publication 3, Figure 1A). In comparison, neuron-derived 
ERVK RT exhibited an increase in mass, comprising 56 or 58 kDa structural isoform and a 68 kDa 
catalytic isoform (Publication 2, Figure 3A and B; Publication 3, Figure 2A). Additionally, the size 
of ERVK RT with RNase H domain was previously determined to be approximately 65 kDa130. 
This variation in sizes may be attributed to the cell types used as sources of ERVK RT, as like 
other proteins, ERVK RT may also acquire differential post-translational modifications 
depending on the cell type131. Nonetheless, our findings depict that ERVK RT is likely to be a 
heterodimer consisting of a smaller structural subunit without RNase H and a larger catalytically 
active subunit with RNase H, similar to RT encoded by exogenous retroviruses. However, a 
caveat of this study is that the sizes and the identities of the cleavage products as well as the 
ERVK RT subunits were inferred from HIV polyprotein cleavage and RT structure, and still remain 
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to be verified empirically. This may be achieved by separating and collecting the ERVK 
polyprotein cleavage products by high pressure liquid chromatography, performing amino acid 
analysis, and confirming their identity by mass spectrometry132. 
Interestingly, the structural RT subunit was found to be expressed at basal levels in both 
astrocytes and neurons, and dose dependently increased with cytokine treatment of cells. 
However, the catalytically active RT subunit was only expressed in the presence of cytokines, 
suggesting that optimal ERVK RT activity likely occurs under neuroinflammatory conditions 
(Publication 2, Figure 1C; Publication 3, Figure 2A). In support of this claim, RT enzymatic 
activity in whole cell extracts was significantly enhanced with cytokine treatment as compared 
to untreated cells (Publication 2, Figure 1B); however, it does not specifically reflect ERVK RT 
activity, but rather global cellular RT activity. Due to a lack of enzymatic assays specifically for 
ERVK RT, it is currently not possible to precisely measure the activity of this ERVK protein. 
Alternatively, currently available enzymatic assays designed to measure exogenous retroviral RT 
activity132 can be modified to specifically measure the activity of ERVK RT in our cell line models, 
which has previously been achieved for a reconstructed infectious clone of ERVK (HML-2)133. 
Nonetheless, the ability of ERVK to produce an active viral RT enzyme has important 
implications for ERVK biology, as well as for the role of this endogneous retrovirus in the 
associated inflammatory diseases. Since RT catalyzes conversion of retroviral RNA into DNA – a 
step necessary for the integration of retroviral genome into the host DNA –  the presence of 
enzymatically active ERVK RT suggests that ERVK reintegration events may be possible as long as 
the activity of viral integrase is retained. Accordingly, insertional polymorphisms in ERVK (HML-
2) loci have been reported in humans134, raising the possibility that ERVK (HML-2) family may be 
active and undergoing reintegration in present-day humans. In addition, enzymatically active RT 
may facilitate retrotransposition of ERVK, which may perturb the function of critical host genes 
and contribute towards disease130. There is evidence that endogenous RT activity and 
retrotransposition can alter gene expression patterns in human cells, including neurons135,136. 
Likewise, enhanced ERVK RT activity in cortical neurons of patients with ALS may contribute to 
neurodegeneration by disrupting the expression of critical genes through retrotransposition 
events. 
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Moreover, RT activity will generate RNA-DNA hybrids and eventually cytoplasmic dsDNA 
during reverse transcription of ERVK RNA genome in astrocytes and neurons. These RNA and 
DNA intermediates may be transmitted in a cell to cell fashion137, as ERVK assembles virions 
with RNA or DNA genomes. It has been shown that ERVK virions can package a synthetic ERVK 
HML-2 genetic probe and transmit it to other cells29. These newly transmitted ERVK nucleotide 
sequences may be detected by PRRs, such as Retinoic acid inducible gene I (RIG-I) and IFN 
inducible protein 16 (IFI16)138.  ERVK RNA:DNA hybrids generated in a cell may also serve as viral 
PAMPs for innate immune detection by Toll like receptor 9 (TLR9)139 or orphan DNA sensors140. 
The interactions of these PRRs with their cognate ligands culminates in the activation of NF-κB 
and IRFs, and the production of pro-inflammatoy cytokines, which aid in restricting viral 
replication. However, ERVK may exploit this process for its further activation, generating a feed 
forward loop consisting of NF-кB/IRF1-induced ERVK expression and innate immune response 
against ERVK-expressing neurons, causing chronic neuronal damage observed in ALS and other 
ERVK-associated neurological diseases.  
Furthermore, sequential ERVK polyprotein processing lends credibility to the fact that 
ERVK encodes and produces a functional viral protease enzyme141. However, whether ERVK 
protease was responsible for cleaving the ERVK polyprotein to generate mature RT in our 
studies remains to be elucidated experimentally. Alternatively, an unidentified cellular protease 
may have been responsible for cleaving ERVK polyprotein. Nonetheless, the production of active 
viral protease has significant implications for ERVK biology and persistence of ERVK expression 
in associated diseases. For instance, ERVK virions are generally thought to be non-infectious 
because of their inability to produce an active protease and thus form mature virus particles30. 
However, mature ERVK virions have been detected in cancer cell lines28, but their infectivity is 
yet to be clearly determined. Recently, ERVK virions derived from these cell lines were 
demonstrated to transmit ERVK sequences to uninfected cells29, challenging the prevailing 
notion that ERVK virions are non-infectious. In line with this, biologically functional ERVK 
protease may lead to the production of mature and infectious ERVK virions in human tissues; re-
infection of host cells may lead to virus-mediated or immune-mediated cellular damage and 
contribute to disease pathology. In addition, similar to HIV protease, ERVK protease may also 
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allow viral PAMPs to escape immune detection through protease-mediated degradation of key 
innate immune sensors, such as RIG-I61. This may foster persistence of inducible ERVK 
expression in the context of inflammation, which is likely to be detrimental for the CNS.    
4.3 | Non-prototypic ERVK polyprotein cleavage may indicate cellular response to  
         degrade ERVK polyprotein/RT and mitigate ERVK activity  
In addition to prototypic polyprotein cleavage pattern leading to the production of 
active ERVK RT in our studies, we also observed that ERVK polyprotein can be completely 
cleaved to generate non-prototypic protein fragments. This was achieved through treatment of 
astrocytes with a combination of TNFα and MG132, which led to the production of 68 and 41 
kDa RT fragments and disappearance of the 125 kDa ERVK polyprotein band (Publication 4, 
Figure 2A). These non-prototypic fragments may represent degraded and inactive ERVK RT, 
although this is yet to be validated experimentally. 
MG132 is a peptide aldehyde that reversibly inhibits the peptidase activities of the 
chymotrypsin-like and caspase-like sites in the 20S subunit of the proteasome142. Thus, MG132 
treatment leads to proteasome inhibtion and protein accumulation in cell cultures143, yet 
cleavage of ERVK polyprotein was observed in the presence of MG132, suggesting that other 
protein degradation pathways may be responsible for homeostatic clearance of ERVK protein 
products (Publication 4, Figure 2A). Another key protein degradation pathway is the autophagy 
system, which has previously been shown to degrade viral proteins144. Proteasome inhibition 
has also been demonstrated to enhance autophagic activity as a compensatory mechanism145. 
Accordingly, in astrocytes, we observed enhanced expression of the autophagy marker, LC3B-
II144, in the presence of MG132, which is indicative of an ongoing autophagy to clear ERVK 
expression (Publication 4, Figures 2A and 6B). Complete clearance of ERVK polyprotein 
associated with a decrease in LC3B-II levels in TNFα and MG132 treated astrocytes, suggesting 
resolution of an autophagic response following ERVK protein degradation (Publication 4, 
Figures 2A and 6B). In addition, confocal microscopy revealed large autophagolysosome-like 
structures with partial clearance of ERVK polyprotein/RT in astrocytes (Publication 4, Figure 6B). 
These findings suggest that autophagy may be a homeostatic mechanism to degrade ERVK 
proteins and regulate ERVK activity in human cells. In fact, many cellular enzymes, including 
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caspases, calpains, and cathepsins are known to cleave and degrade viral proteins. For instance, 
ERVK-10 gag protein is known to be cleaved by caspase, and is associated with the apoptosis of 
ERVK expressing cells146. HIV-1 gp120 protein is also cleaved by caspases and cathepsins147,148. 
Caspase-3 proteolytic activity has been observed in cortical neurons exposed to HIV gp120148. 
Thus, ERVK accumulation may trigger protein degradation pathways to quench viral activity as a 
protective cellular response; unfortunately, the inherent nature of this response may lead to 
enhanced cellular damage and death.     
 
4.4 | ERVK proteinopathy in neurological disease  
  
4.4.1 | ERVK RT aggregation is enhanced in human cell line models of  
                pro-inflammatory cytokine-mediated neuroinflammation   
ERVK-associated neurological disorders, including ALS, are increasingly being recognized 
to have common pathological mechanisms, particularly aggregation of cellular proteins and 
inclusion body formation. Aggregation of wild type and mutant TDP-43, as well as other host 
proteins, is a hallmark of ALS. The role of these protein aggregates in the pathology of 
associated neurodegenerative disorders has been extensively studied (and reviewed 
elsewhere47,149. However, ERVK protein aggregation has never been examined in ALS or in other 
ERVK-associated neurological diseases, despite the fact that ERVK protein levels are significantly 
enhanced in these pathologies. 
For the first time, we have described the formation of ERVK RT aggregates and their 
cellular localization in human cell line models of neurological disease. First of all, we have 
utilized confocal microscopy to demonstrate that pro-inflammatory cytokines enhance cytosolic 
ERVK RT aggregation in astrocytes and neurons. Interestingly, cytokine-induced ERVK 
expression always resulted in the formation of a large ERVK RT aggregate proximal to the 
nucleus, along with the formation of a perinuclear ring (Publication 2, Figure 2; Publication 3, 
Figure 1B). Nuclear ERVK RT expression was also enhanced upon cytokine stimulation, and 
exhibited a speckled pattern (Publication 2, Figure 2; Publication 3, Figure 1B). This ERVK 
staining pattern is consistent with that observed for HIV-1 RT in reverse transcription 
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complexes (RTCs) formed during viral replication150. HIV-1 RTCs have been demonstrated to 
accumulate proximal to the nucleus and form a perinuclear ring before nuclear import of RTCs 
occurs150. The formation of RTCs and their nuclear import is a critical step in retroviral life cycle, 
as it allows reverse transcription of viral RNA genome into DNA, which is then imported into the 
nucleus for integration into the host cell genome. The ERVK RT staining pattern suggests the 
formation of ERVK RTCs in cytokine-stimulated cells, which may be imported into the nucleus as 
indicated by speckled nuclear RT staining. The nuclear transport of ERVK RTCs may lead to ERVK 
re-integration into the host cell genome in the presence of an active viral integrase enzyme. 
Nonetheless, it remains to be confirmed whether the observed ERVK RT aggregates are 
truly RTCs, whether they are imported into the nucleus, and which cellular factors promote 
their nuclear import. Exogenous retroviral RTCs, including those for HIV, have previously been 
purified from infected cells and visualized by fluorescent confocal microscopy150. The identity of 
ERVK RTCs can be confirmed by utilizing these already existing techniques and modifying them 
if necessary, to yield functional ERVK RTCs. In addition, nuclear import assays have been used to 
study the nuclear translocation of HIV RTCs150, and can also be employed to determine whether 
ERVK RTCs are imported into the nucleus. Nuclear import of proteins is mainly mediated by a 
large superfamily of importin factors. Importin 7 is known to shuttle HIV RTCs from the cytosol 
into the nucleus150. Similarly, importin 7 or other related factors may be able to transport ERVK 
RTCs into the nuclei of host cells. This can be determined using nuclear import assays in 
importin knockout cells and cultured cells reconstituted with specific  transport receptors150. 
The enhanced expression and activity of ERVK RT, formation of viral RTCs, and the 
subsequent production and nuclear import of ERVK genomic DNA under neuroinflammatory 
conditions has important implications for ERVK-associated neurological diseases. The nuclear 
transport of ERVK RTCs and subsequent ERVK re-integration into the host cell genome may 
disrupt the expression and function of critical host genes, contributing towards the pathology of 
neurological diseases.  Interestingly, these effects may partially explain differences in disease 
progression and symptom development in individuals with a given disease, as re-integration 
cycles are likely to generate random and un-identical cellular outcomes in each affected cell.  
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In addition, the staining pattern of ERVK RT aggregates resembles that of the specialized 
inclusion bodies called viroplasms, which comprise the viral replication machinery151,152. This 
suggests the formation of putative ERVK viral factories in cytokine-stimulated cells. These 
findings are consistent with the detection of ERVK RT staining in the axons of cortical neurons 
from patients with ALS (Publication 3, Figure 5). Neurotropic viruses are known to transmit 
progeny virions or virion components within neuronal axons, which allows the viral infection to 
spread while escaping extracellular immune responses153. Similarly, speckled ERVK staining in 
neuronal axons may reflect ERVK’s attempt to spread from one neuron to another. The 
morphology of ERVK viroplasms also resembles that of the aggresomes, which are 
compartments that sequester unwanted proteins in specialized inclusions and facilitate their 
clearance by autophagy, thereby dissipating the cytotoxic effects of protein aggregates154,155. 
Likewise, the formation of ERVK RT aggresomes may be a cellular response to protect against 
toxic ERVK protein accumulation. Unfortunately, the appearance of aggresomes and inclusion 
bodies can impair vital cellular functions, including inactivation of the proteasomal pathway 
responsible for clearing protein aggregates155. Interestingly, protein clearance pathways, such 
as the proteasome system and autophagy, are dysregulated in ERVK-associated neurological 
diseases including ALS156. In the absence of functional protein degradation pathways, 
inflammation-induced ERVK viroplasms or aggresomes may persist and perpetuate chronic 
neuronal damage.   
4.4.2 | Failure of the proteasomal and autophagic protein clearance pathways  
              promotes ERVK proteinopathy 
Dysfunction of the proteasomal and autophagy pathways, leading to aggregation of 
cellular proteins, has been extensively documented in ALS156. Recent studies have enlarged our 
understanding of the molecular composition of the protein aggregates resulting from 
proteasome and autophagy disruption. For instance, the proteasome and autophagy system are 
known to clear endogenous TDP-43 accumulation, and disruption of these pathways in ALS 
associates with TDP-43 proteinopathy149,157. However, the influence of these pathways on 
regulation of ERVK expression has remained unexplored. Therefore, we sought to determine 
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whether inhibiting the function of the proteasomal pathway results in ERVK RT aggregation in 
our cell line models of neurological disease.    
As discussed previously, MG132 treatment of cells is well known to abolish the function 
of the proteasome. MG132 treatment enhanced TDP-43-induced ERVK gene transcription, as 
well as polyprotein and RT accumulation in astrocytes (Publication 4, Figures 2 and 4). Confocal 
microscopy further revealed large ERVK RT aggregates proximal to the nucleus with the 
formation of a perinuclear ring; nuclear aggregation of RT was also observed (Publication 4, 
Figure 2A). This staining pattern resembles that of inclusion bodies seen in a variety of 
proteinopathies. Thus, proteasome inhibition in ALS may trigger ERVK proteinopathy through 
increased TDP-43 mediated ERVK transcription, as well as aggregation of newly expressed ERVK 
proteins which are normally cleared by the proteasome. However, the causative link between 
proteasome dysfunction and ERVK RT aggregation in neurological diseases remains to be 
validated in vivo.  
Although in our studies we did not interefere with the autophagy system, our 
observation of cell-type specific functionality of this pathway sheds light on the influence of 
successful versus incomplete autophagy on ERVK protein levels in CNS cells. In contrast to 
astrocytes, TNFα and MG132 treatment of neurons did not culminate in complete degradation 
of the ERVK polyprotein to generate non-prototypic ERVK RT fragments (Publication 4, Figure 
2C). Yet, there was enhanced expression of LC3B-II in the presence of MG132, suggesting that 
autophagy was occuring (Publication 4, Figure 2C). The inability of neurons to clear ERVK 
despite an ongoing autophagic response may be explained by failure or active inhibition of 
autophagy. In line with this, unlike in astrocytes, TNFα and MG132 treatment of neurons did not 
lead to resolution of autophagy, as LC3B-II protein levels remained high and not all TDP-43 was  
cleaved (Publication 4, Figure 2C). The function of other key proteins involved in the autophagy 
pathway, such as optineurin, may have been disrupted by MG132 treatment of neurons, and 
may account for an unsuccessful autophagic response. Alternatively, neurons may not be able 
to clear ERVK proteins unlike astrocytes. 
Recently, impaired autophagic response has been linked to ALS pathology and enhanced 
neuronal death158,159–161. Autophagic dysfunction in ALS is known to stem from mutations in a 
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variety of critical proteins involved in this pathway, such as optineurin, ubiquilin 2, 
sequestosome 1, phosphoinositide 5-phosphatase, and charged multivesicular body protein 
2B161,162,163. Mutations in the latter two proteins have previously been shown to cause LC3B-II 
accumulation as their dysfunction prevents completion of autophagy161,164. Overall, the inability 
of CNS cells to degrade ERVK proteins, as a consequence of impaired autophagic response 
and/or proteasomal system, may trigger neurocognitive impairment through various 
mechanisms including viral protein-mediated synaptic dysfunction, excitotoxicity, and loss of 
neuronal  plasticity, as seen with other neurotropic retroviruses165. 
 Enhanced ERVK protein expression may further interfere with protein degradation 
pathways. A number of viruses have evolved strategies to interfere with autophagy by 
disrupting autophagosome formation or maturation. HTLV-1 tax protein recruits autophagic 
molecules to lipid rafts and thus deregulates autophagy166. Coxsackie virus B3 protease can 
cleave sequestosome 1, rendering it unable to bind ubiquitinated cargo and form 
autophagosomes167. Likewise, ERVK protease may cleave autophagy sensors and adaptor 
molecules, leading to failure of an autophagic response and persistence of viral expression. A 
striking number of viruses also target beclin 1, a protein required for initiation of the formation 
of autophagosome, to disrupt autophagosome biogenesis. Human cytomegalovirus TRS1 
protein, African swine fever virus A179L protein, herpes simplex virus type 1 ICP34.5 protein, 
human herpesvirus 8 orf16 protein, and HIV Nef protein all bind beclin 1 and block 
autophagosome biogenesis (reviewed in168). ERVK proteins may also prevent autophagosome 
formation by interfering with the function of beclin 1 or other proteins involved in autophagy. 
The interactions of ERVK proteins with autophagic molecules, as well as post translational 
modifications of ERVK proteins that may facilitate these interactions, have not been studied. 
Thus, the influence of ERVK expression on autophagic response is an interesting avenue of 
research that clearly needs further exploration.  
4.4.3 | TDP-43 overexpression promotes ERVK proteinopathy  
 There is evidence that TDP-43 mediates transcriptional repression of the HIV-1 
promoter83.  In contrast, TDP-43 overexpression has been associated with enhanced ERVK 
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transcription and protein expression ALS31. In our studies, we have confirmed that TDP-43 
accumulation enhances ERVK re-activation at the transcriptional level. Here we showcase that 
TDP-43 overexpression also promotes ERVK proteinopathy in human cell line models of 
neurological disease. We have utilized confocal microscopy to evaluate TDP-43 and ERVK RT 
aggregation in astrocytes transfected with constructs encoding wild-type and mutant TDP-43. 
Overexpression of wild-type as well as mutant TDP-43 in this cell line recapitulated cytosolic 
TDP-43 aggregation (Publication 4, Figure 5E-F). Enhanced ERVK RT aggregation was observed 
in these cells, with mutant TDP-43 forms generating significantly higher percentage of 
aggregates as compared to wild type TDP-43 (Publication 4, Figure 5F). In addition, 
overexpression of wild type TDP-43 enhanced overall ERVK polyprotein expression, whereas 
overexpression of the truncated TDP-43 reduced ERVK expression in astrocytes (Publication 4, 
Figure 5A-B). This clearance of ERVK polyprotein, despite the absence of any external signals to 
stimulate degradative pathways, may reflect the activity of anti-ERVK endogenous mechanisms 
in astrocytes. In stark contrast, wild type TDP-43 promoted insoluble ERVK polyprotein 
accumulation, and mutant TDP-43 enhanced the availability of soluble ERVK polyprotein in 
neurons (Publication 4, Figure 5C-D). This suggests that neurons are intrinsically unable to fully 
clear ERVK protein accumulation. This may be particularly devastating for individuals carrying 
heterozygous TDP-43 mutations in ALS169,170,171, as wild-type TDP-43 will promote insoluble 
ERVK protein accumulation and mutated TDP-43 will revert it back to the cytosol, culminating in 
neuronal ERVK persistence. 
 Overexpression of TDP-43 in astrocytes and neurons also led to the production of 50 kDa 
TDP-43, which may represent a hyperphosphorylated form of this protein (Publication 4, Figure 
5). Phosphorylated TDP-43 isoforms have been detected in pathological inclusions in ALS172. As 
with majority of other transcription factors, phosphorylation of TDP-43 may facilitate its 
interaction with the ERVK LTR and promote ERVK transcription. In addition, phosphorylated 
TDP-43 aggregates can inhibit proteasome activity173; together, phospho TDP-43 – mediated 
transcriptional re-activation of ERVK and inhibition of proteasomal clearance of ERVK proteins 
may significantly augment retroviral proteinopathy in ALS. 
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Interestingly, ERVK RT co-localized with TDP-43 aggregates in our TDP-43 overexpression 
models in astrocytes (Publication 4, Figure 5E). The ERVK RT and TDP-43 staining pattern in cells 
overexpressing these proteins resembled that of stress granules (SGs)174. SGs are nuclear or 
cytoplasmic aggregates comprised of proteins and RNA molecules that form upon cellular 
stress. TDP-43 has been shown to promote stress granule assembly, and formation of stress 
granules has increasingly been implicated in ALS pathology174,175. TDP-43 has previously been 
shown to colocalize with stress granule markers, and overexpression of wild type as well as 
mutant TDP-43 can enhance the formation of stress granules, although TDP-43 mutants result 
in more stress granules formed per cell176. But, the localization of ERVK proteins to stress 
granules has not been examined. Herein, we have demonstrated that ERVK RT also co-localizes 
with the stress granule marker G3BP1 in response to TNFα and MG132 stimulation of astrocytes 
(Publication 4, Figure 6A), suggesting that ERVK proteins can be recruited to stress granules. 
G3BP1 expression was also significantly enhanced in ERVK+ cortical neurons of patients with 
ALS as compared to neuro-normal controls, but no co-localization between ERVK RT and G3BP1 
was observed (Publication 4, Figure 6C). Exclusion of ERVK RT from stress granules in neurons 
may reflect a viral evasion strategy to escape degradative processes. As TDP-43 is an RNA 
binding protein, it may bind ERVK nucleic acids and shuttle them to SGs as an antiviral 
mechanism, to impede viral RNA translation. Despite the fact that TDP-43 mutants have an 
increased SG association, they may not be able to interact with ERVK RNA. In ALS, TDP-43 
mutations or cleavage may result in a failure to traffic viral RNA to SGs, allowing the translation 
of ERVK polyprotein in neurons. 
One of the mechanisms that cells use to counteract viral infection is inhibition of global 
protein synthesis and recruitment of mRNAs into SGs, where the fate of viral as well as cellular 
mRNAs is determined177. Normally, SG formation is followed by targeting viral mRNAs for 
degradation and cellular mRNAs for translation177. However, a striking number of viruses have 
developed strategies to escape SGs or to take advantage of them for their replication, and 
retroviruses are no exception. Cytosolic expression of HTLV-1 Tax protein inhibits the formation 
of SGs, allowing synthesis of HTLV-1 proteins177. HIV-1 is also known to interfere with SG 
assembly by redistributing staufen-1 from SGs to distinct cytoplasmic granules, where staufen-1 
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is exploited to aid in the assembly of HIV-1 virions178–180. In contrast HIV-2 induces the 
formation of SGs to allow gag protein synthesis and virion production181. Similar to these 
exogenous viruses, ERVK RNAs may escape SGs formed in response to TDP-43 over-expression, 
or alternatively ERVK may exploit SG formation for its protein synthesis – both of these 
processes have the potential to facilitate ERVK proteinopathy. 
 
 
Overall, we have comprehensively described several mechanisms behind aberrant ERVK 
transcription and protein aggregation in neuroinflammatory diseases, particularly ALS and 
HAND. In the studies outlined in this thesis, we have linked pro-inflammatory stimuli, 
impairment of proteasomal and autophagic protein degradation pathways, as well as TDP-43 
dysregulation with ERVK re-activation in ALS and HAND. Thus, ERVK is a novel marker that may 
define the pathophysiology of neuronal loss in these conditions. Consequently, controlling ERVK 
activity in the associated neurological diseases may be beneficial in managing disease 
symptoms and in reverting retrovirus-mediated neuropathology.  
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5.  GLOBAL SUMMARY AND SIGNIFICANCE 
In this research work, we have established human cell line models of ERVK-associated 
neurological disease which have allowed us to expand our understanding of the mechanisms 
behind transcriptional re-activation of ERVK in the context of neuroinflammation (summarized 
in Figure 9). We are the first to demonstrate that inflammation is a key trigger of ERVK activity 
in associated neurological conditions. Pro-inflammatory cytokines that lead to IRF1 and NF-κB 
activation augment ERVK expression in astrocytes and neurons in a cell-type specific manner. 
This is achieved via binding of IRF1 and NF-κB to funcitonal ISREs in the ERVK promoter. We 
have also shown for the first time that TDP-43 is a transcriptional activator of ERVK, and that 
TDP-43 overexpression and aggregation can promote ERVK proteinopathy. In addition, we 
showcase that ERVK protein accumulation can be cleared via the proteasome and autophagy 
systems, and that diruption of these pathways promotes ERVK proteinopathy. Overall, 
simultaneous de-regulation of pro-inflammatory cytokine signaling, TDP-43 function, and 
protein clearance pathways has the potential to significantly enhance ERVK proteinopathy – a 
novel pathological mechanism in ERVK-associated neurological diseases. 
The findings generated from this work have significantly changed our views on 
neuropathogenesis of HAND and ALS, by including ERVK proteinopathy as a novel mechanism of 
neuronal damage in these diseases. Thus, ERVK is a novel marker of neurodegeneration in 
HAND and ALS. Consequently, quenching ERVK activity in these conditions may improve disease 
symptoms, and reverse virus-mediated pathology. This may be achieved through the use of anti-
retroviral drugs, such as viral protease and RT inhibitors. HIV-1 protease inhibitors have been 
used in the past to target ERVK protease activity; however, ERVK protease is highly resistant to 
these drugs182. This is likely because ERVK and HIV-1 proteases, and similarly RT, vary 
significantly at their structural levels. Thus, new ERVK-specific anti-retroviral drugs will be 
required to control ERVK activity in the associated diseases. Alternatively, drugs that trigger 
broad-spectrum anti-viral innate immune responses, such as GSK984, may be able to quench 
ERVK activity in the context of inflammation by stimulating the global production of viral 
restriction factors183.   
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FIGURE 9. Summary of mechanisms behind (A)  astrocytic and (B) neuronal ERVK p roteinopathy 
and the cell-type specific  responses to clear ERVK aggregation. Artwork by M. Manghera.  
 
ERVK protein aggregation can also be targeted in novel therapeutics. Viroplasm 
inhibitors, such as the thiazolide class of antivirals, have been used in the past to prevent 
replication of certain types of viruses184. Such inhibitors may also be beneficial in preventing 
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ERVK viroplasm formation. Small-molecule autophagy enhancers can also be exploited to 
facilitate the degradation of ERVK protein aggregates. Trehalose is an excellent candidate for 
this purpose, as it has previously been demonstrated to increase neuronal survival by 
promoting autophagic clearance of protein aggregates including tau, huntingtin, and SOD1 
inclusions in vitro and in mouse models of neurological disease185.    
Immunomodulatory regimens, such as anti-TNFα therapy186, may further lend benefit to 
managing the clinical symptoms of ERVK-associated diseases such as ALS and HAND. Since NF-
κB plays a crucial role in ERVK transcriptional re-activation, it is desirable to target the activity of 
this pro-inflammatory TF in neurological disease. However, the use of NF-κB inhibitors is 
complicated by the fact that NF-κB is crucial for proper neuronal functioning, such as synaptic 
signaling and plasticity; and thus, inhibiting NF-κB activity may actually exacerbate 
neurodegenerative processes187. Nonetheless, novel ERVK-targeting therapeutics will give hope 
to thousands of Canadians currently living with ALS and HAND, but without an effective 
treatment or a cure. 
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6.  FUTURE DIRECTIONS 
Many interesting avenues of future ERVK research have stemmed from this work. First 
of all, we observed prototypical cleavage of the ERVK polyprotein to generate mature RT 
isoforms under a variety of inducible conditions. This raises the question as to which protease – 
cellular or viral – is responsible for cleaving the ERVK polyprotein. Libraries of human and 
retroviral protease inhibitors can be screened in our inducible ERVK models to pinpoint the 
involved protease(s). The findings can be used to inform novel therapeutics, such as the use of 
protease inhibitors to prevent the formation of functional ERVK proteins. This approach can 
also be extended to screen and identify novel ERVK RT inhibitors for therapeutic use.  
Another interesting research direction stemming from this work is to elucidate which 
autophagic sensors are responsible for detecting ERVK proteins and targeting them for 
degradation in the CNS. Our preliminary findings support the potential role of optineurin, a 
critical component of the autophagy system, in targeting ERVK elements for autophagic 
degradation. Interestingly, optineurin is mutated in some ALS cases, and an impaired 
autophagic response has been linked to ALS pathology and enhanced neuronal death159,163. 
Future studies will focus on determining whether optineurin is required for homeostatic 
clearance of ERVK in astrocytes and neurons, and whether ALS-associated mutations in this 
sensor enhance ERVK proteinopathy in ALS. 
Although in this work we have demonstrated several mechanisms that promote ERVK 
re-activation in the context of neuroinflammation, it remains to be determined whether ERVK 
nucleic acid and protein accumulation further leads to immune activation and contributes to 
neuronal injury. Future studies should aim to determine which innate immune sensors 
recognize ERVK elements in the CNS, and what the subsequent consequences are, including 
characterization of the resulting immune responses and their influence on neuronal survival 
and tissue integrity. Human “mini brains” or cerebral organoids will prove to be useful tools for 
this purpose. This research direction will help us link ERVK re-activation with immunopathology 
of neurodegenerative diseases, such as ALS. In addition, it would be interesting to study the 
influence of functional polymorphisms in molecules such as NF-κB, IRF1, TNFα, and innate 
immune sensors on ERVK biology in the context of neuroinflammatory disease. 
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7.  CONCLUSIONS 
 The ERVK promoter contains functional ISREs. 
 Pro-inflammatory cytokines stimulate ERVK transcription in a cell- type specific manner by 
enhancing the interactions of pro-inflammatory transcription factors NF-κB (p50 and p65) 
and IRF1 with the ISREs on the ERVK promoter.  
 Pro-inflammatory cytokine signaling leads to enhanced cleavage of the ERVK polyprotein to 
yield mature RT isoforms. 
 TDP-43 over-expression leads to enhanced ERVK transcription. 
 ALS-associated TDP-43 mutants promote ERVK protein aggregation. 
 Proteasome and autophagy are homeostatic mechanisms to clear ERVK expression, and 
disruption of these protein degradation pathways causes ERVK polyprotein/RT aggregation. 
 Transcriptional re-activation of ERVK and viral polyprotein/RT aggregation culminates in 
ERVK proteinopathy – a novel pathological mechanism in ERVK-associated 
neurodegenerative diseases. 
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